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Abstract 
ALTERNATIVE PHARMACOKINETIC MODELS IN END STAGE RENAL 
DISEASE DURING CONTINUOUS AMBULATORY PERITONEAL DIALYSIS 
Eugenio A. Cefali, Pharm.D.,Ph.D. 
Thesis Director: Wesley J. Poynor, Ph.D. 
Virginia CoJnlllonwealth University, Richmond, Virginia. 
An important principle of pharmacokinetic modeling is 
to use the least complicated model possible that adequately 
describes the process studied. Pharmacokinetic studies in 
peritoneal dialysis often attempt to describe the time 
course of drug concentration in the dialysate. Peritoneal 
dialysis patients are subjected to the inconvenience and 
risk of infection associated with sampling peritoneal fluid. 
Alternative pharmacokinetic models were used to study drug 
distribution during continuous ambulatory peritoneal dialy­
sis (CAPD). Efficient pharmacokinetic models of distribution 
in the peritoneal cavity were desrcibed for three drugs and 
the classes they represent. 
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Procainamide pnarmacokinetics were determined in six 
CAPD patients. The time course of procainamide or 
N-acetylprocainamide (NAPA) in the peritoneal fluid is of 
less interest than the amount cleared through the perito­
neum. Therefore the peritoneal cavity is treated as a 
terminal compartment. Procainamide and NAPA exhibited mean 
elimination half-lives of 26 and 42.9 hours respectively. 
CAPD accounted for 1.1% and 13% of total body clearance of 
procainamide and NAPA respectively. 
Phenytoin pharmacokinetics were studied to determine 
the time course of dialysate phenytoin concentrations with 
respect to drug unbound to plasma proteins (free phenytoin). 
The peritoneal cavity was modeled as part of the peripheral 
compartment. CAPD did not prove to be an effective elimina­
tion pathway for phenytoin, accounting for only 2.1% of 
total body clearance of phenytoin. 
Closed compartment pharmacokinetic theory was investi­
gated as an alternative modeling method when the drug has no 
other elimination pathway than the peritoneal cavity. In 
this case, vancomycin closed compartment pharmacokinetics 
were compared to open model analysis. Both models were used 
to predict an end of dwell concentration by fitting the data 
from a previous dwell. It was found that the closed model 
approach required less data and provided prediction close to 
the open model predictions. 
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The model used depends on the underlying pharmacokine­
tic characteristics of the drug and the aims of the study. A 
terminal compartment method is sufficient when only clear­
ance due to CAPO is required. When the drug is not 
administered intraperitoneally, the peritoneal space can be 
described as part of the peripheral compartment. Closed 
compartment pharmacokinetics are useful when the drug in 
question is eliminated only through the peritoneum. Whatever 
model is used, the investigator must consider the integrity 
of the peritoneal membranes, ultrafiltration, and volume 
shifts within the peritoneal cavity. 
-1.1 Literature review 
CHAPTER I 
Introduction 
Pharmacokinetics during peritoneal dialysis has attrac­
ted so much attention that pharmacokinetic literature is 
replete with studies titled "The Pharmacokinetics of in 
Peritoneal Dialysis". The body of conjecture in this area 
has developed to the point where several lenghty reviews on 
the topic have been published (24, 26, 45). Since peritoni­
tis is a major drawback to continuous ambulatory peritoneal 
dialysis (CAPO), a pharmacokinetic review of antibiotics 
alone and dosing recommendations also exists (27). 
Discussions of the various pharmacokinetic variables 
(bioavailability, distribution, etc.) are included in these 
reviews (19,45). Bioavailability in end stage renal disease 
patients has not been studied. Suggestions have been made 
that gastrointestinal manifestations of uremia (nausea, vomi­
ting, diarrhea,etc), as well as pH changes in the stomach 
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due to the administration of antacids may have an effect on 
drug absorption. Drug distribution will also be affected in 
this population due to edema and volume depletion. Altered 
protein binding in uremics (20) possibly due to accumulation 
of known and unknown (37) middle molecular weight substances 
also affects drug distribution. These reviews state that 
marginal changes in dosing regimens are required in perito-
·neal dialysis patients when metabolic excretion is a minor 
part of the drug's total elimination. Therefore end stage 
renal disease, the effect of peritoneal dialysis, and heme­
dialysis provide fertile ground for pharmacokinetic studies. 
The pharmacokinetic literature consists of those stu­
dies that attempt to describe overall pharmacokinetic 
parameters (eg., half-life and net dialysis clearance) and 
studies that actually attempt to model the processes. The 
pharmacokinetic parameter most commonly used to describe the 
peritoneum's contibution is a net peritoneal clearance term. 
A good example of the latter type of study was published by 
Jusko et al. in 1976 (29). In this study, the pharmacoki­
netics of gentamicin in children undergoing intermittent 
peritoneal dialysis was investigated. Although they acknow­
ledged the solute kinetic work (2) that indicated equal 
opposing intercompartmental clearances and the effect of 
convection on the overall kinetic profile, the authors used 
a standard two compartment pharmacokinetic model that 
represented the peritoneal cavity as the second compartment. 
3 
1.2 The objective 
The focus of this dissertation is to investigate phar­
macokinetic alternatives of modeling drug distribution in 
end stage renal disease during CAPO. The pharmacokinetic 
parameters obtained from these models should be consistant 
with clinical experience and existing literature. 
Studies were performed where the peritoneal cavity was 
modeled as 1) a terminal compartment (procainamide), 2) part 
of a larger peripheral compartment (phenytoin), and 3) a 
peripheral compartment in a closed model. Since an in-depth 
discussion of closed compartment pharmacokinetics does not 
exist in the literature, this third section is preceeded by 
a theoretical discussion of closed compartment pharmaco­
kinetics. The vancomycin study provides a good example of an 
instance where closed compartment pharmacokinetics would be 
applicable. 
The best model would facilitate the process of obtaining 
pharmacokinetic information efficiently. The clinical scien­
tist, when performing studies in humans, must obtain 
necessary data from the study in the most frugal manner 
possible. Unnecessary sampling adds to the patient's incon­
venience and risk. The least complicated pharmacokinetic 
model is not only less demanding on the patient with respect 
to sampling, but also decreases the cost of the study. 
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Exploring these modeling alternatives aids in optimizing 
pharmacinetic study design so that the valuable information 
sought is more easily attainable. 
CHAPTER II 
Discussion of Mass Transfer during Continuous Ambulatory 
Peritoneal Dialysis 
2.1 Description of continuous ambulatory peritoneal dialysis 
In 1976 Popovich et al. (49) described the use of conti­
nuous ambulatory peritoneal dialysis (CAPD) for the treat­
ment of chronic renal failure. This treatment modality 
differs from the conventional dialysis alternatives in that 
it provides a continuous low level route of excretion for 
metabolic waste products and ingested substances. CAPD uses 
the continuous presence of exogenously instilled dialysate 
fluid as a receptacle for substances which diffuse through 
the peritoneal membrane. The dialysate fluid dwells within 
the peritoneal cavity for between 4 - 10 hours, after which the 
fluid is drained and fresh dialysate is reinstilled. For all 
practical purposes, one can say that CAPD represents a 
continuous, internal, and portable dialysis system. 
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The technique requires the surgical placement of a 
silastic Tenckhoff catheter (65) through the abdomen and 
into the peritoneum under local anesthesia. There it is 
permanently sutured into place. The external end of the 
catheter is fitted with a titanium connecter to which dispo­
sable dialysate tubing can be attached. The opposite end of 
the dialysate tubing is inserted into a 1 to 2 liter dialy­
sate bag using aseptic technique (36). The dialysate bag 
contains an electrolyte solution whose osmolarity is further 
adjusted using 1.5%(366 mosm/1), 2.5%(398 mosm/1) or 
4.25%(505 mOsm/1) dextrose. This dialysate solution is 
instilled into the peritoneal cavity over approximately 10 
minutes. The dialysate tubing is then clamped as close as 
possible to the bag. The bag is then rolled up with the 
dialysate tubing and kept on the patient, still attached to 
the titanium connector. This solution is allowed to dwell 
within the peritoneum for between 4 to 10 hours. At the end 
of this time period, the solution is drained by gravity over 
15 to 20 minutes into the attached, original dialyste bag. 
The bag is then clamped, detached using aseptic technique, 
and discarded. A fresh bag of solution is connected and a 
new dwell is initiated. The dwells are continued throughout 
the day. The patient can easily arrange his schedule around 
the periods when he must instill and drain the solution. 
These periods occur three to four times daily for a period 
of approximately 30 minutes. Although the Tenckhoff catheter 
7 
is permanently secured, the dialysate tubing can be changed 
to help reduce the possibility of contamination. 
The efficiency of peritoneal dialysis has been studied 
and reported (5,23,36,43,50,52,54). Clinical studies 
(5,23,) and reviews (12,24,35,50,53,61,63) have compared the 
solute removal efficiencies of CAPD to hemodialysis, the 
clinical standard. CAPD is less efficient than hemodialysis 
in clearing small solutes such as blood urea nitrogen 
(molecular weight, 60 daltons) and serum creatinine 
(molecular weight, 113 daltons) but is more efficient in 
clearing solutes of molecular weight 500 - 5000 daltons. It 
is speculated that the greater clearance during peritoneal 
dialysis of substances in the 500 to 5000 dalton molecular 
weight range may account for the common observation that 
peritoneal dialysis patients feel better than hemodialysis 
patients (3). Another major difference between CAPD and 
hemodialysis, is the continuous removal of substances during 
CAPD. This provides an equilibrium of these substances in 
the patient. In hemodialysis where there is no elimination 
during the interdialytic periods, it is hypothesized that a 
"disequilibrium syndrome" (11,23,62) may account for the 
uremic symptoms seen in hemodialysis patients. 
Controversy over the relative merits of CAPD over hemo­
dialysis has lead to a recent retrospective study (5). 
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Charytan et al. compared 92 patients who received hemodialy­
sis at a hemodialysis center and 72 patients receiving CAPO 
over twenty-six months. They found that the CAPO patients 
had lower mean serum urea nitrogen, creatinine, potassium, 
phosphate, and albumin while they also had higher serum 
bicarbonate levels and received fewer transfusions than did 
patients on hemodialysis. Activity levels were found to be 
comparable, as were hospitalization rates, mortality, and 
dropout rates. Although hospitalization rates were similar 
(1.40 versus 1.54 admissions per patient year), causes of 
hospitalization were different. CAPO patients were admitted 
for peritonitis, exit site infections, and surgical repair 
of hernias while hemodialysis patients were admitted for 
sepsis related to access-site infection, surgical repair of 
access-sites, severe hypotension, arrythmias, coronary 
ischemia, as well as pulmonary, cardiovascular, and non­
access-site related infections. Although comparable clinical 
outcome was found, it was noted that CAPO was less expensive 
than hemodialysis. Continuous ambulatory peritoneal 
dialysis may not displace hemodialysis but it provides the 
end stage renal disease patient with an acceptable chronic 
dialysis technique. 
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2.2 Solute transport across the peritoneum 
The distribution kinetics of endogenous solutes as well 
as drugs have been investigated ever since the peritoneal 
cavity was envisioned as a site for dialysis (10). Before 
CAPD came into vogue, intermittant peritoneal dialysis (IPD) 
was the alternative to hemodialysis. In IPD the peritoneum 
is cyclically filled and emptied with dialysate by means of 
an infusion device. The length of a dwell during a cycle 
lasted between O (constant dialysate flow) and 20 minutes. 
The cycles wer� repeated for 20 hours at a time, twice 
weekly. Eventhough dialyste remained in the peritoneum for 
no more than 20 minutes at a time, it became common practice 
to refer to the dialysate regimen in terms of dialysate flow 
rate per hour. Dialysate flow rate became a variable whose 
effect on solute kinetics was investigated. Studies (58,62) 
indicated that the rate of removal of small solutes such as 
urea, creatinine, phosphate, uric acid, and potassium 
increased as dialysate flow rate increased (more liters of 
dialysate per hour). 
Although the concept of dialysate flow rate was carried 
into the CAPD literature, use of dialysate dwell time is now 
reported more often. Nolph et al. (43) and Twardowski et 
al. (68) show that equilibration of small solutes such as 
urea occured within 4 hours so that net clearance became 
zero at that time. The clearance of larger solutes continued 
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past four hours of dwell. These studies reinforced the 
practice 4 hour CAPD dwells which are now commonly seen. 
Overnight dwells are continued for 8 to 10 hours for conve­
nience. 
By 1979, the study of peritoneal transfer of solutes 
had developed to the point where discussions and reviews 
12,40,42,48) of the factors that determine solute flow 
during peritoneal dialysis were published. By this time, it 
was accepted that solute transfer across the peritoneum was 
due to diffusive as well as convective transport. Diffusive 
transport was due to: 
1) Splanchnic blood flow rate. 
2) Peritoneal dialysate flow rate. 
3) Concentration gradient. 
4) Membrane area and permeability. 
5) Ionic charge and solute size. 
6) Protein binding. 
Convection is caused by ultrafiltration arising from 
osmotic and hydrostatic pressure gradiants between the 
capillary and the peritoneal cavity. 
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The peritoneal barrier to solute transfer is described 
as consisting of six layers (42): 
1) Stagnant fluid films adjacent to the endothelium of 
the capillary. 
2) The capillary endothelial layer and/or the intercel­
lular channels. 
3) The capillary basement membrane. 
4) The peritoneal interstitium. 
5) The peritoneal mesothelium. 
6) The stagnant fluid films along the peritoneum. 
The reviewers suggested that the clearance of small 
solutes was limited by the permeability of the peritoneum 
and stagnant films. This statement was based on studies they 
reviewed showing that even when the dialysate flow rate 
was increased beyond 200 ml/min, the peritoneal clearance of 
urea (molecular weigth 60 daltons) did not increase beyond 
30 ml/min. Since splanchnic blood flow is approximately 1200 
ml/min, peritoneal clearance would have increased linearly 
with dialysate flow rate if peritoneal clearance was indeed 
dependent on splanchnic blood flow. They also concluded that 
peritoneal clearance of solutes that were of molecular 
weight greater than 5000 daltons was probably limited by 
capillary area and permeability. Evidence for this conclu­
sion came from the fact that vasodilators improved the 
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clearance of the larger solutes to a greater extent than for 
smaller solutes. 
Investigators also focused on ultrafiltration during 
peritoneal dialysis since at the end of most dwells there 
was a net removal of water from the patient. In a 1981 
review(41), Nolph presents a summary of what is known of 
peritoneal ultrafiltration and an hypothesis to explain 
ultrafiltration characteristics. The characteristics of 
ultrafiltration he describes are: 
1) Ultrafiltration occurs when the osmolality of the 
dialysate fluid is greater than the blood. 
2) The rate of ultrafiltration is greatest at the 
beginning of a dwell. 
3) Ultrafiltration rate decreases exponentially as the 
osmolality of the peritoneal fluid approaches that of 
the blood. 
4) The major source of ultrafiltrate is assumed to be 
from the peritoneal capillary circulation (which implies 
that the fluid enters the peritoneal cavity through 
intercellular junctions). 
5) Ultrafiltration increases solute clearance except 
for electrolytes and neutral solutes such as urea. 
The author states that "peritoneal ultrafiltration is a 
paradox in that the system sieves electrolytes and small 
neutral solutes during ultrafiltration while allowing pro­
tein loss". 
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He resolves this paradox in the following manner and 
uses other published studies as possible evidence. Briefly 
stated, Nolph suggests that most of the ultrafiltration 
occurs in the proximal venule where the intercellular junc­
tions are smallest and decreases further along the perito­
neal capillary. He offers published evidence that the 
junctions in the proximal venule are probably much smaller 
than the molecular radii of most electrolytes so that in 
this section, the ultrafiltrate is primarily free water. He 
also suggests that the junctions in the more distal capilla­
ry are of increasing size but at that point the hydrostatic 
pressure in the capillary is too low for ultrafiltration. 
Therefore, ultrafiltration in the distal venule is minimal 
or nonexistant but the junctions are large enough to allow 
"leakage" of larger molecules that are in higher concentra­
tion within the capillary. The "paradox" is hypothesized to 
occur due to free water ultrafiltration early in the venule 
and "leakage" of larger molecules at the distal capillary 
but there is no net movement of electrolytes at this point 
due to a lack of net fluid movement to carry them. 
Although ultrafiltration is an interesting phenomena of 
peritoneal dialysis, most of the solute kinetic studies done 
in CAPO suggest that convection of solutes accounts for a 
small part of peritoneal clearance. Popovich (47) in a 
review suggested that for small solutes, peritoneal dialysis 
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is a diffusive system. Popovich and Moncrief (48) in their 
review indicate that ultrafiltration may be important for 
molecules larger than urea (molecular weight 60 daltons) by 
citing that approximately 6% of urea peritoneal clearance is 
due to ultrafiltration, where 33% of inulin clearance 
(molecular weight 5200 daltons) is due to ultrafiltration. 
The most important effect of ultrafiltration on deter­
mining solute kinetics in CAPD is the dilution of solutes in 
the peritoneal cavity. Depending on the concentration of 
dextrose used in the dialysate fluid and the length of the 
dwell, the peritoneal volume can increase by 50 % 
(14,47,48,51,68). To further complicate the peritoneal con­
centration versus time profile, the increase in volume is 
not linear. The maximum volume occurs from between 2 and 4 
hours with 1.5% dextrose and 4 to beyond 7 hours when 4.25% 
dextrose is used. Reabsorption of fluid resulting in a small 
volume drained than instilled has also been found in the 
above studies. Therefore designing as well as analyzing a 
kinetic study during peritoneal dialysis needs to address 
the issue of changing volume in the peritoneal cavity. 
In an attempt to better understand solute kinetics 
during peritoneal dialysis, models that describe the distri­
bution profile of solutes during peritoneal dialysis have 
also been described. These models usually use a two compar-
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tment model to describe the solute kinetics (2,14,22,51,52) 
although a three compartment model was used to describe 
vitamin B12 kinetics (55). These models also attempt to take 
ultrafiltration into account. Babb et al. (2) in 1973 de­
scribes the kinetics of solutes whose molecular weights 
range from 60 daltons (urea) to approximately 90,000 daltons 
(plasma proteins) during intermittant peritoneal dialysis. 
The model used takes into account diffusive transport as 
described by Fick's law (57) as well as convection in a two 
compartment system. 
d Cd 
Po*A*(Cb - Cd) + Tr*Cb*Qu 
dt 
A Effective area of the peritoneum. 
Cb Concentration in the blood. 
Cd Concentration in the dialysate. 
Po Overall peritoneal mass transfer coefficient. 
Qu Rate of ultrafiltration. 
Tr Solvent drag coefficient. 
eq. 1 
Ultrafiltration rate was estimated as a linear function 
arrived at by determining the total volume drained and 
subtracting the volume instilled. Due to the number (8) and 
wide range of molecular weights studied, these investigators 
were also able to show the inverse relationship of perito­
neal clearance to molecular weight. 
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The above model (eq. 1) was simplified and improved 
(14,51,52) by redefining the product of Po and A as a single 
parameter called the mass transfer area coefficient. This 
was an attempt to actually model the change in peritoneal 
volume due to ultrafiltration, and include an input func­
tion. Farrell (14) describes the following solute kinetics 
model: 
d Cb*Vb 
Kbd*(Cd - Cb) - U*S*Cb + G - Kr*Cb 
dt 
Cd Dialysate concentration. 
Cb Blood concentration. 
G Generation rate of the endogenous substance. 
Kbd The mass transfer area coefficient (volume/time). 
Kr Clearance of solute due to residual elimination 
pathways. 
eq. 2 
S Sieving coefficient = 1 - the reflection coefficient 
for that solute. 
U The ultrafiltration rate for the solute. 
Vb Volume of distribution in the body. 
Popovich (47) defines the mass transfer area coef­
ficient (Kbd) as the maximum clearance possible at infinite 
dialysis flow rate. He also notes that there is tremendous 
interpatient variation in Kbd during CAPD. Twardowski et al. 
(68) found that Kbd for urea was approximately 35 - 40 
ml/min and decreased with increasing molecular weight. They 
also found that Kbd was related to molecular weight by the 
function: 
Kbd 
-0.561 
333.6*(Molecular weight) eq. 3 
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Rewritting Farrell's solute transfer model (eq. 2) in 
pharmacokinetic terms produces an interesting observation. 
dCb*Vb 
dt 
=K2l*Vd*Cd - Kl2*Vb*Cb - U*S*Cb + G - KlO*Vd*Cb eq. 4 
Comparison of equations 2 and 4 indicates that the 
major assumption in the physiologic modeling is that K2l*Vd 
= Kl2*Vb = Kbd. As long as the effects of ultrafiltration 
can be accounted for, K2l*Vd or Kl2*Vb will provide the 
maximum clearance ability of the peritoneum for that solute. 
The mass transfer area coefficient can be used to postulate 
what the rate limiting proccess would be for solute diffu­
sion across the peritoneum (48}. When dialysate flow rate 
and blood flow rate are much larger than Kbd then diffusion 
will be limited by Kbd. This means that increasing blood 
flow or dialysate flow greatly beyond Kbd will not apprecia­
bly increase solute clearance above Kbd. If blood flow and 
Kbd are much greater than dialysate flow rate, then increa­
sing dialysate flow rate (decreasing dwell time in CAPO) 
will increase the daily peritoneal clearance of the solute. 
Knowing Kbd would provide information for using peritoneal 
dialysis to remove solutes in cases of toxicity. 
The physiologic and mechanistic aspect of the convec­
tive transport term U*S*Cb, has been discussed earlier. 
Modeling the convection of endogenous substances has 
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also been investigated. The sieving coefficient (S), is 1 -
the reflection coefficient (51). The reflection coefficient 
is an index of the mole fraction of solute that arrives at 
the membrane but does not get across. One minus this index 
represents the fraction of the solute that actually passes 
through the membrane. Farrell used perturbation analysis to 
determine that S exerts a small effect on the overall model 
unless Kbd is very small. Pyle (50,51) suggests using an 
exponential function to model ultrafiltration which he found 
to fit his volume data well. 
-a*t 
Z*a*exp r eq.5 
a Rate constant for the decline of ultrafiltration. 
r Rate of fluid reabsorption (approximately 1 ml/min). 
t Time. 
U Ultrafiltration rate. 
Z Volume of fluid ultimately ultrafiltered. 
Za = Ultrafiltration rate at time zero. 
Integrating the above equation results in the equation 
describing volume of the peritoneal fluid at any time. 
Vd 
-at 
Z*(exp 1) - r*t + Vdo eq. 6 
Vd = Volume of the dialysate in the peritoneal cavity. 
Vdo = Volume of dialysate in the peritoneal cavity at 
zero time. 
19 
Pyle also states that Cb in the convective transfer 
portion of the model should be a weighted mean of the con­
centrations in the dialysate and blood. Randerson and 
Farrell (55) showed by using perturbation analysis that 
using Cb alone does not cause much error. Although most 
investigators do not see convective forces providing a major 
contibution to overall solute transport, Pyle insists that 
his data demonstrate the opposite. In his dissertation (50) 
Pyle states that approximately half of the values of s 
arrived at by nonlinear least squares regression were out­
side the possible range for that number and therefore elimi­
nates that data from further analysis. Statements based on 
this selective data are open to controversy. 
Modeling solute kinetics is a cumbersome method of 
obtaining clinical information on a patient's ability to 
clear a solute into the peritoneum. The modeling techniques 
used also required use of a radio-labelled volume marker to 
follow the change in volume of the peritoneal fluid. For 
these reasons, investigators attempted to derive parameters 
that would be clinically useful. 
Henderson (22) suggested the use of the term Dialy­
sance to describe a clearance as a parameter. 
Vb*Vd 
Dialysance K --------- eq. 7 
Vd + Vb 
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K is a parameter analogous to the elimination rate constant 
in a one compartment pharmacokinetic model and the other 
terms are described previously. The derivation of the dialy­
sance term assumes no change in volume of the dialysate and 
requires modeling to obtain an elimination rate constant. 
Randerson and Farrell (55) suggest the use of a mean 
clearance term for each dialysate exchange. This term would 
only require the concentration in the dialysate at the end 
of a dwell (Cde), the volume of the peritoneal fluid at the 
end of the dwell (Vde), the length of the dwell (t), and the 
concentrations of the solute in the blood at the beginning 
(Cbi) and the end (Cbe) of the dwell. 
Mean dialysate clearance 
Cde*Vde 
t*0.5*(Cbi + Cbe) 
eq. 8 
Farrell (13) suggests a simplier way of estimating the 
mass transfer area coefficient but it required use of a 
volume marker in the dialysate as well as serial concentra­
tion samples in the bloocr and dialysate. His method uses 
iterative estimation of Kbd at multiple time intervals 
during a single dwell. The mean of these individual Kbd 
values represent the mean mass transfer area coefficient for 
that dwell. Ease of calculation of the mean dialysate 
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clearance resulted in its prevalent use in peritoneal dialy­
sis kinetics literature. 
Solute kinetics across the peritoneum have been most 
comprehensively investigated by w. K. Pyle and reported in 
his dissertation entitled Mass Transfer in Peritoneal Dialy­
sis (51). He drew from the wealth of information in the 
literature to investigate solute kinetics in CAPO and states 
that the best kinetic model in peritoneal dialysis will be 
characterized by a model that allows: 
1) all concentrations to be variable. 
2) dialysate volume to be variable. 
3) ultrafiltration rate to be variable. 
4) an input function. 
5) removal by other means. 
6) transport by diffusion and convection. 
Pyle's contributions include his use of simultaneous mode­
ling of solute and peritoneal volume; correlating increasing 
molecular size of the solute to a decrease in: the degree of 
equilibration between blood and dialysate during a dwell, 
the mass transfer area coefficient, and the seiving coeffi­
cient (S). His dissertation brought together much of the 
significant work that had preceeded him. 
What follows is a discussion of pharmackinetic modeling 
alternatives specific to the clinical impact of a drug's 
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disposition into the peritoneal cavity. The first alterna­
tive treats the peritoneal cavity as a terminal compartment 
when studying the pharmacokinetics of a drug whose site of 
action does not involve the peritoneal cavity (procaina­
mide). The other two alternatives model drug distribution 
across the peritoneum as if the peritoneal cavity exists in 
a peripheral compartment much the same as the early endoge­
nous solute kinetic work. For reasons to be discussed later, 
phenytoin disposition was modeled as if the peritoneal 
cavity were part of a larger peripheral cavity. Since 
antibiotic concentration within the peritoneal cavity is 
important during peritonitis, vancomycin distribution into 
this cavity was modeled but a closed compartment approach 
was used. Using these representative drug/pharmacokinetic 
models as a template, future pharmacokinetic studies in the 
CAPD population may be more efficiently executed. 
Chapter III 
The Pharmacokinetics of Procainamide HCl in Continuous Ambu­
latory Peritoneal Dialysis: Treatment of the Peritoneal 
Cavity as a Terminal Compartment 
3.1 Introduction 
The therapeutic use of procainamide has been reviewed 
by Roden and Woosley (59). Procainamide has been used in 
antidysrhythmic therapy since the early 1950 1 s. The major 
metabolite of procainamide, N-acetylprocainamide (NAPA), has 
been recognized as having antidysrhythmic activity since the 
1970's. Procainamide is indicated for both atrial and ven­
tricular dysrhythmias. 
The oral absorption of procainamide is reported as 75% 
to 95% complete with protein binding at about 15%. The half­
life in patients with normal renal function is 3 to 4 hours, 
with approximately 50% of the dose eliminated unchanged in 
the urine. The remainder is metabolized to NAPA by hepatic 
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N-acetyltransferase. Metabolism of procainamide displays a 
polymodal distribution in humans. Patients can be classified 
as slow, medium, and fast acetylators dependent upon their 
ability to form NAPA. NAPA is primarily eliminated renally, 
exhibiting an elimination half-life of 6 - 8 hours. Small 
amounts of NAPA are deacetylated to procainamide or conver­
ted to desethyl N-acetylprocainamide. 
Procainamide plasma levels above 10 mg/1 are associated 
with adverse effects such as nausea, vomiting, QT prolonga­
tion, and torsades de pointes (ventricular tachycardia 
charactized by a cyclical rise and fall in amplitude of the 
electrocardiogram). When NAPA is administered alone, anti­
dysrhythmic effects are exhibited at concentrations at or 
above 9 mg/1. Side effects due to NAPA are reported through­
out the therapeutic range and increase in frequency when 
concentrations approach 19 mg/1. NAPA frequently produces 
gastrointestinal symptoms but experience with NAPA alone is 
limited so that other adverse effects are not clearly docu­
mented. The combined therapeutic window inclusive for both 
compounds remains controversial. The use of procainamide is 
limited by the development of a "lupus-like syndrome" 
occurring early in patients who are slow acetylators. The 
symptoms usually abate when procainamide is discontinued. 
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Use of procainamide in renal disease presents the cli­
nician with major dosing problems. Not only will plasma 
concentrations of procainamide be elevated due to the renal 
impairment, but accumulation of NAPA will occur. Gibson et 
al. (18) found that the elimination half-life of procaina­
mide in end stage renal disease patients on non-hemodialysis 
days was 13.9 hours. The elimination half-life of NAPA in 
these same patients was 41.5 hours. The dose of procainamide 
must be adjusted so to minimize the NAPA levels in an 
attempt to achieve a tenuous balance between efficacy and 
toxicity. 
This study (71) described below was designed to eluci­
date the pharmacokinetics of procainamide and NAPA in end 
stage renal disease patients undergoing continuous ambulato­
ry peritoneal dialysis. 
3.2 Materials and methodology 
In this study six end stage renal disease patients who 
had been receiving CAPD for 1 to 124 weeks (Table 1) were 
entered into the study after providing informed consent. All 
patients were clinically stable and without evidence of 
peritonitis. None of the patients had known hypersensitivity 
to procainamide and/or hepatic disease. 
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TABLE 1. Patient Demographics for the Procainamid"e Study. 
PATIENT I AGE I SEX I WT. I PRIMARY DURATION OF I CrCL 
No. I yrs I I kg I DIAGNOSIS CAPD (wks) I ml/min --------1------1-----1-----1----------- -------------1--------
1 I 35 I M I 96 I GN 1 I 0 --------1------1-----1-----1----------- -------------1--------
2 I 51 I F I 104 I DN 96 I 0 --------1------1-----1-----1----------- -------------1--------
3 I 26 I M I 61 I GN 124 I 0 --------1------1-----1-----1----------- -------------1--------
4 I 41 I M I 111 I HN 1 I <1. o --------1------1-----1-----1----------- -------------1--------
5 I 24 I F I 77 I GN 12 I <1. 0 --------1------1-----1-----1----------- -------------1--------
6 I 2 5 I M I 51 I cou 2 o I < 1 . o 
GN, Glomerulonephritis; DN, Diabetic nephropathy; HN, Hyper­
tensive nephropathy; COU, Congenital obstructive uropathy. 
Patients underwent a physical examination to determine 
eligibility. Peritonitis was ruled out on the basis of clear 
dialysate and the absence of abdominal pain as well as an 
absence of clinical symptoms of infection. Patients were 
fasted from the evening prior to the study. Each patient was 
completely drained of the preceeding dialysis dwell and then 
administered a 375 mg and a 250 mg oral dose of procainamide 
HCl (Lederle). The peritoneal cavity remained free of dialy­
sate for two hours after administration of the dose. At that 
time, two liters of 1.5% or 2.5% dextrose dialysate solution 
(Dianeal, Travenol Laboratories Inc.) were instilled within 
5 to 10 minutes. This solution remained in the cavity for 
four hours, and was followed by a 4 hour dwell using 4.25% 
dextrose solution. The two exchanges that followed were 
alternated in the same manner with the exception that the 
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fourth exchange remained insitu overnight. The remaining 
exchanges were performed using the patients' usual routine 
of 4 exchanges daily. 
3.3 Sampling 
5 ml venous blood samples were collected in non-anti­
coagulated tubes at o, 0.5, 1, 2, 4, 6, 10, 14, 24, 36, 48, 
and 72 hours following administraion of the dose. Patient 6 
also had blood collected at 3, 96 and 120 hours; patients 3, 
4, and 5 had addition samples at 8 hours; and patients 1, 2, 
and 4, had an additional sample drawn at 96 hours. After 
immediate centrifugation, the harvested serum was then fro­
zen at -20 degrees c until assayed. 
3.4 Chemical analysis. 
Procainamide and NAPA were analyzed by the Clinical 
Drug Analysis Laboratory in the School of Pharmacy, at the 
Medical College of Virginia Campus - Virginia Commonwealth 
University. The analytical method was an HPLC method similar 
to that published by Kabra et. al. (30) where 
N-propionylprocainamide was used as the internal standard. A 
500 microliter aliquot of serum was extracted with 0.5ml of 
KOH and 6 ml of methylene chloride, where the lower organic 
layer was evaporated to dryness after centrifugation for 5 
minutes at 1500 rpm. The sample was then reconstituted with 
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225 microliters of mobile phase consisting of a 9:1 concen­
tration of potassium phosphate buffer (pH 3, 0.025Molar) and 
vacuum-filtered acetonitrile. From this solution, 100 micro­
liters was then injected into the HPLC system consisting of 
a 100 microliter loop injector connected to a Waters #27198 
Micro-bondapak phenyl column maintained at 40 c. The mobile 
phase flow rate was maintained at 2.5 ml/min. Effluent peaks 
were detected using a UV detector fixed at a wave length of 
280 nm. Peak heights were measured using standard techni­
ques. Sample concentrations were read from a standard curve 
of peak height ratios. 
3.5 Pharmacokinetic analysis. 
A two compartment model was used to descirbe the pro­
cainamide data while a one compartment model was sufficient 
to describe the NAPA data in the time frame used. Since 
procainamide's effector compartment is outside the perito­
neal cavity, the peritoneal cavity was treated as a terminal 
compartment. The equations for these models are as follows: 
Cproc 
Ka*F*Xo I 
--------- IA*exp(-Ka*t) + B*exp(-Alpha*t) 
Ve I_ 
+ C*exp(-Beta*t) I eq. 9 
_I 
Cnapa 
where 
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K13*Ka*F*Xo I 
------------- \W*exp(-K30*t) + X*exp(-Ka*t) 
Vn I -'--
I 
+ Y*exp(-Alpha*t) + Z*exp(-Beta*t) I eq.10 
I 
(K21 - Ka) 
A eq. 11 
(Alpha - Ka) (Beta - Ka) 
(K21: - Alpha) 
B eq. 12 
(Ka - Alpha) (Beta - Alpha) 
(K21 - Beta) 
C eq. 13 
(Ka - Beta) (Alpha - Beta) 
(K21 - K30} 
w eq. 14 
(Ka - K30) (Alpha - K30) (Beta - K30) 
X eq. 15 
(K30 - Ka) 
B 
y eq. 16 
(K30 - Alpha) 
C 
z eq. 17 
(K30 - Beta) 
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xo = Dose of procainamide administered, F = Fraction 
absorbed, Ve = Procainamide volume of the central compart­
ment, Vn = NAPA volume of the central compartment, Alpha = 
Distribution hybrid rate constant, and Beta = Elimination 
hybrid rate constant. The remaining rate constants are 
intercompartmental rate constants depicted in figure 1. 
FIGURE 1. Schematic of the model used to fit the 
procainamide data. 
KlO I 
<---------1 
I 
I 
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Pree 
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I 
I 
I Kl3 
I 
J, 
K30 I 
<---------! NAPA 
I Central 
I ____ _ 
Kl2 
-------------> 
<-------------
K21 
I 
Pree I 
Peripheral I 
_____ I 
Ka is the absorption rate constant, KlO is the elimina­
tion rate constant for procainamide into the peritoneal 
cavity, K30 is the rate constant for the elimination of 
NAPA, Kl3 is the first order rate constant for the metabo­
lism of procainamide to NAPA, and Kl2 and K21 are the 
intercompartment rate constants for procainamide. 
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Initial estimates of hybrid rate constants (Ka, Alpha, 
and Beta) as well as the. coefficients (A, B, and C) of the 
tri-exponential equation describing procainamide were ob­
tained by using the program CSTRIP (64). An initial estimate 
for K30 was also obtained by stipping the NAPA data as 
above. Since the drug was not administered intravenously, Xo 
F/Vc and Xo F/Vn were not separated from the rest of their 
respective equations. All other initial estimates were ar­
rived at algebraically. The procainamide data and NAPA data 
were then combined for each patient and reanalyzed simulta­
neously using NONLIN76 (38), where the model contained both 
disposition equations. All the data was weighted evenly. The 
subroutine OFUNC for this data is found in appendix F. The 
model assumes that 1) procainamide is either eliminated 
unchanged into the peritoneal cavity or metabolized to NAPA, 
2) the only route of elimination for NAPA is into the cavity, 
3) there is no renal elimination, and 4) peritoneal clear­
ance throughout the study is not variable. 
Peritoneal clearances (CLO) of each compound during 
individual dwells were calculated using: 
Amount of the compound removed during the dwell 
CLO ------------------------------------------------- eq.18 
Area under the serum curve during the dwell (AUC) 
Area under the curve for each interval was obtained by 
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integrating the respective disposition equation over the 
time interval of the dwell. 
As mentioned previously, the fraction absorbed was not 
separated from the disposition equations. The bioavailabili­
ty term F, is therefore included in the terms for the total 
body clearance (TBC) and beta volume terms (VB) for both 
compounds. The fraction of the administered dose which rep­
resents active drug (S) was assumed to be 0.87 (70). 
VB Xo*S 
F AUCinf*Beta 
TBCproc 
F 
TBCnapa 
F 
Xo*S 
AUCinf 
Xo*S*M 
AUCinf 
M 
K13 
K10 + K13 
eq. 19 
eq. 20 
eq. 21 
eq. 22 
Where Mis the fraction of procainamide metabolized to NAPA. 
TBCnapa 
VBnapa eq. 23 
K30 
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3.6 Results 
Serum concentrations of procainamide and NAPA for the 
six patients are found in appendix A. They are also graphi­
cally depicted in figures 2 through 7. Included in the 
graphs are the predicted concentrations from NONLIN76. Peak 
serum procainamide concentrations occurred from between 0.5 
and 3.0 hours in five of the six patients. Patient 2 exhib­
ited delayed absorption of procainamide since peak concen­
trations were attained between four and six hours. In all 
six patients, peak serum NAPA levels were attained between 
14 and 48 hours from administration of the dose. NAPA levels 
had not declined to below l mg/1 within the 72 hours of the 
study in all of the patients. 
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Using the combined two compartment procainamide, one 
compartment NAPA model to fit the two data sets simultane­
ously, coefficients of determination from between 0.93 to 
0.99 were achieved. Such high coefficients of determination 
indicate that the model could account for 93% to 99% of the 
variability in the data. However as shown in .appendix B, the 
coefficients of variation for the fitted parameters range 
from 0.07 to 31 .  64 with only one value less than 0.1. These 
large coefficients of variation indicate that although the 
model fits the data well, the parameters contain significant 
variability. This is to be expected when attempting a de­
tailed description of the pharmacokinetic profile of an 
orally administered drug and its metabolite. 
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NONLIN76 generated pharmacokinetic parameters for 
procainamide are found in table 2. The generated pharmaco­
kinetic parameters for NAPA are found in table 3. Micro-rate 
constants for the model are listed in table 4. Harmonic 
means and pseudostandard deviations of half-life, volume 
terms, and clearance are used to summarize this data as 
suggested by various authors (6,8,33). Arithmetic means and 
standard deviations are reported for all other parameters. 
The volume and total body clearance terms have the fraction 
absorbed (F) in their denominator since the value of this 
parameter was not determined. The fraction of procainamide 
converted to NAPA (M) is calculated equation 22. It is the 
same as the ratio of clearance due to acetylation and total 
body clearance. 
TABLE 2 
Pharmacokinetic Parameters for Procainamide in Six CAPO 
Patients. 
PT I Ka Alpha I Beta Tl/2 VB/F I TBC/F 
# I 1/hr I 1/hr I 1/hr hr 1/kg I ml/min 
-----1------1-------1------- ------1-------
1 11.889 I 0.10261 0.0205 33.9 2.8 I 92.o 
-----1------1-------1------- ------1-------
2 10.199 I 0.21561 0.0232 29.9 5.9 I 236.o 
-----1------1------- ------- ------1-------
3 12.462 I 0.0957 0.0119 38.7 6.7 I 121.0 
-----1------1------- ------- ------1-------
4 J2.687 I 0.1617 0.0295 23.5 3.1 I 168.a 
-----1------1------- ------- ------1-------
5 13.249 I o.3672 o.0428 16.2 3.6 I 199.2 
-----1------1------- ------- ------1-------
6 12.101 I 0.1191 0.0264 26.3 5.8 I 130.6 
-----1------1------- ------- ------1-------
mean 12.098 I 0.1770 0.02671 26.0 4.1 I 143.0 
-----1------1------- -------1------ ------1-------
sd 10.95341 0.0943 0.00811 9.29 1.6 I 51.83 
Ka = absorption rate constant, Tl/2 = elimination half-life, 
VB beta volume of distribution,. TBC total body 
clearance, F = fraction absorbed. 
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TABLE 3 
Pharamcokinetic Parameters for NAPA in Six CAPD Patients. 
PT I K30 I Tl/2 I VB/F TBC/F I M 
# I 1/hr I hr I 1/kg ml/min I % 
-----1------1------1------ -------1-----
1 10.01041 66.6 I 1.63 21.2 I 84 
-----1------1------1------ -------
2 10.01401 49.1 I 1.62 39.7 87 
-----1------1------1------ -------
3 10.01091 63.6 I 2.32 26.1 93 
-----1------1------1------ -------
4 10.01131 61.3 I 1.04 21.9 40 
-----1------1------1------ -------
5 10.02641 26.3 I 1.15 38.9 92 
-----1------1------1------1-------
6 10.02391 29.0 I 1.64 I 33.4 83 
-----1------1------1------1-------
mean I0.01621 42.9 I 1.46 I 29.8 80 
-----1------1------1------1-------
sd 10.00651 20.1 I o.43 I 1.26 20 
K30 elimination rate constant, Tl/2 = elimination half­
life, VB beta volume of distribution, TBC = total body 
clearance, F = fraction absorbed, M = fraction metabolized. 
TABLE 4 
Intercompartmental Rate Constants. 
PT K12 K13 K21 I KlO 
# 1/hr 1/hr 1/hr I 1/hr ------- ------- -------1-------
1 0.0284 0.0292 0.05921 0.0062 ------- ------- -------1-------
2 0.0779 0.0998 0.04211 0.0189 ------- ------- -------1-------
3 0.0245 0.0550 0.02801 0.0061 ------- ------- -------1-------
4 0.0478 0.0210 0.09111 0.0314 ------- ------- -------1-------
5 0.1588 0.1011 0.13371 0.0163 ------- ------- -------1-------
6 0.0267 0.0670 0.03961 0.0121 
-----1------- ------- -------1-------
mean I 0.0607 0.0622 0.06561 0.0152 
-----1------- ------- -------1-------
sd I 0.0521 0.0340 0.03991 0.0095 
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Table 5 contains the dialysate data for this study. The 
overall dialysate clearance values of procainamide and NAPA 
for the study population was determined by regression of 
total amount excreted in the dialysate of the compound 
versus area under the serum curve for that compound. Figures 
8 and 9 depict these regressions for procainamide and NAPA 
respectively. The regression line in each regression was 
forced through zero, the slope of which provides the dialy­
sate clearance for the compound. 
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TABLE 5 
Procainamide and NAPA Dialysate Data. 
Pt. I Dwell I Volume Dextrose I Proc. I NAPA I Proc. Dial. INAPA Dial. 
# I Lengthl Cone. I Cone. I Cone. I Clearance I Clearance 
I (hrs) I (1) (%) I (mg/1) I (mg/1) I (ml/min) I (ml/min) 
-----1-------1------ --------- ------1------ -----------1----------
I 3.83 I 2.80 4.25 0.31 I 0.13 1. 7 I 2.55 
l I 4.00 I 2.25 2.50 <0.1 I 0.73 N/A 7.20 
I 7.00 I 2.70 4.25 <0.1 I 0.99 N/A 5.38 
-----1-------1------ --------- ------1.------ ----------- ----------
I 3.92 I 2.30 1.50 0.10 I 0.36 0.67 3.52 
I 4.00 I 3.05 4.25 0.11 I 0.68 1.23 6.11 
2 I 8.33 2.20 1.50 0.12 I 1. 20 0.79 3.04 
I 4.67 3.00 4.25 <0.1 I 0.79 N/A 4.49 
-----1------- --------- ------1------ ----------- ----------
I 3.92 2.33 2.50 0.24 I 0.62 0.97 4.76 
I 8.50 2.58 4.25 0.26 I 1.30 1.18 3.19 
3 I 4.83 2.45 2.50 0.20 I 1.10 3.59 4.08 
110.00 2.75 4.25 0.33 I 1.40 4.27 2.87 
-----1------- --------- ------1------ ----------- ----------
I 4.50 3.00 4.25 0.38 I 0.34 2.96 5.83 
4 I 3.75 2.70 4.25 0.13 I 0.59 2.39 6.06 
I 5.75 2.23 2.50 0.15 I 0.71 3.73 3.56 
-----1------- --------- ------1------ ----------- ----------
I 3.75 2.10 4.25 0.17 I 1.50 1. 31 5.31 
I 3.92 1.95 2.50 0.18 I 1. 60 1.58 4.04 
5 I 9.58 2.10 4.25 0.18 I 2.50 0.98 2.84 
110.17 1.83 2.50 0.14 I 2.10 2.26 I 4.77 
-----1------- --------- ------1------ -----------1----------
I 3.75 I 1. 72 1.50 1.90 I 1.40 5.55 I 4.34 
I 9.68 I 1.65 2.50 0.78 I 2.40 2.07 I 3.20 
I 3.83 I 1.80 1.50 0.42 I 1. 70 5.27 I 4.02 
6 111. 83 I 2.05 4.25 0.19 I 2.00 1. 65 I 2.09 
111. 75 I 1.98 2.50 <0.1 I 1.20 N/A I 1. 74 
I 3.88 I 2.05 1.50 <0.1 I 0.78 N/A I 4.42 
110.00 I 2.15 2.50 <0.1 I 0.48 N/A I 1.91 
N/A = Data was not available. 
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Dialysate Clearance Plot of Procainarnide 
FIGURE 8 
p 
R 
0 
R 
E 
M 
V 
E 
D 
2.000 
1. 846 
1. 692 
1. 538 
1. 385 
1. 231 
1.077 
Q.923 
0.769 
Q.615 
0.462 
Q.308 
0.154 
Q.000 
0.000 o.oe7 0.174 0.261 o.349 o.436 o.523· 0.610 
PT * * * 1 
.. .. ..  5 
PROC AUC 
0 0 0 2 
a a a 6 
Clearance = 1.372 ml/min R squared = 0.698 
FIGURE 9 Dialysate Clearance Plot of NAPA 
10 
9 
N 
p 7 
R 
5 E 
M 
V 3 
E 
2 D 
0 
a.a Q.2 
PT 
Q.4 o.e a.a 1.0 1.2 1.4 1. 6 .i.  8 
NAPA AUC 
* * * ·1 0 0 0 2 0 0 0 3 A A A .. .. .. 6 a a a 6 7 
Clearance = 3.243 ml/min R squared = 0.903 
2.0 
4 
42 
3.7 Discussion 
The model used to fit this data consisted of a 
simultaneous two compartment procainamide equation and one 
compartment NAPA equation. Procainamide and its metabolites 
are of no clinical consequence in the peritoneal cavity and 
are poorly cleared through the peritoneum. For these 
reasons, it was appropriate not to follow the compounds 
dispositions in the peritoneal cavity and therefore treat 
the cavity as a terminal compartment. This simplifies the 
model and lessens the patient's inconvenience by avoiding 
serial sampling of dialysate. Drugs that fit this profile 
should be studied in a similar fashion. Peritoneal clear­
ances of procainamide and NAPA accounted for only a small 
part of total body clearance for these compounds, therefore 
a closed compartment model would be inappropriate. 
In our study the elimination half-life of procainamide 
in end stage renal disease patients during continuous ambu­
latory peritoneal dialysis ranged from 16.2 to 38.7 hours 
with a harmonic mean of 26 hours. In our population 40% to 
93% (mean 80%) of procainamide was metabolized to NAPA in 
the 72 hours of the study. Comparison of these procainamide 
elimination half-lives with other studies would be inconclu­
sive since the drug does exhibit at least bimodality of 
acetylator phenotype and rarely is the phenotype character­
ized. The elimination half-life for NAPA ranged from 26.3 to 
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66.6 hours with a harmonic mean of 42.9 hours. Serum samples 
were obtained for 72 or 96 hours so that the NAPA half-lives 
may actually be underestimated. The extended half-lives of 
the compounds along with their possible adverse effects 
complicates prescribing the drug in this population. 
The harmonic means for the volume terms of procainamide 
and NAPA were 4.7 1/kg and 1.46 1/kg respectively. When a 
bioavailability of .85 is assumed, these values convert to 4 
1/kg and 1.25 1/kg respectively. The procainamide volume 
term is larger than that reported by Gibson et al. (18) in 
patients with normal renal function as well as renal 
failure (2 1/kg). Since an oral dose of procainamide was 
used, perhaps the tablets were less bioavailable in this 
population. The volume term for NAPA is similar to that 
reported by Gibson et al. (18). 
Assuming the bioavailability as being .85, the harmonic 
mean total body clearance of procainamide adjusts to 121.6 
ml/min and that for NAPA is 25.3 ml/min. The population 
dialysate clearance regression plots (figures 8 and 9) show 
that the dialysate clearance of procainamide is 1.37 ml/min 
(R = 0.7) and for NAPA is 3.24 ml/min (R 0.9). This 
indicates that 1.1% of procainamide clearance is accounted 
for by peritoneal dialysis while 13% of NAPA total body 
clearance is accounted for by CAPO. The remaining clearance 
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might be due to residual renal function, further metabolism, 
and other routes of elimination. 
Procainamide is an antidysrhythmic that although is 
metabolized as well as eliminated renally, presents a dosing 
problem in treating patients with renal failure. The 
significantly prolonged half-lives of parent drug and meta­
bolite cause this dilemma. Figure 10 depicts a multiple dose 
simulation were the mean compartmental parameters of this 
study are used in our model to simulate a multiple dose 
regimen of 625 mg of procainamide every 12 hours for 10 
days. The SPICE2 (69) program is found in appendix K and the 
simulated levels are found in appendices u and V. This 
regimen was chosen because procainamide levels would remain 
between 2 and 8 mg/1 throughout the simulation. 
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N-acetylprocainamide levels rapidly accummulate and are 
still rising aft_er 10 days. This simulation demonstrates 
that the dosing regimen of procainamide, which is usually 
administered every 3 to 4 hours in patients with normal 
renal function, must be prescribed in a dosing regimen of at 
least every 12 hours during end stage renal disease.. The 
decision to use procainamide in an end stage renal disease 
patient on CAPO will commit the clinician to rigorous moni­
toring of the patient's serum levels and clinical presenta­
tion. Since peritoneal dialysis poorly_eliminates both the 
parent or the acetylated metabolite, the CAPO patient is 
likely to experience adverse effects due to accumulation of 
the compounds. One might hope to perhaps administer a 
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loading dose of procainamide and then find a dosing interval 
of perhaps every 24 hours where patient and clinician can 
exploit the metabolite's therapeutic effects while avoiding 
adverse effects. 
CHAPTER IV 
Pharmacokinetics of Phenytoin Sodium in Continuous 
Ambulatory Peritoneal Dialysis: The Peritoneal Cavity as 
Part of the Peripheral Compartment 
4.1 Introduction 
The basic and clinical pharmacology of phenytoin has 
been reviewed by Jones et al. (28). Phenytoin was the first 
antiepileptic that provided its therapeutic effect without 
sedation. It is effective in complex partial, elementary 
partial, and grand mal seizures. Phenytoin has also been 
indicated for the treatment of digoxin-induced dysrhythmias. 
The oral absorption of phenytoin sodium is approximated 
as 80% - 95% in the best formulations. It is recognized that 
due to the poor water solubility of unionized phenytoin, the 
size and form of the phenytoin acid crystals are a major 
determinant of bioavailability (28). 
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Protein binding of phenytoin in patients with normal 
renal function is approximately 90%. Unbound phenytoin dis­
tributes widely; the volume of distribution ranges from 1.6 
to 2.5 1/kg. It is found in physiologic fluids such as 
cerebrospinal fluid, saliva, and gastrointestinal fluid. 
Phenytoin is hydroxylated in the liver to its major 
metabolite 5-(p-hydroxyphenyl)-5-phenylhydantoin (HPPH), 
which has little or no anticonvulsant activity. 50 - 90% of 
a dose of phenytoin is accounted for by HPPH, 5% is excreted 
in the urine and the remainder is accounted for by minor 
non-active metabolites. Phenytoin as well as its metabolites 
are excreted in the bile and undergo enterohepatic recyc­
ling. 
Hydroxylation of phenytoin is known to be concentration 
dependent. Although Michaelis - Menten kinetics discribe the 
elimination of phenytoin, first order pharmacokinetics may 
be used at low concentrations. It is suggested that first 
order pharmacokinetics prevail when phenytoin concentrations 
are less than 0.1 times Km. When the concentration of pheny­
toin is greater than 10 times Km, metabolism proceeds at a 
constant rate (Vmax). The interpatient values of Km and Vmax 
are highly variable; patients with very low Km's present the 
greatest dosing challenge. Variablity of these parameters 
has been attributed to age, pregnancy, liver function, and 
drug interactions. 
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Phenytoin plasma levels of 10 to 20 mg/1 are considered 
to be in the therapeutic range. Central nervous system 
adverse effects are most often seen when plasma concentra­
tions exceed 20 mg/1. These include nervousness, hand 
tremor, ataxia, nystagmus, and diplopia. Long term use of 
phenytoin has been associated with peripheral neuropathy, 
hypocalcemia, osteomalacia, and gingival hyperplasia. The 
concentration range most often quoted includes bound and 
unbound phenytoin. Use of the 10 to 20 mg/1 range assumes 
that 10% of the drug is not bound to plasma proteins. 
Patients in renal failure are known to have lower concentra­
tions of albumin than normal and their binding capacity is 
questionable. Therefore the protein binding of phenytoin in 
renal failure patients deserves further discussion. 
Recently, Emilio Perucca reviewed the relevance of 
plasma protein binding of phenytoin to therapeutic drug 
monitoring (46). In reference to renal failure, he notes 
that the decreased bound fraction of phenytoin is highly 
correlated to depletion of albumin and severity of renal 
failure as reflected by serum creatinine level. This binding 
phenomena correlates so well with renal function that plasma 
binding capacity approaches normal values 10 to 15 days 
after renal transplantation. Apart from decreased albumin 
concenctration, decreased plasma binding of phenytoin in end 
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stage renal disease has been attributed to possible altera­
tion of albumin structure in uremia and the accumulation of 
endogenous binding inhibitors. The theory of accumulated 
binding inhibitors has provided a more convincing argument. 
The inhibitors of protein binding in uremia are character­
ized as consisting of readily reversible and less reversible 
inhibitors based on hydrodynamic and charcoal dialysis 
experiments. For these reasons, end stage renal disease 
patients will have higher free fractions of phenytoin and 
will require lower total concentrations than patients with 
normal renal function. 
Phenytoin is used in renal disease patients to treat 
uremia-induced seizures as well as coexisting seizure disor­
ders. Although approximately 5% of phenytoin is eliminated 
renally, this pharmacokinetic investigation of phenytoin in 
end stage renal disease patients during CAPD (34) had sever­
al objectives. The disposition of free phenytoin in this 
patient population has not been previously described. Since 
only free phenytoin passes through the peritoneum, it would 
be significant if a relationship existed between free plasma 
phenytoin concentration and dialysate phenytoin concentra­
tion. If the latter relationship did exist, then using end 
of dwell dialysate concentration as a measure of free pheny­
toin concentration might be a less expensive, less invasive 
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technique of monitoring phenytoin concentration in this 
patient population. 
4.2 Materials and Methodology 
This study included six end stage renal disease 
patients undergoing CAPD for six months to 1.5 years, and 
ranged in age from 26 to 72 years (Table 6). All patients 
were clinically stable and without evidence of peritonitis. 
None of the patients had known hypersensitivity to phenytoin 
and/or hepatic disease. Patients were excluded if they had 
ingested medications known to displace phenytoin from its 
binding sites (eg. warfarin, sulfamethoxizole, etc.). 
TABLE 6 Patient Demographics for the Phenytoin Study 
PATIENT I AGE SEX I WT. 
No. I yrs I kg 
I I --------1----- -----1-----
l I 53 M I 80.9 --------1----- -----1-----
2 I 26 M I 53. 9 --------1----- -----1-----
3 I 28 M I 60. o --------1----- -----1-----
4 I 72 F I 55. 5 --------1----- -----1-----
5 I 50 F I 75. 7 --------1----- -----1-----
6 I 38 F I 54. 5 
PRIMARY 
DIAGNOSIS 
----------
HN ----------
cou ----------
GN ----------
DN ----------
DN ----------
ORN 
DURATION Sr Cr mg/dl 
OF CAPD BUN mg/dl 
(months) Sr Alb gm/dl --------- ------------
6 >15,72,3.6 --------- ------------
7 7.8,40,3.4 --------- ------------
18 12.9,72,3.6 --------- ------------
7 8.5,56,2.9 --------- ------------
8 12.1,80,3.4 --------- _____ , _______ 
11 6.8,54,3.7 
GN, Glomerulonephritis; DN, Diabetic nephropathy; HN, Hyper­
tensive nephropathy; COU, Congenital obstructive uropathy, 
ORN, Obstructive reflux nephropathy. 
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Patients underwent a physical examination to determine 
eligibility. Peritonitis was ruled out on the basis of clear 
dialysate and absence of abdominal pain as well as an ab­
sence of clinical symptoms of infection. Each patient was 
completely drained of the preceeding dialysis dwell and then 
instilled with the first dwell of the study. Dialysis volume 
and dextrose concentration used during the 24 hours of the 
study was based on the patient's usual needs. All patients 
received 4 dialysate exchanges during the study. The first 
dwell for all patients lasted six hours, the second and 
third dwells lasted 4 hours each, and the final dwell lasted 
eight hours. Administration of phenytoin occurred immediate­
ly after the first dwell was instilled. 
A 5mg/kg dose of phenytoin (Dilantin, Parke Davis) Waf 
administered intravenously through an intravenous catheter 
placed in a forearm vein. The dose was infused over 15 
minutes while blood pressure was monitored every five mi­
nutes during the infusion. 
4.3 Sampling 
7 ml venous blood samples were collected in non-anti­
coagulated tubes through a heparin lock. Prior to each blood 
sample, 1 ml of blood was removed to clear the heparin lock 
of heparin, and discarded. Samples were drawn at o, 0.25, 
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0.5, 0.75, 1, 1.5, 2, 3, 4, 6, hours after the phenytoin 
infusion had started; 0.5, 1, 2, 4, hours after the second 
exchange began; 4 hours after the third exchange started; 
and 4 and 8 hours after the fourth exchange. After each 
blood sample, the heparin lock was flushed with 30units of 
heparin. Blood samples were allowed to clot, centrifuged, 
and the serum was harvested and frozen at -20 degrees C. 
Serial dialysate samples were obtained in the following 
manner. To be sure that the dialysate sample was not repre­
sentative of the peritoneal catheter alone, it was flushed 
by allowing approximately 100 ml of peritoneal fluid to 
drain into the attached dialysate bag. This aliquot was then 
reinstilled into the peritoneal cavity and another 100 ml 
aliquot was obtained. The sample was then obtained from this 
aliquot by puncturing the injection port of the dialysis bag 
using aseptic technique with a needle and 5 ml sterile 
syringe. End of dwell dialysate samples were also obtained 
from the dialysate bag after the patient had emptied the 
peritoneal cavity. The volume of dialysate removed from the 
patient was measured. All dialysate samples were immediately 
frozen at -20 degrees c. 
4.4 Analysis of Phenytoin Concentrations 
Free phenytoin was seperated from that bound to serum 
proteins by ultrafiltration using the Amicon Micropartition 
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System-1. Ultrafiltration was conducted by centrifuging the 
serum sample in the .Amicon filter for 15 minutes at 37 
degrees C. Total, free, as well as dialysate phenytoin 
concentrations were analyzed using fluorescence polarization 
immunoassay following the directions outlined by the 
manufacturer of the TDX system, Abbott Diagnostics. 
4.5 Pharmacokinetic Analysis 
A two compartment open model was used to descirbe the 
phentoin data. Plots of serum phenytoin concentration versus 
time (figures 12 to 17) showed no evidence of saturable 
elimination. Saturable elimination was not expected due to 
the low concentrations seen in this study. Since phenytoin 
is significantly bound to plasma proteins, protein binding 
was taken into account by fitting only the free serum pheny­
toin concentrations simultaneously with the dialysate 
concentrations. Table 9 indicated that the protein binding 
of phenytoin in this population exhibited little intraindi­
vidual or interindividual variation. Therefore each 
patient's free fraction was held constant in the model at 
their individual value. 
Unlike the procainamide/NAPA study, the concentration 
time profile of phenytoin in the peritoneal cavity was of 
interest. Therefore a model to describe this profile was 
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necessary. As was discussed earlier, modeling solute dispo­
sition across the peritoneum is an intricate undertaking due 
to varying ultrafiltration and volume. Since a volume marker 
in the peritoneal space was not used, alterations in volume 
due to ultrafiltration could not be determined. Intraperito­
neal administration of phenytoin to descriminate the 
peritoneum's contribution to the overall serum profile was 
not feasible due to questionable phenytoin bioavailability 
from the peritoneal cavity. Phenytoin is insoluble in 5% 
dextrose solutions in concentrations as low as 400 mg/1 
(67). Due to the poor solubility of phenytoin in dextrose 
solutions over the pH ranges in the peritoneal cavity 
(approximately pH 5 in fresh dialysate to pH 7 at the end of 
a dwell) for the residence time of the dialysate, adminis­
tration of phenytoin would be against good clinical and 
scientific judgment. For these reasons, this data was 
analyzed as if the peritoneal cavity was a sampling site to 
the peripheral compartment. This modeling technique is 
analogous to the common practice of sampling blood as a 
window to the central compartment. The model also assumed 
that free drug immediately equilibrated with bound drug and 
KlO accounted for any residual renal elimination as well as 
metabolism. 
It was judged that the variablity of ultrafiltration 
due to dextrose concentration and volume in the cavity as 
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well as the varied length of the dwells would only allow the 
data from the first dwell (six hours) to be fit with the 
serum data. It was thought that since both dextrose concen­
tration and length of dwell varied in the study, attempting 
to simultaneously fit all of the dialysate data as if the 
dwells were equal would only confuse the model. The equa­
tions for this model are as follows: 
Ko I 
Cfs IA*{K21 - Alpha)*exp{-Alpha*t) + 
� I_ 
Ko*Kl2 
Cdial 
Vp 
where: 
A 
B 
B*(K21 - Beta)*exp{-Beta*t) I eq. 24 
_I 
I I 
IA*exp(-Alpha*t) + B*exp(-Beta*t) I eq. 25 
I_ _I 
(1 - exp{Alpha*T)) 
-Alpha*(Beta - Alpha) 
(1 - exp{Beta*T)) 
-Beta*(Alpha - Beta) 
eq. 26 
eq. 27 
Ko = Infusion rate of phenytoin, Ve Free phenytoin volume 
of the central compartment, Vp = Free phenytoin volume of 
the peripheral compartment, Alpha = Distribution hybrid rate 
constant, and Beta = Elimination hybrid rate constant, and T 
= The length of the infusion. The remaining rate constants 
are intercompartmental rate constants depicted in figure 11. 
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FIGURE 11 Schematic of the model used to fit the phenytoin 
data. 
KlO I 
<---------1 
I 
Ko I 
Phenytoin 
Central 
I _____ _ 
Kl2 
-------------> 
<-------------
K21 
I 
Phenytoin I 
Peripheral I 
______ I 
Ko is the infusion rate constant of phenytoin, KlO is 
the elimination rate constant for phenytoin from the central 
compartment, Kl2 and K21 are the intercompartment rate con­
stants for phenytoin. 
Initial estimates of hybrid rate constants (Alpha and 
Beta) as well as the coefficients (A and B) of the biexpo­
nential equation describing phenytoin were obtained by using 
the program ESTRIP (64). All other initial estimates were 
derived algebraically. The free phenytoin serum data and 
dialysate data were then combined for each patient and 
reanalyzed simultaneously using NONLIN84 (39) where the 
model contained both disposition equations. All the data was 
weighted evenly. The subroutine DFUNC for this data is found 
in appendix G. 
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Peritoneal clearances (CLD) of each compound during 
individual dwells were calculated using: 
Amount of the compound removed during a dwell 
CLD ----------------------------------------------- eq. 28 
Area under the serum curve during a dwell (AUC) 
Area under the curve for each interval was obtained by 
integrating the central compartment disposition equation 
over the time interval of the dwell. The Beta volume of 
distribution was determined by: 
VB 
Ko*T 
AUCinf*Beta 
Total body clearance of phenytoin was calculated as: 
TBC 
Ko*T 
AUCinf 
eq. 29 
eq. 30 
Half-life of phenytoin was calculated in the usual manner 
(0.693/Beta). 
Linear regression analysis was used to determine if a 
relationship existed between free concentration of phenytoin 
in serum and dialysate concentration at the end of the dwell 
(table 11). 
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4.6 Results 
A low dose of phenytoin (5 mg/kg) was chosen for this 
study in order to minimize saturable elimination as well as 
to minimize adverse effects. Serum and dialysate concentra­
tions of phenytoin for the six patients are found in 
appendix C. They are also graphically depicted in figures 12 
through 17. Graphs 18 through 23 depict the free serum and 
dialysate as well as the predicted phenytoin concentrations 
from NONLIN84. (appendix G) .Since serum concentrations fell 
quickly at high concentrations, it was assumed that metabo­
lism was occurring at a first order rate. The coefficient of 
determination for the simultaneous fits. ranged from 0.83 to 
0.97, indicating that the model used described the data 
well. Appendix D contains the coefficients of variation for 
the parameters used to fit this data. The values ranged from 
0.04 to 0.25 with only six greater than 0.15. These low 
coefficients of variation indicate that the paramters con­
tain only a small amount of variability. 
Patient six showed an unexpected and unexplainable rise 
in dialysate phenytoin concentration at the end of the first 
dwell. The dialysate phenytoin concentrations of only pa­
tient 1 actually reached equilibrium with free phenytoin in 
the serum during the first dwell. Patients 2 and 3 very 
closely reached equilibrium in the same time. The dialysate 
concentrations near the end of the first dwell for patients 
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3 and 4 surpassed the free concentrations while the opposite 
was true for patients 5 and 6. From this small study it is 
not possible to confidently resolve whether at the end of a 
dwell if the dialysate levels are predictive of free pheny­
toin in the serum. 
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FIGURE 15 PHENYTOIN CAPD DATA Pt. 4 
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PHENYTOIN CAPD DATA Pt. 6 
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phenytoin are found in table 7. The micro-rate constants are 
found in table 16. Harmonic means and pseudostandard devia­
tions of half-life, volume terms, and clearance were also 
used to summarize this data. Arithmetic means and standard 
deviations are reported for all other parameters. Mean dial­
ysate clearance in this study was determined by regression 
of the amount removed versus area under the curve during the 
dwell (figure 24). Table 16 contains the dialysate data for 
this study. 
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Dialysate Clearance Plot of Phenytoin 
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TABLE 7 
7 8 
Pharmacokinetic Parameterd for Phenytoin in six CAPO 
Patients. 
PT I Alpha! Beta I T1/2 I VB I TBC Ve Vp 
# I 1/hr I 1/hr· I hr !liters! 1/hr I liters! liters 
-----1------1-------1------1------1--------1------- -------
1 14.500 I 0.02981 23.291 418.31 9.30 I 70.33 330.6 
-----1------1-------1------1------1--------1------- -------
2 11.657 I o.04801 14.441 341.21 16.38 I 185.4 135.1 
-----1------1-------1------1------1--------1------- -------
3 13.203 I 0.02691 25.791 357.61 9.66 I 97.18 240.7 
-----1------1-------1------1------1--------1------- -------
4 14.321 I 0.07511 9.231 296.91 22.26 I 85.17 179.2 
-----1------1-------1------1------1--------1------- -------
5 12.015 I o.02841 24.381 333.11 9.46 I 147.6 210.1 
-----1------1-------1------1------1--------1------- -------
6 12.599 I 0.03651 19.011 333. I 16.65 I 206.1 124.9 
-----1------1-------1------1------1--------1------- -------
mean 13.059 I 0.04081 17.00I 360.51 12.43 I 112.6 182.2 
-----1------1-------1------1---- -1--------1-------1-------
sd 11.169 I 0.01851 8.721 33.651 4.33 I 49.45 I 64.87 
Ka = absorption rate constant, Tl/2 = elimination half-life, 
VB = beta volume of distribution, TBC • total body clear­
ance, Ve = volume of the central compartment, Vp = volume of 
the peripheral compartment. 
TABLE 8 
Intercompartmental Rate Constants. 
PT I Kl2· K21 I KlO 
# I 1/hr I 1/hr I 1/hr -----1-------1-------1--------
1 I 3.572 I o.788 I 0.11 -----1-------1-------1--------
2 I o.674 I o.974 I 0.082 -----1-------1-------1--------
3 I 2.216 I 0.921 I 0.094 -----1-------1-------1--------
4 I 2.891 I 1.245 I 0.26 -----1-------1-------1--------
5 I 1.059 I o.985 I 0.06 -----1-------1-------1--------
6 I o.859 I 1.121 I 0.054 -----1-------1-------1--------
mean I 1.878 I 1.101 I 0.12 -----1-------1-------1--------
sd I 1.200 I o.339 I 0.080 
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The fraction of phenytoin bound to plasma proteins 
(free concentration/total concentration) is reported in 
table 9. Within patient binding variation was very small as 
demonstrated by the small standard deviations which ranged 
from 0.02 to 0.04. 
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TABLE 9 
Fraction of Phenytoin Bound to Plasma Proteins. 
PT jFraction S.D. jNumber of 
# I Bound I Samples 
-----1-------- -------1---------
1 I o.77 o.o3 I 14 
-----1-------- -------1---------
2 I o.83 o.o3 16 
-----1-------- ------- ---------
3 I o.76 0.02 16 
-----1-------- ------- ---------
4 I o.76 o.o4 16 
-----1-------- ------- ---------
5 I o.74 o.o3 16 
-----1-------- ------- ---------
6 I o.83 0.02 15 
-----1-------- ------- ---------
mean I 0.78 93 
-----1-------- ------- ---------
sd I 0.05 
Table 10 contains the dialysate data. Dialysate 
clearances are tabulated according to length of dwell. 
TABLE 10 
Phenytoin Dialysate Data. 
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DIALYSATE CLEARANCE (1/hr} 
Patient I 1st Dwell 12nd Dwell I 3rd Dwell I 4th Dwell 
# I 6 hours I 4 hours I 4 hours I 8 hours 
--------------1-----------1----------1-----------1----------
l I o.189 I o.487 I o.387 I o.374 
Final Vol. (1) I 3.555 2.385 I 2.154 I 3.175 
Initial Vol I 2.080 2.080 I 2.080 I 2.080 
% Dextrose I 4.25 2.5 I 2.5 I ? 
Phenytoin I I I 
Cone. (mg/1) I 0.37 0.62 I 0.54 I 0.48 
--------------1----------- ----------1-----------1----------
2 I 0.212 o.329 I o.304 I 0.16 
Final Vol. (1) I 1. 55 1. 6 I 1. 6 I 1. 85 
Initial Vol. I 1.565 1.565 I 1.565 I 1.565 
% Dextrose I 1. 5 2 • 5 I 1. 5 I 2 . 5 
Phenytoin I I I 
Cone. (mg/1) I 0.61 0.44 I 0.34 I 0.24 -------------- ---- ------1---------- ----------- ----------
3 0.185 I o.412 o.255 
Final Vol. (1) 1.39 I 1.84 1.8 
Initial Vol. 1.565 I 1.565 1.565 
% Dextrose 1. 5 I 2 • 5 1. 5 
Phenytoin I 
Cone. (mg/1) 0.73 I 0.61 0.33 
0.248 
2.2 
1.565 
4.25 
0.45 -------------- -----------1---------- ----------- ----------
4 0.201 0.402 
Final Vol. (1) 1. 6 1. 72 
Initial Vol. 1.565 1.565 
% Dextrose 2 . 5 2 . 5 
Phenytoin 
Cone. (mg/1) 
5 
Final Vol. (1) 
Initial Vol. 
% Dextrose 
Phenytoin 
Cone. (mg/1) 
6 
Final Vol. (1) 
Initial Vol. 
% Dextrose 
Phenytoin 
Cone. (mg/1) 
0.64 -----------
0.24 
2.5 
2.08 
2.5 
0.66 -----------
0.777* 
2.525 
2.08 
2.5 
1.4 
0.45 ----------
0.352 
2.6 
2.08 
? 
0.49 ----------
0.413 
2.4 
2.08 
? 
0.46 
0.37 
1.56 
1.565 
2.5 
0.33 -----------
0.327 
2.45 
2.08 
? 
0.46 -----------
0.474 
2.7 
2.08 
? 
0.38 
0.228 
1.975 
1.565 
4.25 
0.21 ----------
0.226 
2.75 
2.08 
? 
0.44 -----------
0.223 
2.55 
2.08 
? 
0.3 
* Identified as an outlier and not included in the dialysate 
regression plot. ? Not reported. 
71 
TABLE 11 
correlations of End of Dwell Dialysate and Free Serum 
Concenration. 
FREE FREE FREE FREE 
SERUM SERUM SERUM SERUM 
CONC. CONC. CONC. CONC. 
DWELL ONE -0.190 
DWELL TWO 0.430 
DWELL THREE 0.718 
DWELL FOUR 0.843 
4.7 Discussion 
The pharmacokinetic model treated the free phenytoin 
serum concentrations as if all the phenytoin in the central 
and peripheral compartments was unbound to plasma proteins. 
This is similar to modeling a drug such as digoxin as if 
there were no tissue binding in the central or peripheral 
compartment. Both analyses yield very large volume terms 
because of this binding. 
In this study, the elimination half-life of phenytoin 
in end stage renal disease patients during continuous ambu­
latory peritoneal dialysis ranged from 9.23 to 25.79 hours 
with a harmonic mean of 17 hours. These half-lives are 
similar to those reported in normals (56). However the fact 
that phenytoin exhibits saturable metabolism precludes com­
parison of the half-life in this study to those in other 
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studies. The harmonic mean beta volume of distribution (VB) 
when divided by the mean patient weight in this study (62.75 
kg) is 5.74 1/kg. This value is similar to the value (5.4 
1/kg) in 4 uremic patients studied by Odar-Cederlof and 
Borga (44). These authors found a smaller half-life (7.71 
hours) so that total body clearance in their study would 
naturally be larger. The dialysate clearance regression plot 
for phenytoin forced through zero (figure 24) shows that the 
dialysate clearance of phenytoin is 0.258 1/hr or 4.3 ml/min 
(R = 0.897). Total body clearance of phenytoin was 12.43 
1/hr which indicates that 2.1% of phenytoin clearance is 
accounted for by peritoneal dialysis. Therefore, CAPD does 
not account for appreciable elimination of phenytoin. 
The fraction of phenytoin bound to plasma proteins in 
these CAPD patients (78%) was lower than that expected in 
patients with normal renal function (90%). Similar protein 
binding values are reported by Odar-Cedarlof and Borga (44) 
in uremic patients. Reasons for lower fractional protein 
binding would be lower plasma protein concentrations 
(albumin levels ranged from 2.9 gm/dl to 3.8 gm/dl) or the 
continued presence of "middle molecular weight substances" 
that displace phenytoin and/or alter the binding ability of 
plasma proteins. The latter hints at the probability that 
CAPD does not remove enough of these "phantom" substances to 
allow normal protein binding. 
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One of the goals in the study was to investigate wheth­
er the peritoneal cavity would resemble an invivo equilibrium 
dialysis protein binding system. Graphs of free serum and 
dialysate phenytoin for patients 2 through 6 (figures 19 
through 23) show that the dialysate levels rarely maintain 
equilibrium with free serum levels and sometimes surpass 
them. Table 11 which shows the correlations of end of dwell 
dialysate versus free serum concentration indicates that the 
best correlations occur as steady state is approached. This 
may be explained by realizing that at these times total body 
distribution is over and the body is closer to equilibrium. 
For these reasons, a single dwell may not adequately mimic 
an equilibriium dialysis system. Therefore it is recom­
mended that end of dialysate phenytoin concentrations be 
used cautiously to reflect free phenytoin concentrations. 
The model used to fit this data consisted of a two 
compartment phenytoin equation where the peritoneal cavity 
was assumed to represent a sampling site for the peripheral 
compartment. The concentration time profile in the perito­
neal cavity was followed to ascertain whether dialysate 
concentration would be equal to free serum concentration at 
the end of a dwell. The profile might also help determine 
whether the peritoneal space functions as an invivo equilib­
rium dialysis protein binding system. As the free serum 
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concentrations were of interest, it was appropriate to model 
the free serum concentrations and not the total concentra­
tion. 
The best way to have studied distribution of phenytoin 
into the peritoneal compartment would have been to adminis­
ter phenytoin intraperitoneally after allowing adequate wash 
out from the intravenous part of the study. An example of 
such a study was recently published by Janike et al (25). 
They studied cefamandole pharmacokinetics during CAPD where 
the drug was administered intravenously as well as intraper­
itoneally in two different legs of the study. Blood as well 
as dialysate samples were obtained in both studies. Since 
the volume of the peritoneum is small in relation to the 
rest of the body, intraperitoneal administration of the drug 
provides elucidation of the contribution of the peritoneal 
space as an identifiable compartment. The advantage to con­
ducting a study in such a fashion is that the peritoneal 
cavity is uniquely identified along with overall distribu­
tion in the body. As mentioned earlier, poor solubility and 
questionable bioavailability of phenytoin from the invivo 
dialysate precluded intraperitoneal administration. 
The use phenytoin in an end stage renal disease patient 
on CAPD will require intense monitoring of the patient's 
serum levels and clinical presentation. After administration 
of a loading dose, maintenance doses should be adjusted by 
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monitoring free phenytoin concentrations. Since this study 
used an intravenous dose, speculation on adequate oral 
maintenance doses due to unknown bioavailability in these 
patients cannot be made. This patient population would pro­
bably require prolonged hospital stay to titrate phenytoin 
dose. CAPO does not appreciably remove phenytoin and its 
effect on the phenytoin metabolites is unknown. 
CHAPTER V 
Theoretical Discussion of Closed Compartment Pharmacokinetics 
5.1 Introduction 
The preceding chapters described pharmacokinetic stu­
dies in CAPO that were appropriately fit to open models. 
Vancomycin is an antibiotic that is cleared from the body 
almost completely by the kideys. Patients in end stage renal 
disease are functionally if not anatomically anephric so 
that vancomycin disposition in these patients can be de­
scribed by a closed model. During CAPO, intradwell periods 
can be modeled by closed compartment pharmacokinetics since 
the drug remains invivo. Comprehensive discussions of closed 
compartment pharmacokinetics do not exist. For this reason, 
the vancomycin study is preceded by an admittedly lengthy 
treatise on closed compartment pharmacokinetics. 
Most often, when concentration time data are fit to a 
pharmacokinetic model, an "open" model is used. "Open" 
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pfiarmacokinetic models allow an exit from the model for the 
substance of interest. Many equations, theories, and overall 
characteristics for this type of model have been developed 
and are widely recognized. For instance, it is well known 
that as long as the xenobiotic does not exibit saturable 
elimination in the concentration range of interest, total 
body clearance will be constant. The reader need only 
consult one of the vast number of basic pharmacokinetic 
texts to appreciate how well the concepts involved in "open" 
model pharmacokinetics have been studied and characterized. 
In a "closed" model on the other hand, exit from the 
model is not allowed. No exit from the model means that 
although the xenobiotic is free to flow anywhere within the 
model, the substance can not undergo excretion in its parent 
form nor is it metabolized. In the majority of animals, for 
a majority of xenobiotics, a closed model does not apply 
because elimination in some form occurs throughout the time 
that the substance is in residence. Although the concept of 
a "closed" model is unfamiliar to most pharmacokineticists, 
any scientist who has read or actually conducted an equilib­
rium dialysis protein binding experiment has dealt with 
"closed" compartment kinetics. An example of an instance 
where "closed" compartment pharmacokinetics would apply 
would be for a drug that is eliminated via the renal route 
but is administered to a patient in end stage renal disease. 
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Unless the patient is dialyzed, the drug would remain with 
the patient. Commonly, "open" models are used to describe 
the distribution of xenobiotics in this patient population. 
Only recently has an attempt been made to apply the "closed" 
model concept to pharmacokinetics (60). 
5.2 Derivation of a two compartment closed model 
The equations that describe distribution in a "closed" 
model are derived as follows. The derivations are of a two 
compartment model since drugs described by two compartment 
models are commonly encountered. Let C represent the amount 
of drug in the compartment into which drug is initially 
dosed. Let P represent the amount of drug in the peripheral 
compartment. A bolus input will be assumed. 
dC 
dt 
P*K21-C*Kl2 eq. 31 
dP 
dt 
C*Kl2-P*K21 eq. 32 
The LaPLace transform of which is: 
sC-Co P*K21-C*Kl2 eq. 33 sP-Po C*Kl2-P*K21 eq. 34 
sC+C*Kl2 P*K2l+Co eq. 35 sP+P*K21 C*Kl2+Po eq. 36 
P*K21 + Co C*Kl2 + Po 
C ------------ eq. 37 p ------------- eq. 38 
s + Kl2 s + K21 
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By substituting equations 37 and 38 into equations 33 and 34 
the following equations are produced: 
(C*K12 + Po)K21 
sc - Co --------------- - CK12 
s + K21 
(P*K21 + Co)K12 
sP - Po --------------- - PK21 
s + K12 
Rearranging equations 39 and 40, the amount of drug in 
either compartment can be determined. 
c 
Co(s + K21) + Po*K21 
(s + K21) (s + K12)-K12*K21 
Po(s + K12) + Co*K12 
p 
(s + K21) (s + K12)-K12*K21 
When the drug is dosed into c, Po = 0: 
c 
Co(s + K21) 
(s + K21) (s + K12)-K12*K21 
Co*K12 
p 
(s + K21) (s + K12)-K12*K21 
Rearranging equations 43 and 44: 
C 
sea + Co*K21 
s(s + K12 + K21) 
eq. 39 
eq. 40 
eq. 41 
eq. 42 
eq. 43 
eq. 44 
eq. 45 
Co*Kl2 
p 
s(s + K12 + K21) 
Using Anti-LaPlace forms to solve for C: 
As + B 
(s + a) (s + b) 
(B - A*a)e - (B - A*b)e 
b - a 
where A =  Co, B = CoK21, a =  K12 + K21, b o. 
Taking the Anti-LaPlace and rearranging: 
Co(K12*exp(-t(Kl2 + K21)) + K21) 
C = --------------------------------
K12 + K21 
Using Anti-LaPlace forms to solve for P: 
A A 
s(s + a) a 
(1 - exp(-a*t)) 
where A CoK12, a =  (K12 + K21). 
Taking the Anti-LaPlace and rearranging: 
At t 
Css 
p 
Co*K12(1 - exp(-t(K12 + K21)) 
K12 + K21 
o, c = Co and P 
Co*K21 
o. At t = infinity: 
Co*K12 
eq. 51 Pss 
K12 + K21 K12 + K21 
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eq. 46 
eq. 47 
eq. 48 
eq. 49 
eq. 50 
eq. 52 
One of the most interesting characteristics of the 
equations thus far, is that the exponent is the sum of the 
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intercompartmental rate constants multiplied by time. In 
open model pharmacokinetics, the exponent contains a hybrid 
of the intercompartmental rate constants derived from the 
roots of a polyexponential equation (17). The exponent asso­
ciated with the elimination phase in open models is used to 
find the elimination half-life of the compound and used to 
predict when steady state will occur. Elimination half-life 
has no meaning in closed models since there is no elimina­
tion of the compound from the model. A closed model does 
approach an equilibrium where there is no net flux in the 
model. The time that this steady state or a fraction of it 
occurs can be calculated. 
Expansion of equation 48 yields: 
Where Css 
Co*Kl2*exp(-t(K12 + K21)) Co*K21 
------------------------- + ---------
K12 + K21 
Co*K21 
K12 + K21 
K12 + K21 
eq. 53 
eq. 54 
Ct - Css the amount of xenobiotic left to be transferred 
into the peripheral compartment at time = t. 
Co - Css = the amount that will have been transferred into 
the peripheral compartment by time = steady state 
(Tss). 
Ct - Css 
-------- =the fraction remaining to be transferred into the 
Co - Css peripheral compartment at time = t. 
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1 -
Ct - Css 
Co - Css 
= the fraction transferred into the peripheral 
compartment as of time = t (also the fraction 
of steady state, Fss). 
ct - Css 
1 - ----------
Co - Ct 
Fss 
Co - Css Co - Css 
where Fss < or 1. 
Since from equations 54 and 48 Css 
Co*K21 
--------- and 
K12 + K21 
Co(K12*exp(-t(K12 + K21)) + K21) 
Ct --------------------------------
K12 + K21 
substitutiion yields Co - Ct = 
Co(K12 + K21) - Co(K12*exp(-t(K12 + K21)) + K21) 
K12 + K21 
and Co - Css 
Co(K12 + K21) - CoK21 
K12 + K21 
eq. 55 
eq. 56 
eq. 57 
Further substitution into equation 55 and rearrangement 
yields an equation that describes the time course to 
equilibrium. 
Fss 
ln (1 - Fss) 
-(K12 + K21) 
1 - exp(-t(K12 + K21)) 
Time to a fraction of steady 
state (Tfss). 
eq. 58 
eq. 59 
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The above equation can be used to find the time it 
takes to achieve one half of steady state. When Fss = .5, 
ln(l - Fss) = -0.6932. Therefore, the "steady state half­
life (Tl/2ss)" = 0.6932/(K12 + K21). Although not directly 
comparable to the half-life one is accustomed to in open 
model pharmacokinetics, the steady state half-life can be of 
value in closed model pharmacokinetics. T1/2ss follows a 
geometric progression just as the more common half-life 
does. Therefore, it would take five T1/2ss to achieve 97% of 
steady state or transfer 97% of what will ever be trans­
ferred into the peripheral compartment. Subsequent doses 
disturb the previous equilibrium so that an new steady state 
is achieved after each dose. 
The term for the volume of compartment C that has had 
drug cleared from it per unit time (clearance) into compart­
ment P can also be derived. In an open model, eventually all 
of the administered drug will be eliminated from the central 
compartment which produces a finite area under the curve for 
the central compartment. This is not true of a closed model. 
In a closed model, there will always be some amount of drug 
remaining in compartment C so that the area under the curve 
for that compartment will be infinite. Therefore total 
amount eliminated at steady state divided by the area under 
the curve to steady state is not a valid equation for clear­
ance from compartment c. Looking at the amount in compart-
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ment P as the total amount excreted produces a viable way to 
discuss clearance in a closed model. 
p 
Co*Kl2(1 - exp(-t(K12 + K21)) 
K12 + K21 
The rate by which P accumulates is given by: 
dP 
Co*K12*exp(-t(Kl2 + K21)) 
dt 
Instantaneous clearance 
dP 
dt 
Ct 
where Ct 
C 
Ve 
eq. 50 
eq. 60 
eq.61 
Substituting equations 48 and 60 into equation 61 yields the 
equation for the time course of clearance in a two compart­
ment closed model. 
Clearance 
K12*exp(-t(K12 + K21)) * (K12 + K21)Vc 
K12*exp(-t(K12 + K21)) + K21 
eq. 62 
Equation 62 for clearance indicates that at time = 
zero, clearance is equal to Vc*K12 but goes to zero at time 
= infinity (steady state). This nonconstant clearance is due 
to the fact that net transfer of the model goes to zero at 
steady state. From the above equation, -time to a fraction of 
85 
maximal clearance Fc*CLRo, can be calculated. Fe is less 
than 1 and CLRo is equal to Vc*K12. Equation 62 is rewritten 
as: 
K12*exp(-t(K12 + K21)) * (K12 + K21)Vc 
Fc*Vc*Kl2 ------- ------------------------------ eq. 63 
Kl2*exp(-t(K12 + K21)) + K21 
and rearranged as: 
Fc*K21 
(K12 + K21 - Fc*K12) 
I Fc*K21 I 
I ----------------- I 
ln I K12(1 - Fe) + K21 I 
I_ _I 
-(K12 + K21) 
exp(-t(K12 + K21)) 
Time to a fraction of 
maximal clearance (Tfc). 
Fe < or = 1. 
The equation to calculate Fe at any time is: 
Fe 
exp(-t(K12 + K21)) * (K12 + K21) 
K12exp(-t(K12 + K21)) + K21 
eq. 64 
eq. 65 
eq. 66 
When a dose is administered into the nonsampling compart­
ment, the equations for the amount in each compartment are 
written as follows: 
C 
Po*K21 
--------- (1 - exp(-t(K12 + K21))) 
K12 + K21 
eq. 67 
p 
Po(K21*exp(-t(K12 + K21)) + K12) 
K12 + K21 
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eq. 68 
In this case at t O, C O and P Po. At t = infinity; 
Css 
Po*K21 
K12 + K21 
Ct 
eq. 69 Pss 
Po*K12 
K12 + K21 
eq. 70 
Fss eq. 71 Fss 1 - exp(-t(K12 + K21)) eq. 72 
Css 
ln(l - Fss) 
-(K12 + K21) 
Time to Fss*Css. 
Fss < or =  1 
Clearance 
K21*exp(-t(K12 + K21)) * (K12 + K21)Vp 
K21*exp(-t(K12 + K21)) + K12 
I Fc*K12 I I ----------------- I 
ln I K21(1 - Fe) + K12 I 
I_ _I 
-(K12 + K21) 
Time to a fraction of 
of maximal clearance 
(Tfc). 
Fe 
exp(-t(K12 + K21)) * (K12 + K21) 
K21*exp(-t(K12 + K21)) + K12 
eq. 73 
eq. 74 
eq. 75 
eq. 76 
Patients in the end stage of renal disease (creatinine 
clearance of less than 20 ml/min) can exhibit closed 
compartment pharmacokinetics for xenbiotics or their metabo­
lites that are eliminated renally. Of special interest, is 
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the end stage renal disease patient who uses· continuous 
ambulatory peritoneal dialysis (CAPO) to remove metabolic 
waste products from their general circulation. The kinetics 
of physiologic substances across the peritoneal membrane 
have been discussed. CAPO is an interesting example ·of 
closed compartment pharmacokinetics because not only does 
the patient have no significant site of elimination for 
substances that are primarily excreted in urine, but allows 
sampling and administration of a substance into a peripheral 
compartment. The literature abounds with open compartment 
pharmacokinetic papers on the pharmacokinetics of drugs 
during CAPO. This will be the first serious look at the 
process as a closed model that will outline characteristics 
of the model. 
5.3 Simulations of two compartment closed models 
Before a model is applied to a clinical situation, 
simulation of the basic model should be performed. First the 
characteristics and behavior of the model are delineated so 
as to later assist in prediction of the model's performance 
when its constraints are tested. Simulations of the model 
test their performance under theoretical instances thereby 
facilitating application of the model to the actual problem. 
Simulations will be performed using the network thermo­
dynamics program called SPICE2(69). SPICE2 is a computer 
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simulations program written at the University of California 
at Berkley that was designed for the electrical engineering 
discipline. However, as Thakker (66) has shown, the electri­
cal symbols used in the program can be easily translated 
into pharmacokinetic terms. Voltage can be thought of as 
concentration (mass/volume), current as flow (mass/ time), 
capacitance as volume, and a node as a compartment. Further 
flexibilty is attained by using "dependent sources". Concen­
tration dependent flow is provided by a G element, concen­
tration dependent concentration is provided through an E 
element, flow dependent concentration is simulated through 
an F element, and an H element will provide flow dependent 
flow. A major strength of the program is that using the 
program only requires a mechanistic understanding of the 
model such as which compartments are connected to each other. 
Differential equations or their sometimes cumbersome inte­
gral counterparts are not used. Therefore SPICE2 lends it­
self quite nicely to the discipline of pharmacokinetics and 
also simulation of the distribution of xenobiotics in closed 
models. The programs that were submitted to SPICE2 for 
simulation are found in appendices L through P. 
Of interest in these simulations, was how changing the 
relationship of the rate constants to each other and the 
volume of each compartment effected the overall distribution 
of the compound. It was also important to investigate conse-
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quences of assuming a closed model when in fact, the model 
was actually open. Since in CAPO, the volume of the perito­
neal cavity changes with time, the effect of allowing the 
peripheral compartment to change during the simulation was 
investigated. 
5.3.1 Closed compartment simulations where Ve = 10 liters 
and Vp = 2 liters. Bolus dose (Co) of 100mg into 
compartment c. 
The first simulations are of a two compartment closed 
model where the volume of the central compartment (where the 
bolus dose is administered) has a value of 10 liters and the 
peripheral compartment has a volume of two liters. To inves­
tigate the relationship of the rate constants (Kl2 and K21) 
to the distribution profile of the model, a starting point 
from which to simulate around was necessary. At steady 
state, one might expect that the concentrations in each 
compartment would be equal. The equation for the change in 
concentration in the central compartment is: 
dCc*Vc 
Cp*Vp*K21 - Cc*Vc*Kl2 eq. 77 
dt 
where: 
Cc is the concentration in the central compartment, 
Cp is the concentration in the peripheral compartment, 
Ve is the volume of the centrtal compartment, 
Vp is the volume of the peripheral compartment, 
Kl2 and K21 are rate constants, and t is time. 
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At steady state, dCc*Vc/dt is equal to zero and 
Cc*Vc*Kl2 is .equal to Cp*Vp*K21. If tc and Cp are equal, 
then Vc*Kl2 must equal Vp*K21. The values of the volume 
terms in this simulation are Ve = 10 liters and Vp = 2 
liters. Dose into the central compartment (Co) was 100 mg. 
To give the model a half-life of accumulation into the 
peripheral compartment (Tl/2ss) a value of 10 hours, Kl2 + 
K21 would equal 0.0693 1/hr. Substituting 0.0693 - Kl2 for 
K21 further substitution of the volume values and rear­
rangement produces; 
10*Kl2 
12Kl2 
Kl2 
K21 
2(0.0693 - Kl2) 
0.1386 
0.01155 1/hr 
0.05775 1/hr. 
The concentration versus time profile for the case where Kl2 
= 0.01155 1/hr and K21 = 0.05775 1/hr is shown in figure 25. 
FIGURE 25 
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Using the equations derived earlier, the following 
characteristics are determined: 
Ccss = 8.33 mg/1 
Tl/2ss = 10 hrs 
Time to 97% of steady state (T97%) = 50 hrs 
Concentration in c at that time is (Ccss97%) 8.38 mg/1 
Concentration in P at that time (Cpss97%) = 8.07 mg/1. 
The graph and the output (Table 12) of the simulation 
verify these results. Because SPICE2 does not use any of the 
equations in its simulation, the results demonstrate that 
the derivation of the equations and the equations themselves 
are correct. 
TABLE 12 
Two compartment closed model where Ve = 10 liters and Vp 2 
liters. Bolus dose (Co) of 100mg into compartment C. Kl2 
0.01155 1/hr, K21 0.05775 1/hr. 
Time Cc Cp !Clearance Kl2 K21 I Net 
I flow flow I flow 
hrs mg/1 mg/1 I 1/hr mg/hr mg/hr I mg/hr -------- -------- --------,--------- ------- --------,------
0.0000 10.0000 0.0000 I 0.1155 1.1550 0.0000 I 1.1550 
10.0000 9.1674 4.1628 I 0.0630 1. 0588 0.4808 j0.5780 
20.0000 8.7499 6.2505 I 0.0330 1.0106 0.7219 j0.2887 
30.0000 8.5416 7.2919 I 0.0169 0.9866 0.8422 j0.1443 
40.0000 8.4372 7.8138 I 0.0085 0.9745 0.9025 j0.0720 
50.0000 8.3853 8.0733 I 0.0043 0.9685 0.9325 j0.0360 
60.0000 8.3593 8.2036 I 0.0022 0.9655 0.9475 j0.0180 
70.0000 8.3463 8.2684 I 0.0011 0.9640 0.9550 j0.0090 
90.0000 8.3366 8.3172 I 0.0003 0.9629 0.9606 10.0022 
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Figure 26 shows that a1i the f_lows incl.uding clearance 
. . . 
from compartment C tend to ziro. The reason :for this· is that 
the model becomes static .at steady state. The following 
cl.earance characteristics can be calculated using their 
respective equations: 
Clro = 0.1155 1/hr 
Fe at 97% steady state .(Fc97%ss) = 0.04 
Time to 0.5 of maximal clearance (Tfc.5) 11. 38 hrs. 
Again, figure 26 and table 12 verify the equations used 
to find the above characteristics. 
FIGURE 26 
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Figures 27 and 28 demonstrate the res·u1ts when the 
values of Kl2 and K21 are reversed. Figures 29 and 30 as 
well as figures 31 and 32 are simulations of the model when 
one of the rate constants is between 0.01155 and 0.05775 
while the other is set at 0.05775. Figures 33 and 34 show 
the result when both rate constants are equal to 0.05775 
which completes this series of simulations where the volume 
of compartment c is 10 liters and the volume of compartment 
Pis 2 liters. The simulation output for figures 27 through 
34 are in appendix W. The programs are found in appendix L. 
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FIGURE 34 
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These figures show that although all the flows tend 
toward zero, only when Vc*Kl2 = Vp*K21 will the concentra­
tion in the central compartment equal the concentration in 
the peripheral compartment. In all other cases, the concen­
tration in compartment P will always be greater than the 
concentration in compartment C. This is due to the fact that 
Vp is 5 times smaller than Ve. Cc will only approach Cp when 
the amount in c is 5 times greater than the amount in P. 
This is seen in figure 36. 
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Figure 35 is a graph that compares the clearance versus 
time profiles for the above simulations. Of note is the 
observation that the curves vary in shape from a sigmoid 
type (when Kl2 is 5 times greater than K21) to a 
logarithmic curve. This is explained by the denominator of 
the clearance equation 62. 
Clearance 
K12*exp(-t(K12 + K21)) * (K12 + K21)Vc 
K12exp(-t(K12 + K21)) + K21 
eq. 62 
When the K12 is much greater than K21, the denominator 
is dominated by the larger rate constant, K12. Early on, the 
effect is that clearance falls rapidly due to a large denom­
inator. At the time point when K12*exp(-t(K12 + K21)) 
approaches and becomes smaller than K21, K21 begins to 
dominate the denominator. Now the denominator resembles the 
more constant form of the other simulations and the rate of 
change in clearance decreases. The characteristics of the 
simulations shown in figures 25, 27, 29, 31, and 33 are 
found in table 13. 
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TABLE 13 
Two compartment closed model where Ve = 10 liters and Vp 2 
liters. Bolus dose (Co) of 100mg into compartment C. 
K12 I 0.01155 
K21 I 0.05775 
------1---------
Ccss I 
mg/1 8.33333 ------ ---------
Cpss 
mg/1 8.33333 ---------
Tl/2ss 
0.057751 0.030001 
0.01155 0.05775 -------- --------
1.66667 6.58120 -------- --------
41.66667 17.09402 -------- --------
0.057751 0.05775 
0.030001 0.05775 ---------1---------
1 
3.418801 5.00000 ---------1---------
1 
32.905981 25.00000 
hrs 10.00000 10.00000 7.89744 7.89744 6.00000 
Tfss97% 
hrs 49.66839 49.66839 39.22529 39.22529 29.80103 ---------1-------- -------- --------- ---------
Ccss97% 
mg/1 8.38667 1.93333 6.69060 3.62940 5.16000 
Cpss97% 
mg/1 
Clro 
1/hr 
Clrss97% 
1/hr 
Fc97%ss ------
Tfc.5 
hrs 
8.06667 
0.11550 
0.00441 ---------
0.03816 ---------
11. 37745 
40.33333 16.54701 31.85299 24.20000 -------- -------- ---------1---------
1 
0.57750 0.30000 0.577501 0.57750 -------- -------- ---------1---------
0.09559 --------
0.16552 --------
28.07951 
1 I 
0.014351 0.050921 0.03581 
--------1---------1---------
1 I 
0.047831 0.088171 0.06202 --------1---------1---------
1 I 
10.530521 15.582521 9.51179 
Ccss = steady state concentration in compartment C, Cpss 
steady state concentration in compartment P, Tl/2ss = time 
to get to one half steady state, Tfss97% = time to get to 
97% steady state, Ccss97% = the concentration in C at 97% of 
steady state, Cpss97% = the concentrtation in compartment P 
at 97% of steady state, Clro = Clearance at zero time, 
Clrss97% = clearance at 97% of steady state, Fc97%ss = the 
fraction of maximal clearance at 97% of stedy state, Tfc.5 = 
time to get to one-half of maximal clearance. 
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5.3.2 Closed compartment simulations where Ve = 10 liters 
and Vp = 2 liters. Bolus dose (Po) of 100mg into 
compartment P. 
Figures 36 through 46 are graphs obtained when the 
above model is simulated with the dose being administered 
into compartment P. Figures 36 and 37 are of the case where 
Vc*Kl2 = Vp*K21. As in the previous set of simulations, this 
is the only case where the concentrations of the compart­
ments will equal each other at steady state. In all other 
cases, the concentration compartment P is greater than that 
in compartment c at steady state. Figure 46 is a graph 
depicting the clearance versus time profiles for this set of 
simulations. Of note is: 1) the clearances are much smaller 
than those of the simulation where the dose was administered 
into compartment C; 2) the sigmoid shaped curve occurs 
again, but this time in the case where Kl2 = 0.01155 and K21 
= 0.05775. This is due to the fact that although the clear­
ance equation for peripherally administered dose is of the 
same form as when the dose is administered into C, the rate 
constants are now switched. 
K2l*exp(-t(Kl2 + K21)) * (Kl2 + K2l)*Vp 
Clearance -------------------------------------- eq. 74 
K2l*exp(-t(Kl2 + K21)) + Kl2 
The denominator of the clearance equation explains the 
shape of the sigmoid curve. Due to the five fold difference 
between Kl2 and K21 , the denominator switches form once the 
left hand side of the denominator is less than Kl2. 
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CLOSED COMPARTMENT KINETICS 
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CLOSED COMPARTMENT KINETICS 
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CLOSED COMPARTMENT KINETICS 
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CLOSED COMPARTMENT KINETICS 
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FIGURE 46 
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Table 14 displays the characteristics of this set of 
simulations. The output from the Spice2 program can be found 
in appendix x. The Spice2 input program listing is found in 
appendix M. 
108 
TABLE 14 
Two compartment closed model where Ve = 10 liters and Vp = 2 
liters. Bolus dose (Po) of 100mg into compartment P. 
Kl2 = 0.011551 0.057751 0.03000 0.057751 0.05775 
K21 = 0.057751 0.011551 0.05775 0.030001 0.05775 
-------- --------1---------1--------- ---------1---------
Ccss I I I 
mg/1 8.333331 1.666671 6.58120 3.418801 5.00000 
-------- --------1---------1--------- ---------1---------
Cpss I I I 
mg/1 8.333331 41.666671 17.09402 32.905981 25.00000 
-------- --------1---------1--------- ---------1---------
Tl/2ss I I I 
hrs 10.000001 10.000001 7.89744 7.897441 6.00000 
-------- --------1---------1--------- ---------1---------
Tfss97% I I I I I 
hrs 149.668391 49.668391 39.225291 39.225291 29.80103 
--------1--------1---------1---------1---------1---------
Ccss97% I I I I I 
mg/1 I 8.066671 1.613331 6.370601 3.309401 4.84000 
--------1--------1--------- ---------1---------1---------
Cpss97% I I I I 
mg/1 I 9.666671 41.93333 18.147011 33.452991 25.80000 
--------1--------1--------- --------- ---------1---------
Clro I I I 
1/hr I 0.115501 0.02310 0.11550 0.060001 0.11550 
--------1--------1--------- --------- ---------1---------
Clrss97%1 I I 
1/hr I 0.019121 0.00088 0.01018 0.002871 0.00116 
--------1------- 1--------- --------- ---------1---------
1 I I 
Fc97%ssl 0.165521 0.03816 0.08817 0.047831 0.06202 
--------1--------1--------- --------- ---------1---------
Tfc.5 I I I 
hrs 128.079511 11.37745 15.58252 10.530521 9.51179 
Ccss = steady state concentration in compartment c, Cpss = 
steady state concentration in compartment P, Tl/2ss = time 
to get to onehalf steady state, Tfss97% = time to get to 97% 
steady state, Ccss97% = the concentration in C at 97% of 
steady state, Cpss97% = the concentrtation in compartment P 
at 97% of steady state, Clro = Clearance at zero time, 
Clrss97% = clearance at 97% of steady state, Fc97%ss = the 
fraction of maximal clearance at 97% of stedy state, Tfc.5 = 
time to get to one-half of maximal clearance. 
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Comparing table 14 to table 13, we find that the 
values for Ccss, Cpss, Tl/2ss, and Tfss97% are the same. 
This is due to the fact that the equations for these parame­
ters are the same and the doses are the same. This indicates 
that steady state concentrations and half-life are indepen­
dent of location of the dose. Ccss97% and Cpss97% are 
different than those found in table 13. The reason for this 
is that the dose is in compartment Pin table 14 so that 
the steady state concentrations are approached in different 
directions. Initial clearance in this simulation is calcu­
lated as Vp * K21. Since Vp is much smaller than Ve, Clro in 
table 14 is smaller than the same parameter in table 13. For 
the same reason, Clrss97% will also be smaller in this case. 
5.3.3 Closed compartment simulations where Ve = 10 liters 
and Vp = 10 liters. Bolus dose (Co) of 100mg into 
compartment c 
In the next simulations, the two compartments will 
be of equal volume. The compartments will be indistinguish­
able so that the compartment that will receive the dose will 
be named c and the other P. The rate constants between the 
compartments will remain as they were in the previous simu­
lations. Figures 47 through 57 depict the concentration, 
flow, and clearance profiles for these simulations. These 
SPICE2 programs are found in appendix N. 
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CLOSED COMPARTMENT KINETICS 
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FIGURE 57 
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In this set of simulations, only when Kl2 = K21 are 
the steady state concentrations equal (figure 55). When the 
volumes of the two compartments are equal, the steady state 
concentrations are soley dependent on the ratio of the rate 
constants between the compartments. 
Ccss K21 
Cpss Kl2 
eq. 78 
As figures 47 and 51 demonstrate, when K21 is greater 
than K12, Ccss will be larger than Cpss. When the opposite 
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is true, Cpss surpasses Ccss (figures 49 and 53). The clear­
ance curves for this set of simulations is depicted in 
figure 57. These curves are superimposible on figure 35 
since the clearances of the two sets of simulations are the 
same. The output of these simulations are found in appendix 
Y. 
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TABLE 15 
Two compartment closed model where Ve = 10 liters and Vp 
10 liters. Bolus dose (Co) of 100mg into compartment c. 
Kl2 I 0.01155 I 0.057751 0.030001 o.057751 o.05775 
K21 = I 0.05775 I 0.011551 0.057751 0.030001 0.05775 
------ ---------1--- ----1--------1---------1---------
Ccss I I I I 
mg/1 8.33333 I 1.666671 6.581201 3.418801 5.ooooo 
Cpss 
mg/1 
Tl/2ss 
hrs 
Tfss97% 
--------- --------1--------1---------1---------
1.66667 
I I I 
8.333331 3.418801 6.5812 I 5.ooooo 
--------- --------1--------1---------1---------
I I I 
10. 00000 10. 00000 7. 897 44 I 7. 897 44 I 6. 00000 
--------- -------- --------1---------1---------
1 
hrs 49.66839 49.66839 39.225291 39.22529 29.80103 ------1---------
Ccss97% 
mg/1 8.38667 
-------- --------1--------- ---------
1 
1.93333 6.690601 3.62940 5.16000 ------ --------- -------- --------1--------- ---------
Cpss97% 
mg/1 1. 61333 
1 
8.06666 3.309401 6.3706 4.84000 ------ --------- -------- --------1--------- ---------
Clro 
1/hr 0.11550 
1 
0.57750 0.300001 0.57750 0.57750 ------ --------- -------- --------,--------- ---------
Clrss97% 
1/hr 
Fc97%ss 
Tfc.5 
hrs 
0.00441 
1 
0.09559 0.014351 0.05092 0.03581 --------- -------- --------1--------- ---------
1 
0.03816 0.16552 0.047831 0.08817 0.06202 --------- -------- --------1--------- ---------
1 
11.37745 28.07951 10.530521 15.58252 9.51179 
Ccss = steady state concentration in compartment C, Cpss 
steady state concentration in compartment P, Tl/2ss = time 
to get to one half steady state, Tfss97% = time to get to 
97% steady state, Ccss97% = the concentration in C at 97% of 
steady state, Cpss97% = the concentrtation in compartment P 
at 97% of steady state, Clro = Clearance at zero time, 
Clrss97% = clearance at 97% of steady state, Fc97%ss = the 
fraction of maximal clearance at 97% of stedy state, Tfc.5 = 
time to get to one-half of maximal clearance. 
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As would be expected, table 15 differs from table 13 
only in Cpss and Cpss97% due to the increase in Vp from 2 
liters to 10 liters. Since only Vp is different, only para­
meters dependent on Vp were changed. 
5.3.4 Closed compartment simulations where Ve = 10 liters 
and Vp = varies. Bolus dose (Co) of 100mg in compart­
ment c. 
In peritoneal dialysis, the volume of fluid in the 
peritoneum changes (51). The following set of simulations 
investigate the model when the volume of compartment P 
changes from 2 liters to 2.6 liters and then approaches 2 
liters again. Figure 58 is a graph of the volume of P versus 
time. The form of this curve was based on the ultrafil­
tration model used by Pyle (51). In this simulation, the 
volume that enters P comes from outside the model so that 
the volume of C does not change. Figures 59, 61, 63, 65, and 
67 depict the concentration versus time profiles of this 
simulation. The flows and clearance of each simulation 
(appendix 0) are shown in figures 60, 62, 64, and 66. 
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These figures would be exact copies of the concentra­
tion versus time curves from the earlier simulations 
(figures 25, 27, 29, and 31). At first, comparison of the 
graphs from these simulations may indeed appear to yield 
duplicate graphs. However, notice that in the case where Kl2 
= 0.01155 1/hr and K21 = 0.05775 1/hr, the concentrations do 
not equal each other in 90 hours. In none of the concentra­
tion versus time plots does it appear that compartment P 
achieves steady state. The flow curves however show that the 
model reaches steady state within the 90 hrs (change in net 
flow equals 0). Therefore in this case, concentration pro­
files alone do not help predict when steady state will be 
achieved. Even if volume balance were maintained between the 
two compartments, the 30% change in volume of compartment P 
over the 6% change in the volume of C would have produce a 
similar end result. 
The change in volume of compartment Pis so large that 
it must be taken into account. Due to the shape of the 
volume curve (figure 58), the effect of volume change on Cp 
in this simulation was dilution of the early concentrations. 
The later concentration points appoached their constant 
volume analogs as the volume in P approached 2 liters. The 
clearance curves of figure 69 are the same as those in 
figures 57 and 35 since the volume of P does not enter in 
the clearance function. Output from this simulation will be 
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found in appendix z. The characteristics in table 16 are 
consistant with the above discussion. 
TABLE 16 
Two compartment closed model where Ve = 10 liters and Vp 
changes. Bolus dose (Co) of 100mg into compartment c. 
Kl2 I 0.01155 0.057751 0.030001 0.057751 0.05775 
K21 = I 0.05775 0.011551 0.057751 0.030001 0.05775 
------1--------- --------1--------1---------1---------
Ccss I I I I 
mg/1 I 8.33333 1.666671 6.581201 3.418801 5.ooooo 
------1--------- --------1--------1---------1---------
Cpss I I I I 
mg/1 I 7.94150 41.66500116.316001 32.950001 23.87000 
------1--------- --------1--------1---------1---------
Tl/2ss I 
hrs 10.00000 10.00000 7.89744 7.897441 6.00000 
Tfss97% 
hrs ------
Ccss97% 
mg/1 
Cpss97% 
mg/1 
Clro 
1/hr 
--------- -------- -------- ---------1---------
49.66839 49.66839 39.22529 39.22529 29.80103 --------- -------- -------- --------- ---------
8.38667 1. 93333 6.69060 3.62940 5.16000 --------- -------- -------- --------- ---------
6.90900 34.54500 13.83500 26.63200 19.70500 ---------1-------- -------- --------- ---------
1 I 
0.11550 I o.57750 0.300001 o.51150 0.57750 ------ ---------1-------- --------1--------- ---------
Clrss97% 
1/hr 
1 I 
0.00441 I 0.09559 o.014351 0.05092 0.03581 ---------1-------- --------1--------- ---------
1 I 
Fc97%ss 0.03816 I 0.16552 0.047831 0.08817 0.06202 
---------1-------- --------1---------1---------
Tfc.5 I I I I 
hrs 111.37745 128.07951 10.530521 15.582521 9.51179 
Ccss = steady state concentration in compartment c, Cpss 
steady state concentration in compartment P, Tl/2ss = time 
to get to one half steady state, Tfss97% = time to get to 
97% steady state, Ccss97% = the concentration in C at 97% of 
steady state, Cpss97% = the concentrtation in compartment P 
at 97% of steady state, Clro = Clearance at zero time, 
Clrss97% = clearance at 97% of steady state, Fc97%ss = the 
fraction of maximal clearance at 97% of stedy state, Tfc.5 = 
time to get to one-half of maximal clearance. 
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Since the volume of compartment Pis static, table 16 
is exactly the same as table 13 (where Ve 10 liters and Vp 
= 2 liters) except for Cpss and Cpss97%. In this simulation, 
eventhough the concentrations in P do not plateau, steady 
state is achieved when net flow of drug between the compart­
ments is zero. Cpss and Cpss97% represent the concentration 
in compartment P with respect to when the net flow is zero. 
This simulation points out the necessity of monitoring vol­
ume in a compartment whose volume changes drastically if one 
expects to properly fit this type of data. 
In the above simulation, if drug were administered into 
the peripheral compartment instead of the central compart­
ment, Ccss should be the same as before. The flow of drug 
between the compartments would be the same as in the case 
with drug administered into a static peripheral compartment 
so that time to steady state would be the same. The major 
differences would be found in the concentration time profile 
of compartment P and in the clearance versus time profile. 
Figure 70 depicts this simulation for the case where 
K12 = 0.01155 and K21 = 0.05775. These parameters were 
chosen because in this case, if volumes were static Ccss 
would equal Cpss. The curve describing Cp is diluted as 
expected and Cc is unaffected. Figure 71 shows the clearance 
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profile for this simulation. This curve is exaggerated as 
compared to the corresponding curve in figure 46 because in 
figure 71, there is a larger volume to clear of drug during 
the early time points. This simulation further exemplifies 
the uselessness of a true clearance term in closed model 
pharmacokinetics. The output of this simulation is found in 
appendix X and the program is in appendix P. 
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FIGURE 71 
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5.4 Performance of a closed model when minimal elimination 
from the model actually exists. 
As mentioned earlier, examples of closed models exist 
in real life. Strictly speaking, however the above statement 
is false since the body finds pathways for elimination of 
compounds when the standard pathways (renal, and major meta­
bolic pathways) are not functiorial. Examples of alternate, 
although less efficient pathways of elimination include; 
sweat, saliva, secretion into bowel, excretion into hair, 
and elimination via exhalation. 
130 
The following simulations are made using an open model 
where the elimination pathway is diminished in consecutive 
simulations to investigate where a closed model would be 
sufficient to describe the concentration profile. The inter­
compartmental rate constants used to test the closed 
compartment assumption in the truely open model will be Kl2 
= o.01155 1/hr, K21 = 0.05775 1/hr; and Kl2 = 0.05775 1/hr, 
K21 = 0.05775 1/hr. The elimination rate constant KlO, will 
range from 0.6 to 0.006. The SPICE2 program for this simula­
tion is found in appendix Q. The output is in appendix AA. 
To test if a closed.model could adequately describe the 
concentration time profiles for the above simulations, 
NONLIN84 was used to attempt to fit the simulated data. The 
closed model equations for Cc and Cp were used to simultane­
ously fit the data from the two compartments. The appropri­
ate intercompartmental rate constants as well as volume of 
distribution values served as initial estimates. The 
NONLIN84 subroutine used for the fit is found in appendix T. 
When KlO was actually 0.6 to 0.03, the model fit very 
poorly if at all. Figures 72 and 73 are examples of poor 
fits obtained when the actual rate constants were Kl2 = 
0.01155 1/hr, K21 = 0.05775 1/hr, and KlO = 0.03 1/hr. 
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Figures 74 through 77 are residual plots expressed as % 
deviation from the simulated data where KlO varies from 
0.006 to 0.0012. In all cases, simulations where KlO was 
0.006 regardless of the underlying micro-rate constants, had 
the largest% deviations. The simulations where·KlO = 0.0012 
1/hr provided the best fits. The simulations where Kl2 = 
0.05775 1/hr and K21 
than those where Kl2 
0.01155 1/hr performed better overall 
0.01155 1/hr and K21 = 0.05775 1/hr. 
Representative profiles of the simulations/fits are shown 
in figures 78 through 85. 
FIGURE 74 
CLOSED MODEL FIT OF 2 POOL OPEN MODEL 
z 
0 
� 
5 w 
Cl 
� 
K10 
12 
% DEVIA11 ON IN Cc, 
10 
8 
6 
4 
2 
0 
-2 
-4 
-6 
-8 
-10 
-12 
-14 
-16 
-18 
-20 
0 
• .006 
• 
+ 
... t 
10 20 
• .003 
30 
0 .002 
K12 = 0.01155 K21 = 0.05775 
.. • 
• 
40 50 60 70 80 90 
11ME {HRS) 
,. .0017 )( .001+ - .0012 1/HR 
133 
CLOSED MODEL FIT OF 2 POOL OPEN MODEL 
FIGURE 75 % DEVIA110N IN C , K12 = 0.01155 K21 = 0.05775 10��---'-����-'--'-�����������----, 
B 
6 
4 
• 
+ 
• 
• 
+ • 
� i_�
+
��::::::::::=:::=::::::�.�-e=:::;::::=---� 
-2 
-4 • 
-6 
-B 
-10 • 
-12 
-14 
-16-+-���-.-�---,,--�..--�-,.-�-.-�--.��.-----; 
0 10 20 JO 
Kl O = • .006 + .003 � .002 
FIGURE 76 
40 50 60 70 BO 90 
11ME (HRS) 
"' .0017 x .001 + - .0012 1/HR 
CLOS ED MODEL FIT OF 2 POOL OPEN MO DEL 
% DEVIATION IN Cc, K12 = 0.05775 K21 = 0.01155 
z 
0 
5 w Cl 
� 
• 
10 
Kl O = a .006 + .003 
• • 
... 
20 JO 
� .002 
+ 
• 
40 50 60 
11ME (HRS) 
A .0017 X .001 + 
... 
• 
70 
+ 
• 
BO 90 
.0012 1/HR 
134 
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CLOSED MODEL FIT OF 2 POOL OPEN MODEL 
K12 = 0.05775 K21 = 0.01155 K10 =0.0012 FIGURE 81 
45 
PERIPHERAL COMPARTMENT 
40 -
ci' 35 
2 JO ...._, 
z 
25 0 
F 
20 
z 15 
u 
z 10 0 
u 
5 
10 20 JO 40 50 60 70 80 90 
"TIME (HRS) 
"'OPEN MODEL - CLOSED MODEL FIT 
FIGURE 82 
CLOSED MODEL FIT OF 2 POOL OPEN MODEL 
11 Kl 2 = 0.01155 K21 = 0.05775 Kl O = 0.006 
CENTRAL COMPARTMENT - 10 
ci' 
9 ...._, 
z 
0 
F 8 • 
7 
• 
u • z 
0 
6 u 
• 
• • 
5 
0 10 20 JO 40 50 60 70 80 90 
"TIME (HRS) 
• OPEN MODEL - CLOSED MODEL FIT 
137 
CLOSED MODEL FIT OF 2 POOL OPEN MODEL 
K12 = 0.011 55 K21 = 0.0577 5 K10 = 0.006 FIGURE 83 7 
<) -
...J 
<) 
<) 
5 
z 4 0 
g J 
z 
2 z 
0 
() 
PERIPHERAL COMPARTMENT 
10 2 0  JO 40 50 60 70 60 90 
11ME (HRS) 
" OPEN MODEL - CLOSED MODEL FIT 
FIGURE 84 
CLOSED MODEL FIT OF 2 POOL OPEN MODEL 
1 0.2 �-
K_1_2 _= _0_. 0_1_1_5_5_K_2_1_=_0_.0_5_7 _7 _5_K_1_ 0_=_0 _.0_0_1-"2
-
� 
1 o CEN1RAL COMPARTMENT 
..---.. 9.6 
...J ci' 9.6 
� 9.4 9.2 
5 9 
F 8.8 
g 8.6 
� 8.4 
o 8 .2 
5 8 
o 7.8 
7.6 
• 
• 
• • 
7 .4 -i----,-----r----,--T"""""-....---,------.-----,-----l 0 10 2 0  JO 40 50 60 70 80 90 
11ME (HRS) 
• OPEN MODEL - CLOSED MODEL FIT 
138 
FIGURE 85 
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Table 17 provides a parameter comparison of the closed 
model fits for representative simulations where K12 = 
0.01155 1/hr and K21 = 0.05775 1/hr. If the model fits the 
data exactly, the coefficient of determination would equal 
1.0. Only in the case where KlO was 0.0012 1/hr did the 
closed compartment fit result in a coefficient of determina­
tion of close to 1.0 (0.995). As the actual total body 
clearance and ratio of simulated K10 to K12 diminish, the 
coefficient of determination for the fit increases in value. 
This observation is expected since as the open model becomes 
closed, the concentration versus time profiles take on 
closed model characteristics. 
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TABLE 17 
Closed Model Fit of a Two compartment Open Model. 
Parameter Comparison. 
jSimulatedjFitted !Simulated Fitted jSimulatedjFitted 
I Value I Value I Value Value I Value I Value 
-------1---------1-------1--------- -------,---------,-------
! I I I 
Ve (l) 10 j9.533 I 10 9.971 I 10 j9.865 
------- ---------,-------,--------- -------1---------1-------
1 I I I 
Vp (1) 2 j6.354 I 2 3.475 I 2 j2.892 
------- ---------1-------1--------- -------1---------1-------
-1 I I I I 
K12 hr 0.01155 j0.034921 0.01155 0.020611 0.01155 j0.01707 
------- ---------1-------1--------- -------1---------1-------
-1 I I I I I 
K21 hr 0.05775 j0.049541 0.05775 0.057461 0.05775 j0.05794 
------- ---------,-------,--------- -------1---------1-------
-1 I I I I 
K10 hr 0.006 I N/A I 0.002 N/A I 0.0012 I N/A 
------- ---------1-------1--------- -------1---------1-------
2 I I I I 
R N/A j0.902 I N/A 0.986 I N/A j0.995 
------- ---------,-------,--------- -------1---------1-------
1 I I I 
K10/K12 0.5195 I N/A I 0.1732 N/A I 0.1039 I N/A 
------- ---------,-------,--------- -------1---------1-------
TBC I I I I I 
ml/min I 1 I N/A I 0.33 N/A I 0.2 I N/A 
2 
N/A = does not apply, R Coefficient of determination, TBC 
total body clearance. 
Table 18 provides a parameter comparison of the closed 
model fits for representative simulations where K12 = 
0.05775 1/hr and K21 = 0.01155 1/hr. In this table all of 
the coefficients of determination are close to 1.0. As in 
table 17, as actual total body clearance and ratio of simu­
lated K10 to K12 diminish, the coefficient of determination 
for the fit increases in value. 
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TABLE 18 
Closed Model Fir of a Two Compartment Open Model. 
Parameter Comparison. 
Simulated Fitted !Simulated Fitted ISimulatedlFitted 
Value Value I Value Value I Value !Value 
------- --------- -------1--------- -------1---------1-------
1 I I 
Ve (1) 10 9.859 I 10 9.945 I 10 19.966 
------- --------- -------1--------- -------1---------1-------
1 I I 
Vp (1) 2 2.324 I 2 2.108 2 12.065 ------- --------- -------1--------- ------- ---------1-------
-1 I I 
K12 hr 0.05775 0.070141 0.05775 o.06180 0.05775 10.06017 ------- --------- -------1--------- ------- ---------1-------
-11 I I I 
K21 hr I 0.01155 10.011851 0.01155 0.01164 0.01155 10.01160 
-------1---------1-------1--------- ------- ---------1-------
-11 I I I 
KlO hr I 0.006 I N/A I 0.002 N/A 0.0012 I N/A 
-------1---------1-------1--------- ------- ---------1-------
2 I I I I 
R I N/A I0.999 I N/A 1.0 NJAIDin�Id1.o 
-------1---------1-------1--------- ------- ---------1-------
1 I I I 
Kl0/K12I 0.1039 I N/A I 0.03463 N/A I 0.02078 I N/A 
-------1---------1-------1--------- -------1---------1-------
TBC I I I I I I 
ml/min I 1 I N/A I 0.33 IN/A I 0.2 I N/A 
N/A = does not apply, R 
total body clearance. 
2 
Coefficient of determination, TBC 
Comparing tables 17 and 18, a question becomes obvious. 
Why do the simulations in table 18 perform better than 
those in table 17? If the closed model fit of an open model 
simulation depended only or primarily on the true model's 
total body clearance, then equal performance would have been 
expected. Re-examination and recomparison of the tables 
shows a obvious relationship between coefficient of determi-
CT :;nrn!:lid 
T9 
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nation and the ratio of KlO to K12. As KlO approaches and 
becomes less than 10% of K12, the coefficient of detennina­
tion approaches 1.0. 
Figure 35 depicted the intercompartmental clearance 
profiles of various closed compartment simulations where K12 
= 0.01155 1/hr, K21 = 0.05775 1/hr; and K12 = 0.05775 1/hr, 
K21 = 0.01155 1/hr are included. Figures 86 and 87 depict 
the intercompartmental clearance profiles for three repre­
sentative open model simulations used so far. 
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FIGURE 87 
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Comparing figure 35 to figures 86 and 87, one notices 
that the overall shape of the curves is maintained. The 
difference being that in figures 86 and 87, KlO allows the 
intercompartmental clearance to become positive (net clear­
ance is into compartment C) instead of going to zero. These 
two figures indicate that a draw back to using a closed 
compartment model to describe a process that is truely open 
is that intercompartmental clearance will be underestimated 
at the time when the closed model is assumed to be at equi­
librium. 
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The possibility that this observation may effect the 
models ability to predict concentrations after multiple 
doses, required multiple dose simulations of the best 
single-dose performing models. The best performing single­
dose simulations determined by inspection of the % deviation 
graphs (Figures 76 and 77), and parameter comparison (Table 
17) are the instances where K12-= 0.05775 1/hr, K21 = 
0.01155 1/hr, and KlO is either 0.006 or 0.0012 1/hr. In the 
case where Kl2 = 0.01155 1/hr and K21 = 0.05775 1/hr, only 
when KlO = 0.0012 1/hr does the simulation perform adequate­
ly. 
Multiple dose simualtions were therefore done on the 
above parameter examples. The SPICE2 simulation program is 
found in appendices R ands. The output is in appendix BB. 
Figures 88 through 92 depict the results. 
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PERFORMANCE OF THE CLOSED tv10DEL 
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PERFORMANCE OF THE CLOSED MODEL 
ASSUMPTION ON MULTIPLE DOSE. 
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Figure 90 indicates, as expected, that upon multiple 
dosing the closed model quickly loses its predictive ability 
when K12 = 0.01155 1/hr. Figures 88 and 89 demonstrate that 
the closed model assumption performs more favorably when K12 
= 0.05775. In these cases, the greatest overprediction 
occurs in compartment P. Figures 91 and 92 which are en­
largements of the Cc versus time profiles, still show that 
the over prediction is smaller in compartment C. Although · 
figures 88 and 89 use the same underlying intercompartmental 
rate constants {Kl2 = 0.05775 1/hr, K21 = 0.01155 1/hr), 
figure 88 demonstrates a better predictive ability. In this 
simulation, the model was more closely closed (KlO = 
0.0012). The better predictive ability of compartment c in 
figures 88 and 89 is due to the fits' overestimation of Kl2 
(7% and 4% respectively) as compared to the slight overesti­
mation of K21 (0.8% and 0.4% respectively). Greater over­
estimation of Kl2 leads to greater overprediction of Cp as 
compared to Cc. 
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Table 19 summarizes the performance of the best three 
simulations/fits. The major error incurreed in assuming a 
model is closed when it is infact an open model, is in the 
predictive capacity upon multiple dosing. Although the data 
will fit better as the model approaches "closedness" 
(Kl0/Kl2 < 10%), if enough time is allowed a closed model 
will always overpredict concentration in an open system. 
This is due to the fact that all open models asymptotically 
approach a steady-state during multiple dosing and a closed 
model does not. When the time frame is limited and the model 
approaches the limits of closedness, a closed model will 
perform well. 
TABLE 19 
Multiple Dose Predictability of the Closed Model Assumption 
I Kl2 = 0.01155 I 12 = 0.05775 I Kl2 = 0.05775 
I K21 = 0.05775 I K21 = 0.01155 I K21 = 0.01155 
I KlO = 0.0012 I KlO = 0.006 I KlO = 0.0012 -----------1---------------1---------------1----------------
Single Dose! I I 
2 I o.995 I o.999 I 1.0 
Fit R I I I -----------1---------------1---------------1----------------
% everest. I I I 
at t = 540 I 15,17 I 11,19 I 2.6,3.8 
Cc,Cp I I I -----------1---------------1---------------1----------------
% everest. I I I 
at t = 900 I 43,32 I 30,44 I 6.7,8.5 
Cc,Cp I I I 
CHAPTER VI 
vancomycin Disposition during Continuous Ambulatory Perito­
neal Dialysis: A Closed Compartment Modeling Approach 
6.1 Introduction 
The use of vancomycin has been extensively reviewed by 
several authors (1,9,15,32). Vancomycin is a glycopeptide 
antibiotic in a class of its own. The fermentation product 
of Nocardia orientalis (also known as Streptomyces 
orientalis), it was introduced to the medical community in 
1956 for treatment of penicillin-resistant staphylococcal 
infections. Vancomycin's mechanism of action consists of the 
interference of peptidoglycan biosynthesis and inhibition of 
RNA synthesis making it bacteriocidal to many gram-positive 
organisms. 
Due to a high incidence of renal failure attributed to 
impurities in the early preparation, its use decreased with 
the introduction of the less nephrotoxic penicillin, 
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methicillin. However as the incidence of resistance to 
methicillin increased, the newer, purer formulation of 
vancomycin was reintroduced for use in these cases of 
methicillin-resistant stapylococcal infections. 
Orally, vancomycin is indicated for bacterial pseudo­
membraneous colitis. Vancomycin is also prescribed in the 
treatment of bacterial peritonitis in CAPO patients (31). 
The offending pathogen in this population is often staphylo­
coccus epidermidis or aureus. Since vancomycin is highly 
effective against these bacteria and since vancomycin has an 
extremely long half-life in ESRD (8-10 days), it is the 
obvious choice of clinicians. Vancomycin is also used in the 
treatment of infections due to Streptococcus viridens, 
Streptococcus bovis, and Streptococcus faecalis. Although 
these Group D streptococcae are not sensitive to vancomycin 
alone, when used in combination with an aminoglycoside, 
vancomycin does provide an excellent alternative to peni­
cillin-allergic patients. 
The purer form of vancomycin, although probably less 
nephrotoxic when used alone, is not without its problems. 
Ototoxicity is still a consequence of poorly monitored van­
comycin therapy. High tone hearing loss and tinnitus are the 
harbingers of more extensive eighth cranial nerve damage. 
These early symptoms of hearing loss are usually exhibited 
when serum concentrations reach 40 to 60 mg/1. Vancomycin 
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must be diluted to a concentration of less than 10 mg/ml and 
infused intravenously over no less than one hour to decrease 
the incidence of phlebitis and the incidence of fever, 
chills, erythemia, and pruritis know as "red neck syndrome" 
during administration. 
Intravenous doses of vancomycin in patients with normal 
renal function exhibit two or three compartment pharmacoki­
netics with an elimination half-life of approximately six 
hours (15). 50 to 60% of vancomycin is bound to plasma 
proteins. Renal excretion accounts for almost 100% of the 
elimination of vancomycin thereby exhibiting markedly dif­
ferent pharmacokinetics in end stage renal disease. The 
elimination half-life of vancomycin in anuric patients is 
approximately 7.5 days (1). Hemodialysis does not remove 
vancomycin so that these patients only require 1 gm of 
vancomycin every 7 to 10 days (the dose in patients with 
normally functioning kidneys is 500 mg every six hours or 1 
gm every 12 hours). CAPO does remove vancomycin so that 
these patients require a 1 gm intravenous bolus dose and 20 
to 50 mg/1 vancomycin in each dialysate exchange (15). 
The purpose of this section was to determine if a 
closed compartment pharmacokinetic model would provide any 
advantage over an open model. Since vancomycin is for all 
practical purposes only excreted renal-ly, it should fit the 
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criteria for closed compartment pharmacokinetics in patients 
with end stage renal disease. For this evaluation, data from 
a published vancomycin study (21) was further analyzed. In 
this study, the pharmacokinetics of vancomycin in CAPO were 
examined during peritonitis. 
6.2 Materials and Methodology 
Five CAPO patients representing seven episodes of peri­
tonitis entered the study. Informed consent was obtained. 
Peritonitis was diagnosed by the criteria of cloudy 
dialysate and an elevated white blood cell count in the 
peritoneal fluid (> 100 cells/cubic mm). Physical examina­
tions and laboratory screening profiles were obtained on 
each admission. No patient exhibited residual renal function. 
TABLE 20. Vancomycin Patient demographics. 
PATIENT I AGE SEX WEIGHT ETIOLOGY OF CULTURED 
No. I yrs. kg. RENAL FAILURE I ORGANISM --------1----- -------- ---------------1--------------
1 I 36 M 54.5 HN 1s. epidermidis --------1----- -------- ---------------1--------------
2a I 29 M 57.5 GN JS. epidermidis --------1----- -------- ---------------1--------------
2b I IS. epidermidis --------1----- -------- ---------------1--------------
2c I JA. herellea --------1----- -------- ---------------1--------------
3 I 59 F · 48 HN IS. epidermidis --------1----- -------- ---------------1--------------
4 I 50 M 110 UK Is. epidermidis 
I IP. aeruginosa --------1-----1----- -------- ---------------1--------------
5 I 28 I M 64.5 GN 1s. aureus 
HN, hypertension; GN, glomerulonephritis; UK, unknown. Pa­
tient 2 presented with three episodes of peritonitis 
(a,b,c). Patient 4 presented with two organisms in one 
episode of peritonitis. 
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On admission into the study, each patient's peritoneal 
cavity was flushed twice with two liters of 1.5% dextrose 
dialysate solution. Once completely drained of peritoneal 
fluid, each patient received a 1 gm dose of vancomycin 
diluted in 250-500 ml of 5% dextrose intravenously over 30 
min. The patient's usual regimen of peritoneal dialysis was 
restarted after completion of the intravenous vancomycin 
infusion. Cefazolin sodium was added to each dialysate at a 
concentration of 125 mg/1 throughout the study. If a gram­
negative pathogen was discovered or suspected, gentamicin 
was administered intravenously until the pathogen was 
identified. 
6.3 Sampling 
3 ml blood samples were obtained immediately following 
the vancomycin infusion and then at o.5, l, 2, 4, 6, 8, 12, 
and 18 hours following the infusion; and then every 24 hours 
for the remainder of the 7 day study. 5 ml dialysate samples 
were obtained serially during at least one dialysate ex­
change. Dialysate samples were also obtained at the end of 
each dwell once the total collected volume had been deter­
mined and adjusted for any serial samples obtained. All 
samples were stored at -20 degrees C until analysis. 
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6.4 Vancomycin Analysis 
vancomycin was measured in duplicate in both serum and 
dialysate by radioimmunoassay (American Diagnostics, Newport 
Beach, California, USA). The limit of sensitivity for this 
assay was 1 mg/1 with an interassay coefficient of variation 
of 7.2%. No cross reactivity was demonstrated between the 
analyte and cefazolin or gentamicin. 
6.5 Pharmacokinetic Analysis 
The CAPO clearance of vancomycin was calculated by 
the accepted equation (Cd X Ve)/(Cp X T), where Cd is the 
concentration of vancomycin at the end of the dwell, Ve is 
the collected volume of dialysate, Cp is the serum concen­
tration at the midpoint of the collection period and T is 
the duration of the exchange in minutes. In the original 
paper a two compartment open model, where the peritoneal 
cavity was treated as a terminal compartment, was used to 
fit the post infusion serum data. From the fits, pharmacoki­
netic parameters were obtained to describe the disposition 
of vancomycin in these patients. 
6.6 Results 
The harmonic mean half-life was reported as 103.91 
hours, mean total body clearance was reported as 4.09 
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ml/min. The CAPD clearances ranged from 1.2 to 9.36 ml/min. 
CAPD clearances on day 1 of the study averaged 3.84 ml/min 
and decreased to 2.89 ml/min on the average for dwells in 
the latter part of the study. It was demonstrated that 
higher dialysate vancomycin levels were found in the longer 
exchanges (approximately 5 mg/1 in 5 hour dwells and greater 
than 8 mg/1 for .8 to 13 hour dwells). 
These results indicate that CAPD accounts for a major 
portion of vancomycin clearance. They further demonstrate 
that vancomycin would be a likely candidate to investigate 
closed compartment pharmacokinetics. 
6.7 Closed Compartment Analysis 
For the closed compartment reanalysis, a two compart­
ment closed model was used to attempt to describe the data 
from this study (appendix E). Since vancomycin was only 
administered intravenously, the peritoneal cavity was 
treated as a sampling site for the peripheral compartment. 
This fit was then compared to a two compartment open model. 
NONLIN84 (39) was used to fit the model to the dialy­
sate data from the first dwell and the corresponding serum 
data simultaneously (appendices H and I). The parameters 
obtained from these fits were then used to predict dialysate 
concentrations at the end of a subsequent dwell. Due to the 
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fact that end of dwell volumes will vary, all predictions 
were adjusted to the actual volume at the end of that dwell. 
End of dwell concentrations were chosen for comparison 
because only at this time can an accurate estimate of dialy­
sate volume be obtained. 
Data from Patient 3 was not included since only 3 
serum values are available during the first dwell. This 
would allow no degrees of freedom and a fit that would be 
overly biased by the dialysate data. The open compartment 
model requires 5 parameters so that the data from Patient 2b 
was not included since the serum data in this instance 
consists of 4 points resulting in the O degrees of freedom 
instance as with Patient 3. Since the original study (21) 
indicated that CAPO clearance decreased with time and since 
dialysate factors (length of dwell, dextrose concentra­
tion,etc.) were not held constant throughout the study, only 
the dialysate data during the first dwell was used in the 
fits. 
Figures 93 through 99 depict the concentration versus 
time profiles for the dialysate and serum data during the 
study. The closed compartment fit of the data is depicted in 
figures 100 through 105. 
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Vancomycin CAPD Data 
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Vancomycin Closed Compartment Fit 
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Vancomycin Closed Compartment Fit 
FIGUR1,
0
l�0-3 _________ �_rum __ 
a_m_D1_a_�_s�_A_�_t_o_we_n ________ � 
z 
C 
� 
C 
60 
50 
40 
30 
20 
10 
0 
C Obo. Sdrum 
2 
Time (In) 
NONUN84 
3 
o Obo. Dlal)'$Qte 
4 
FIGURE 104 
z 
C 
� 
Vancomycin Closed Compartment Fit 
Serum am Dla1y"1s A�t Owea 
40 
PaUent 4-
35 
30 
25 
20 
15 
10 
5 
0-1"'----,--------.----...,.------,-----,-----1 
0 
C Obo. Sdrum 
2 
Time(m) 
-- NONUN84 o Obo. Olol)'$Qlo 
6 
163 
FIGURE 105 Vancomycin Clos,ed Compartment Fit 
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The coefficients of determination ranged from 0.66 to 
0.93 for the closed compartment fits. Patients 1 and 5 had 
the lowest coefficients of determination, 0.66 and 0.76 
respectively. Table 21 demonstrates the predictive ability 
of the closed model in this population. Notice that patients 
1 and 5 have the largest percent error in dwell number 2. 
This would be expected since the model did not describe 
their data well as evidenced by the coefficients of 
determination. 
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TABLE 21 
End of Dwell Concentration Table Closed Compartment Model. 
Patient Patient Patient I Patient I Patient I Patient 
1 2a 2b I 2c I 4 I 5 --------- -------- -------- -------- --------1--------1--------
Xo (mg) 1000.000 1000.000 1000.000 1000.00011000.00011000.ooo 
Xd(mg) 35.180 25.960 27.750 31.1101 27.7501 26.250 
Xo-Xd(mg) 964.820 974.040 972.250 968.8901 972.2501 973.750 
Kl2(1/hr) 0.180 0.169 0.087 0.2411 0.1611 0.183 
K21(1/hr) 0.179 0.105 0.141 0.172 I 0.1851 0.118 
K(l/hr) 0.359 0.274 0.228 0.4131 0.3461 0.301 
Vp(l) 23.340 30.750 13.720 24.0701 24.0101 26.360 
Coef. det 0.66 0.91 0.81 0.93 I 0.84 I 0.76 --------- -------- -------- -------- --------1--------1--------
T dwell 11 I I 
(hr) 4.000 4.000 4.000 4.000 4.0001 4.000 
End Vol.l I 
(l) 2.460 2.200 1.850 1.830 1.850 1. 750 
Real Cd 
(mg/1) 14.300 11. 800 15.000 17.000 11. 900 15.000 
Pred Cd 
(mg/1) 16.372 13.355 16.639 19.597 14.524 16.145 
% Error 14.499 13.175 10.929 15.274 22.050 7.634 --------- -------- -------- -------- -------- -------- --------
T dwell 2 
(hr) 9.000 4.000 7.000 4.000 4.000 10.000 
End Vol.2 
(1) 2.810 2.450 2.450 2.140 2.650 2.035 
Real Cd I 
(mg/1) 11. 200 10.400 16.000 16.5001 N/A 13.000 
Pred Cd I 
(mg/1) 19.907 13.008 21. 559 18.9871 14 .121 21. 361 
Corr Cd I 
(mg/1) 17.428 11. 681 16.279 16.2371 9.858 18.361 
% Error 55.605 12. 313 1. 745 -1. 597 I N/A 41. 242 
Xo = dose, Xd = amount in dialysate, Vp = volume of the 
peripheral compartment, Coef. det. = coefficient of determi­
nation, T dwell= length of the dwell, End Vol= end of 
dwell volume, Real Cd= actual end of dwell concentration, 
Pred Cd= predicted end of dwell concentration, Corr Cd 
concentrations corrected for end of dwell volume. N/A = not 
available. 
The poor performance of the model for Patients 1 and 5 
would raise the questions of model mis-specification or 
perhaps widely varying data. A two compartment open model 
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may therefore provide better fits of the data for these two 
patients. However using the open model comparison in this 
analysis offers more evidence for a closed compartment 
model. 
Open model analysis of the same data provides fits 
shown in figures 106 and 107. Convergence occurred for 
Patients 4 and 5 only. In attempting to fit the open model 
to the data of Patients 1, 2a, and 2c, the program was 
sabotaged by a overflow in the math library due to a divi­
sion by zero (appendix J). The searching algorithm attemped 
to bring the beta parameter to zero by rapidly arriving at 
0.00001 and stopping. Substituting o for beta in the equa­
tions: 
Cp 
Cc = A*exp(-alpha*t) + B*exp(-beta*t) 
Kl2*Ko 
Vp(beta-alpha) 
(exp(-alpha*t) - exp(-beta*t)) 
results in equations in the forms: 
Cp 
cc = A*exp(-alpha*t) + B 
Kl2*Ko 
Vp(alpha) 
(1 - exp(-alpha*t)) 
eq. 79 
eq. 80 
eq. 81 
eq. 82 
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,These equations show that the open model equations 
collapse to equations in the exact form of the closed model 
equations. Apparently, Patients 4 and 5 had enough open 
model character to allow convergence of the open model fits. 
FIGURE 106 
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Table 22 indicates that the open model provides a 
slightly better prediction of later dialysate concentrations 
than the closed model for these two patients. Patient 5 
still demonstrates a large percent error in spite of a more 
adequate coefficient of determination than in the closed 
model ( 0.85 versus 0.76). Variability in the concentration 
data may account for a large amount of the modeling error. 
Table 22 also demonstrates that the two models were similar 
in their dialysate concentration predictablility. 
This analysis indicates that a closed compartment 
pharmacokinetic analysis of vancomycin is a useful 
alternative especially when data are too sparse for open 
model analysis. 
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TABLE 22 
End of Dwell Concentration Table: Open Compartment Model. 
I Patient 4 I Patient 5 -----------1-----------1----------
Xo (mg) I 1000. ooo I 1000. ooo 
Xd(mg) I 27.750 I 26.250 
xo-Xd(mg) I 972.250 I 973.750 
K12(1/hr) I 0.320 I 0.479 
Alpha ( 1/hr) I 1. 071 I 1.106 
Beta(l/hr) I 0.020 I 0.011 
Vp(l) I 24.670 I 35.100 
Coef. det. I 0.97 I 0.85 -----------,----------- ----------
T dwell 1 I 
(hrs) I 4.000 4.000 
End Vol.1 
(1) 1.850 1.750 
Real Cd 
(mg/1) 11.900 15.000 
Pred Cd 
(mg/1) 11. 22 11. 770 
% Error -5.692 -21.495 
T dwell 2 
(hrs) 4.000 10.000 
End Vol.2 
(1) 2.650 2.035 
Real Cd 
(mg/1) N/A 13. 000 
Pred Cd 
(mg/1) 10.911 10.890 
Corr Cd 
(mg/1) 7.617 9.364 
% Error N/A -27.965 
Xo = dose, Xd = amount in dialysate, Vp = volume of the 
peripheral compartment, Coef. det. coefficient of 
determination. T dwell = length of the dwell, End Vol = end 
of dwell volume, Real Cd actual end of dwell 
concentration, Pred Cd predicted end of dwell 
concentration, Corr Cd = concentrations corrected for end of 
dwell volume. N/A = not available. 
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6.8 critique of the Closed Compartment Analysis of 
Vancomycin during CAPO by Rogge et al. 
A closed compartment approach has been suggested by 
Rogge et al (60). The authors derive equations describing 
blood and dialysate concentrations similar to the equations 
derived in the theoretical section of this dissertation. 
They define the variable, sigma, which is the ratio of the 
central distibution volume to the dialysate volume ( this 
assumes that either the volumes are constant or that the 
vary in a parallel manner). Defined as micro-rate constants, 
sigma is the ratio of K21/K12 and 1 + sigma is equal to (Kl2 
+ K21)/K12. The exponent of the disposition equations in the 
paper is "k" defined as "the first-order rate constant for 
transfer of drug from peritoneum to plasma". K however must 
actually be the sum of the micro-rate constants K12 and K21 
to properly discribe the process. The authors go on to 
describe equations to calculate loading dialysate concentra­
tion to rapidly attain a desired equilibrium dialysate and 
plasma concentration. 
A major difference in our treatices occurs in the 
discussion of clearance during CAPO. It is accepted that the 
traditional calculation of CAPO clearance routinely reported 
is actually an average clearance •. The authors suggest that a 
better calculation of CAPO clearance is intrinsic CAPO 
clearance equal to "k" times the volume of the central 
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compartment which is unaffected by dialysate volume or dwell 
time. The clearance equation derived in the theoretical 
section of this dissertation shows that 1) clearance in a 
closed model is not constant but assymptotically approaches 
zero quickly. 2) "intrinsic" clearance is equal to Vc*K12 
not Vc*(K12+K21) as suggested by these authors. The intrin­
sic clearance is only true at zero time. Reporting intrinsic 
clearance would only confuse evaluation of the ability of 
CAPO to clear a substance since this number would be arti­
ficially large. 
In the rest of the paper, the authors describe a study 
where 5 CAPO patients receive intraperitoneal doses of 
vancomycin and pharmacokinetic parameters are obtained. The 
pitfall in using the intrinsic clearance equation is evident 
when the authors report that the CAPO clearances of vanco­
mycin are between 314 ml/min and 508 ml/min. The clearance 
of vancomycin in patients with normal renal function (which 
is constant) is no greater than that of creatinine clearance 
(120 ml/min) at best. Comparing these clearances would lead 
one to believe that the drug is cleared more efficiently by 
the peritoneum than by the kidneys. Initial or "intrinsic" 
CAPO clearances in no way reflect clinical observation. The 
standard "average" CAPO clearance calculation yields the 
accepted 2 - 4 ml/min CAPO clearance which better indicates 
what is seen clinically. 
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.The authors predict in the last sentence of the paper 
that "apparent" clearances would increase dramatically if 
the dwell occured for only one hour. As discussed in the 
discussion section of the CAPO chapter of this dissertation, 
Pyle and others have suggested that CAPO clearance would not 
surpass dialysate flow rate. A one hour dwell of two liters 
of dialysate woul� yield a dialysate flow rate of 33.3 
ml/min which is still much lower than Rogge's "intrinsic" 
CAPO clearances. Extrapolating an "apparant" CAPO clearance 
of 300 ml/min would require a dialysate flow of 300 ml/min 
or 18 1/hr and further demonstrates the uselessness of the 
intrinsic clearance term. Although closed compartment 
pharmacokinetic modeling may be helpful in predicting doses 
and concentrations where data is scarce, the apparent clear­
ance calculation which is used in open models should still 
be used in the closed model case. 
CHAPTER VII 
Conclusions 
As is true in all pharmacokinetic modeling, modeling 
drug distribution in continuous ambulatory peritoneal dialy­
sis first requires a statement of the aim of the model. 
Since the peritoneal cavity does not represent an effector 
site for drugs used in common practice, one would be hard 
pressed to defend serial sampling of dialysate fluid in 
these cases. Treating the peritoneal cavity as a terminal 
compartment, as was done in the procainamide study, is the 
best alternative when the aim of the study is to determine 
the amount removed by CAPO. In this case only end of dwell 
samples are required which is more convenient to the pa­
tient, and the dialysate is treated as if it were urine. End 
of dwell sampling of dialysate also avoids the variable 
peritoneal volume problem. 
When the concentration time profile in the peritoneal 
cavity is of interest, several modeling alternatives are 
available. The cavity can be considered as a sampling site 
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into the peripheral compartment when it would not be 
feasible to administer the drug intraperitoneally. Such was 
the case in the phenytoin study. The better alternative 
would be to administer drug intraperitoneally as well as 
intravenously. This alternative requires either labeling one 
of the two doses and administering them simultaneously or 
conducting two consecutive studies with appropriate wash out 
time. When the drug is only eliminated through the perito­
neum, use of closed compartment pharmacokinetic equations 
may provide similar predictive ability as open model equa­
tions but with less data. These alternatives are less 
convenient to the patient and subject him to a greater 
chance of infection due to serial sampling of the peritoneal 
fluid. 
In all the modeling alternatives, except for the termi­
nal compartment method, the assumption that the peritoneal 
space does not change appreciably in volume must be made. A 
change in peritoneal fluid volume will obviously distort the 
concentration-time profile in the peritoneal cavity. If the 
concentration time points are not adjusted for this change, 
the resulting parameters must be considered as reflecting 
both the time course of drug distribution and fluid distri­
bution in the peritoneal cavity. When the peritoneal space 
is treated as part of the peripheral compartment, fluid 
entering the peritoneum must be considered as occurring 
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throughout the peripheral compartment. Apart from adminis­
tering nonabsorbable, labelled volume tracers (acceptable 
volume tracers do not exist as of yet), the investigator can 
only control peritoneal volume by instilling dialysis 
solution of the lowest osmotic strength taht the patient can 
clinically use. 
Whatever the model, the investigator should attempt to 
assure himself that the peritoneal membrane is not inflarnmed 
thereby increasing solute transfer. Although CAPO provides 
an interesting pharmacokinetic problem to model, the 
peritoneal clearances of most drugs is so small that only 
small changes in dosing regimens need to be made when a 
renal failure patient begins CAPO. Literature reviews such 
as by Janknegt and Keks (26) support this conclusion. 
List of References 
175 
176 
List of References 
1. Apple GB, Given DB, Levine LR; Cooper GL. Vancomycin and 
the kidney. Am J Kid Dis 1986;7:75-80. 
2. Babb AL, Johansen PJ, Strand MJ, Tenckhoff H, Scribner 
BH. Bi-directional permeability of the human peritoneum 
to middle molecules. In: Moorhead JF ed). Dialysis 
Transplantation Nephrology, Proceedings of the Tenth 
Congress of the European Dialysis and Transplant Asso­
ciation Vol. X. New York: Pitman Medical, 1973:247-63. 
3. Blumenkrantz MJ, Roberts M. Progress in peritoneal dialy­
sis: an historical prospective. Contr Nephrol 
1979;17:101-10. 
4. Brown RD, Manno JE. Estrip, a Basic computer program for 
obtaining initial polyexponential parameter estimates. J 
Pharm Sci 1978;67:1687-91. 
5. Charytan c, Spinowitz BS, Galler M. A comparative study 
of continuous ambulatory peritoneal dialysis and center 
hemodialysis: efficacy complications, and outcome in the 
treatment of end-stage renal disease. Arch Intern Med 
1986;146:1138-43. 
6. Chiou WL. New calculation method for mean apparent drug 
volume of distribution and application to dosage 
regimens. J Pharm Sci 1979;68:1067-69. 
7. Chiou WL. New calculation method for mean total body 
clearance of drugs and its application to dosage 
regimens. J Pharm Sci 1980,69:90-1. 
8. Chou Y. Statistical analysis with business and economic 
implications, ed. New York: Holt, Rinehart and Winston, 
Inc, 1963:67-9. 
177 
9. Cunha BA, Ristuccia AM. Clinical usefulness of 
vancomycin. Clin Pharm 1983;2:417-24. 
10. Oiaz-Buxo JA. Intermittent, continuous ambulatory, and 
continuous cycling peritoneal dialysis. In: Nissenson 
AR, Fine RN, Gentile DE, eds. Clinical dialysis Vol. I. 
Norwalk: Appleton-Century-Crofts, 1984:263-306. 
11. Digenis GE, Rabinovich S, Medline A, Rodella H, Wu G, 
oreopoulos OG. Electron microscopic study of the 
peritoneal kinetics of iron dextran during peritoneal 
dialysis in the rabbit. Nephron 1984;37:108-12. 
12. Exaire E, Trevino-Becerra A, Monteon F. An overview of 
treatment with peritoneal dialysis in drug poisoning. 
Contr Nephrol 1979;17:39-43. 
13. Farrell PC. Kinetic modeling: applications in renal and 
related diseases. Kid Int 1983;24:487-95. 
14. Farrell PC. Kinetic modeling in peritoneal dialysis. In: 
Nissenson AR, Fine RN, Gentile DE, eds. Clinical 
dialysis Vol. I. Norwalk: Appleton-century-Crofts, 
1984:307-318. 
15. Fekety R. Vancomycin. Med Clin North Am 1982;66:175-80. 
16. Funck-Brantano JL, Man NK. An overveiw of clinical 
implications of middle molecules and their kinetics in 
uremia. Artif Organs 1981;4(Suppl) :125-32. 
17. Gibaldi M, Perrier o.  Pharmacokinetics, ed 2. 
Philadelphia: Marcel Dekker, Inc, 1982:84-92. 
18. Gibson TP, Atkinson AJ, Matusk E, Nelson LO, Briggs WA. 
Kinetics· of procainamide and n-acetylprocainamide in 
renal failure. Kid Int 1977;12:422-29. 
19. Golper TA, Bennett WM. Drug Usage in Dialysis Patients. 
In: Nissenson AR, Fine RN, Gentile DE eds. Clinical 
dialysis, Vol. I. Norwalk: Appleton-century-Crofts, 
1984:609-24. 
20. Gulyassy PF, Depner TA. Abnormal drug binding in uremia. 
Dail Transpl 1979;8:19-23. 
21. Hartford AM, Sica DA, Tartaglioni TA, Polk RA, Dalton 
HP, Poynor W. Vancomycin pharmacokinetics in continuous 
ambulatory peritoneal dialysis patients with peritonitis. 
Nephron 1986;43:217-22. 
178 
22. Henderson LW, Nolph KD. Altered permeability of the 
peritoneal membrane after using hypertonic peritoneal 
dialysis fluid. J Clin Invest 1969;48:992-1001. 
23. Hiatt MP, Pyle WK, Moncrief JW, Popovich RP. A 
comparison of the relative efficiency of CAPO and 
hemodialysis in the control of solute concentration. 
Artif Organs 1980;4:37-43. 
24. Hutchinson TA, Harvey CE. Survival with different forms 
of dialysis treatment: a prognostically controlled 
comparison. ASAIO 1985;8:13-17. 
25. Janicke DM, Morse GD, Apicella MA, Jusko WJ, Walshe JJ. 
Pharmacokinetic modeling of bidirectional transfer 
during peritoneal dialysis. Clin Pharmacol Ther 
1986 ;40: 209-1.8. 
26. Janknegt R, Keks CHW. Pharmacokinetic aspects during 
continuous ambulatory peritoneal dialysis: a literature 
review. Pharm Weekbl Sci Ed 1984;6:229-36. 
27. Johnson CA, Zimmerman SW, Rogge M. The pharmacokinetics 
of antibiotics used to treat peritoneal dialysis­
associated peritonitis. Am J Kid Dis. 1984;4:3-17. 
28. Jones GL, Wimbish GH, McIntosh WE. Phenytoin: basic and 
clinical pharmacology. Med Res Rev 1983;3:383-34. 
29. Jusko WJ, Baliah T, Kim KH, Gerbracht LM, Yaffe SJ. 
Pharmacokinetics of gentamicin during peritoneal 
dialysis in children. Kid Int 1976;9:430-38. 
30. Kabra PM, Chen SH, Marton LJ. Liquid-chromatographic 
determination of antidysrhythmic drugs: procainamide, 
lidocaine, quinidine, disopyramide, and propranolol. 
Ther Drug Monitor 1981;3:91-101. 
31. Krothapalli RK, Senekjian HO, Ayus JC. Efficacy of 
intravenous vancomycin in the treatment of gram-positive 
peritonitis in long-term peritoneal dialysis. Am J Med 
1983;75:345-48. 
32. Kucers A. Vancomycin. J Antimicrob Chemother 
1984;14:564-66. 
33. Lam FC, Hung CT, Perrier DG. Estimation of variance for 
harmonic mean half-lives. J Phann Sci 1985;74:229-31. 
179 
34. Lisby SM. Disposition and protein binding of phenytoin 
in patients undergoing continuous ambulatory peritoneal 
dialysis. Pharm.D. Thesis. Virginia Commonwealth 
University, Richmond. 1985. 
35. Maher JF. Transport kinetics of drugs and peritoneal 
dialysis. In: Gahl GM, Kessel M, Nolph KD, eds. Advances 
in peritoneal dialysis: proceedings of the second 
international symposium on peritoneal dialysis. 
Amsterdam: Excerpta Medica, 1981:37-40. 
36. Mattocks AM, El-Bassiouni EA. Peritoneal dialysis: a 
review. J Pharm Sci 1971;60:1767-82. 
37. McNamara PJ, Lalka D, Gibaldi M. Endogenous accumulation 
products and serum protein binding in uremia. J Lab Clin 
Med 1981;98:730-40. 
38. Metzler CM, Elfring GL, McEwen AJ. A package of computer 
programs for pharmacokinetic modeling. Biometrics 
1974;1:562. 
39. Metzler CM, Weiner DL. Nonlin84 users guide. Statistical 
Consultants Inc, Lexington 1984. 
40. Nolph KO. Peritoneal clearances. J Lab Clin Med 
1979;94:519-25. 
41. Nolph KD, Miller FN, Pyle WK, Popovich RP, Sorkin MI. An 
hypothesis to explain the ultrafiltration 
characteristics of peritoneal dialysis. Kid Int 
1981;20:543-48. 
42. Nolph KD, Popovich RP, Ghods AJ, Tardowski z. 
Determinants of low clearances of small solutes during 
peritoneal dialysis. Kid Int 1978;13:117-23. 
43. Nolph KD, Twardowski ZJ, Popovich RP, Rubin J. 
Equilibration of peritoneal dialysis solutions during 
long-dwell exchanges. J Lab Clin Med 1979;93:246-56. 
44. Oder-Cederlof I, Berga o. Kinetics of diphenylhydantoin 
in uraemic patients: consequences of decreased plasma 
protein binding. Europ J Clin Pharmacol 1974;7:31-7. 
45. Paton TW, Cornish WR, Manuel MA, Hardy BG. Drug therapy 
in patients undergoing peritoneal dialysis: clinical 
pharmacokinetic considerations. Clin Pharmacokin 
1985;10:404-426. 
180 
46. Perucca E. Plasma protein binding of phenytoin· in health 
and disease: relevance to therapeutic drug monitoring. 
Ther Drug Mon 1980;2:331-44. 
47. Popovich RP. Physiological transport parameters in 
patients. Dial Transpl 1978;7:823. 
48. Popovich RP, Moncrief JW. Kinetic modeling of peritoneal 
transport. Contr Nephrol 1979;17:59-72. 
49. Popovich RP, Moncrief JW, Decherd JF, Bomar JB, Pyle Wk. 
The definition of a novel portable/wearable equilibrium 
peritoneal dialysis technique. ASAIO abstracts. 
1976;5:64. 
50. Popovich RP, Moncrief JW, Nolph KO, Ghods AJ, Twardowski 
ZJ, Pyle WK. Continuous ambulatory peritoneal dialysis. 
Ann Int Med 1978;88:449-56. 
51. Pyle WK. Mass transfer in peritoneal dialysis. PhD. 
Thesis. University of Texas, Austin. (1981). 
52. Pyle WK, Moncrief JW, Popovich RP. Peritoneal transport 
evaluation in CAPO. In: Moncrief JW, Popovich RP, eds. 
CAPO update: continuous ambulatory peritoneal dialysis. 
New York: Masson, 1981;35-51. 
53. Pyle WK, Popovich RP, Moncrief JW. Mass transfer in 
peritoneal dialysis. In: Gahl GM, Kessel M, Nolph KD, 
eds. Advances in peritoneal dialysis: proceedings of the 
second international symposium on peritoneal dialysis. 
Amsterdam: Excerpta Medica, 1981:41-46. 
54. Quevedo SG, Young JH, Carrie BJ, Holman HR. Continuous 
ambulatory peritoneal dialysis: bridging the gap between 
evaluation and pratice in chronic illness. Ann Int Med 
1986;104:430-32. 
55. Randerson DH, Farrell PC. Mass transfer properties of 
the human peritoneum. ASAIO. 1980;3:140-46. 
56. Richens A. Clinical pharmacokinetics of phenytoin. Clin 
Pharmacokin 1979;4:153-69. 
57. Riggs OS. The mathematical approach to physiological 
problems: a critical primer, ed 3. Cambridge: The M.I.T. 
Press, 1976:222-28. 
181 
58. Robson M, oreopoulos DG, Izatt S, Ogilvie R, Rapoport A, 
DeVeber GA. Influence of exchange volume and dialysate 
flow rate on solute clearance in peritoneal dialysis. 
Kid Int 1978;14:486-90. 
59. Roden DM, Woosley RL. Class I antiarrhythmic agents: 
quinidine, procainamide and n-acetylprocainamide, 
disopyramide. Pharmac Ther 1984;23:179-91. 
60. Rogge MC, Johnson CA, Zimmerman SW, Welling PG. 
Vancomycin disposition during continuous ambulatory 
peritoneal dialysis: a pharmacokinetic analysis of 
peritoneal drug transport. Antimicrob Agents Chemother 
1985;27:578-82. 
61. Roxe DM, Del Greco F, Hughes JH, Krumlovsky F, Ghantous 
w, Ivanovich P, Quintanilla A, Salkin M, Stone N, Reins 
M. Hemodialysis vs. peritoneal dialysis: results of a 3-
year prospective controlled study. Kid Int 1981;19:341-
48. 
62. Rubin J, Adair C, Barnes T, Bower J. Dialysate flow rate 
and peritoneal clearance. Arn J Kid Dis. 1984;4:260-67. 
63. Rubin J, Barnes T, Bower J. Morbidity and mortality in 
CAPD and home hemodialysis: one center's five-year 
experience. ASAIO. 1985;8:22-7. 
64. Sedman AJ, Wagner JG. Cstrip, a fortran IV computer 
program for obtaining initial polyexponential parameter 
estimates. J Pharm Sci 1976;65:1006-10. 
65. Tenckhoff H. Catheter implantation. Dial Transpl 
1972;1:18-20. 
66. Thakker KM, Wood JH, Mikulecky DC. Dynamic simulation of 
pharmacokinetic systems using the electrical circuit 
analysis program SPICE2. Comput Prog Biomed 1982;15:61-
72. 
67. Trissel LA. Handbook on injectable drugs, ed. 3. 
Bethesda: American Society of Hospital Pharmacists' Inc, 
1983:380. 
68. Twardowski Z, Ksiazek A, Majdan M, Janicka L, Bochenska­
Nowacka E, Sokolowska G, Gutka A, Zbihowska A. Kinetics 
of continuous ambulatory peritoneal dialysis (CAPD) with 
four exchanges per day. Clin Neph 1981;15:119-30. 
182 
69.- Vladimirescu A, Newton AR, Pederson DO. Spice version 
2G.O user's guide. Oepartment of electrical engineering 
and computer sciences, University of California, 
Berkley. 1980. 
70. Winter ME, Katcher BS, Koda-Kimble MA. Basic clinical 
pharmacokinetics. San Francisco: Applied Therapeutics, 
Inc, 1981:102. 
71. Yonce CS. Pharmacokinetics of procainamide HCl in 
continuous ambulatory peritoneal dialysis (CAPO). 
Pharm.D. Thesis, Virginia Commonwealth University, 
Richmond. 1984. 
183 
APPENDIX A 
Procainamide and N-acetylprocainamide serum concentrations 
during CAPO. 
Patient Time Proc. Est. Pree Napa Est. Napa 
1 0.50000 2.30000 2.05730 0.00000 0.00000 
1. 00000 2.40000 2.79370 0.15000 0.06169 
2.00000 3.30000 3.04850 0.24000 0.16090 
4.00000 2.70000 2.77550 0.40000 0.35222 
6.00000 2.50000 2.48120 0.57000 0.51947 
10.00000 2.00000 2.01920 0.81000 0.79262 
14.00000 1.70000 1. 68330 1.00000 1.00270 
24.00000 1. 20000 1.16400 1. 30000 1.34750 
34.83000 0.82000 0.85555 1.50000 1. 54590 
50.75000 0.62000 0.58936 1. 70000 1. 65880 
73.31000 0.33000 0.36583 1.60000 1. 62520 
95.78000 0.24000 0.23040 1.50000 1. 48210 
Patient Time Proc. Est. Pree Napa Est. Napa 
2 0.50000 0.11000 0.40093 
1.00000 0.48000 0.72657 
2.00000 0.91000 1.19420 0.18000 0.12688 
4.00000 1. 90000 1. 62000 0.59000 0.39194 
6.00000 1.80000 1. 65980 0.80000 0.68817 
10.00000 1. 30000 1. 32750 1. 20000 1. 20200 
14.00000 0.89000 0.93965 1.50000 1. 54620 
24.00000 0.47000 0.41140 1. 70000 1. 88490 
48.00000 0.20000 0.16400 1. 50000 1. 80340 
72. 00000 0.12000 0.09293 1. 40000 1. 51870 
96.00000 1. 20000 1. 21550 
Patient Time Proc. Est. Pree Napa Est. Napa 
3 0.50000 3.00000 3.06750 0.29000 0.05094 
1.00000 3.90000 3.83540 0.47000 0.14776 
2.00000 3.80000 3.85090 0.68000 0.35953 
4.00000 3.10000 3.28570 0.99000 0.73927 
6.00000 3.00000 2.78900 1. 20000 1.05220 
8.00000 2.40000 2.37600 1. 30000 1. 30900 
10.00000 2.00000 2. 03240 1. 50000 1. 51930 
14.00000 1.60000 1.50740 1.80000 1. 83050 
24.00000 0.91000 0.78419 2.20000 2.20520 
36.00000 0.48000 0.43460 2.10000 2.28970 
48.00000 0.31000 0.28780 2.10000 2.22300 
72. 00000 0.20000 0.16490 2.00000 1. 95560 
184 
APPENDIX A (cont.) 
Procainamide and N-acetylprocainamide serum concentrations 
during CAPO. 
Patient Time Proc. Est. Proc Napa Est. Napa 
4 l. 00000 2.40000 2.42120 
2.00000 2.40000 2.36680 0.28000 0.17509 
4.00000 2.00000 l. 99280 0.41000 0.35322 
6.00000 l.50000 l.69710 0.53000 0.49918 
8.00000 l.60000 l. 46840 0.64000 0.62008 
10.00000 l. 30000 l. 28920 0.76000 0. 72130 
14.00000 l.10000 l.03100 0.88000 0.87976 
24.00000 0.65000 0.67771 1.00000 l.11720 
36.00000 0.43000 0.45735 l. 30000 l. 23890 
48.00000 0.28000 0.31832 l. 20000 l. 26270 
72.17000 0.17000 0.15564 l. 20000 l.16040 
96.00000 l. 00000 0.98316 
Patient Time Proc. Est. Proc Napa Est. Napa 
5 0.50000 3.70000 3.92470 0.53000 0.19126 
l.00000 4.50000 4.21260 l. 20000 0.50066 
2.00000 3.10000 3.45030 l. 50000 l.05880 
4.00000 2.50000 2.26780 l.90000 l. 82130 
6.00000 l.90000 l. 64640 2.20000 2.29040 
8.00000 l.70000 l. 30250 2.50000 2.59930 
10.00000 l. 30000 l.09550 2.70000 2.81410 
14.00000 0.95000 0.85602 2.80000 3.08080 
24.00000 0.50000 0.54233 3.20000 3.25940 
36.00000 0.26000 0.32426 2.90000 3.02150 
48.00000 0.20000 0.19410 2.50000 2.58870 
72.00000 2.10000 l. 68200 
Patient Time Proc. Est. Proc Napa Est. Napa 
6 0.50000 3.80000 4.03170 0.44000 0.15708 
l.00000 4.80000 4.68530 0.90000 0.36189 
2.00000 4.50000 4.61140 1.20000 0.78988 
3.00000 4.40000 4.20650 l. 80000 l.17970 
4.00000 3.70000 3.80400 l.80000 l. 52220 
6.00000 3.40000 3.11460 2.10000 2.08100 
10.00000 2.20000 2.12570 2.40000 2.81090 
14.00000 2.00000 l. 49250 3.20000 3.19000 
24.00000 0.81000 0.71205 3.20000 3.36000 
36.00000 0.36000 0.37988 2.60000 3.01770 
48.00000 0.23000 0.24296 2.50000 2.55300 
72.00000 0.10000 0.12171 l.70000 l. 72440 
96.00000 l. 50000 l.11840 
120.0000 1.00000 0.70762 
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Coefficients of Variance for the Fitted Procainamide 
Parameters. 
!Patient Patient !Patient 
I 1 2 I 3 ----1-------- --------1--------
Kl2 I 0.61 18.84 I 0.80 ----1-------- --------1--------
K13 I o.48 25.30 I 0.61 ----1-------- --------1--------
K21 I 0.92 3.03 I 2.12 ----1-------- --------1--------
KJO I 0.28 0.58 I 0.29 ----1-------- --------1--- ----
KlO I 1. 52 31. 64 I 1. 77 ----1-------- --------1--------
Ka I 0.07 16.33 I 0.16 
Patient 
4 
0.41 
1. 39 
0.54 
0.20 
0.82 
0.34 
Patient Patient 
5 6 -------- -------
0.60 0.96 -------- -------
0.47 0.77 -------- -------
0.69 1.44 -------- -------
0.40 0.30 -------- -------
1. 23 3.25 -------- -------
0.41 0.25 
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APPENDIX C 
Phenytoin Serum and Dialysate Data with NONLIN84 Predicted 
Values. 
Patient #1 FREE DRUG LEVELS TOTAL DRUG LEVELS 
SERUM DIALYSATE SERUM 
TIME REAL NONLIN REAL NONLIN REAL 
0.00 o.oo o.oo o.oo 0.00 
0.25 0.26 0.35 
0.27 3.31 3.27 0.38 14.26 
0.50 1.54 1. 72 0.71 0.71 6.14 
0.75 1.27 1.15 0.81 0.82 5.50 
1. 00 1.18 0.95 0.86 0.85 5.89 
1.50 0.86 0.90 0.85 4.48 
2.00 0.84 0.88 0.84 3.67 
3.00 0.76 0.81 0.79 0.82 3.22 
4.00 0.73 0.79 0.76 0.79 3.54 
6.00 0.75 0.74 0.37 3.18 
6.85 0.67 0.73 0.36 2.91 
7.35 0.63 0.72 0.47 2.75 
8.35 0.59 0.69 0.47 3.13 
10. 35 0.69 0.65 2.62 
10.50 0.62 
14.88 0.58 0.57 0.54 2.62 
19.75 0.56 0.49 0.48 2.38 
23.75 0.49 0.44 0.48 1. 87 
Patient #2 FREE DRUG LEVELS TOTAL DRUG LEVELS 
SERUM DIALYSATE SERUM 
TIME REAL NONLIN REAL NONLIN REAL 
0.25 0.09 0.14 
0.28 1.25 1.21 8.20 
0.52 1.00 1.05 0.32 0.35 6.24 
0.75 0.90 0.95 0.44 0.46 6.01 
1. 00 0.92 0.87 0.58 0.54 5.86 
1.50 0.79 0.78 0.64 0.63 4.98 
2.00 0.71 0.73 0.66 0.65 4.81 
3.00 0.69 0.68 0.56 0.64 4.51 
4.00 0.67 0.64 0.64 0.62 3.95 
5.85 0.61 0.57 
6.02 0.62 0.58 3.94 
6.70 0.56 0.56 0.27 3.43 
7.25 0.53 0.55 0.36 3.31 
8.22 0.53 0.52 0.27 3.16 
10.00 0.44 
10.20 0.45 0.47 0.34 2.87 
14.32 0.40 0.39 2.11 
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17.53 0.32 o. 3.4 0.25 1. 33 
22.50 0.26 0.26 
22.53 0.24 1.25 
Phenytoin Serum and Dialysate Data with NONLIN84 Predicted 
Values. 
Patient #3 FREE DRUG LEVELS TOTAL DRUG LEVELS 
TIME REAL NONLIN REAL NONLIN REAL 
0.27 2.20 2.11 0.18 0.28 9.43 
0.50 1. 26 1.42 0.44 0.54 5.27 
0.75 1. 03 1. 07 0.44 0.68 4.38 
1. 00 0.88 0.91 0.78 0.73 3.88 
1.50 0.89 0.79 0.89 0.76 3.47 
2.00 0.82 o. 77 0.80 0.76 3.54 
3.00 0.75 0.74 0.76 0.74 3.17 
4.00 0.73 o. 72 0.77 o. 72 3.09 
5.85 0.73 0.69 
6.00 0.70 0.68 2.69 
6.85 0.64 0.67 0.37 3.09 
7.33 0.68 0.66 0.47 2.73 
8.40 0.67 0.64 0.56 2.31 
10.33 0.60 0.61 0.61 2.69 
14.77 0.51 0.54 0.33 2.29 
19.00 0.45 0.48 0.55 1. 77 
23.00 0.41 0.43 1. 58 
Patient #4 FREE DRUG LEVELS TOTAL DRUG LEVELS 
SERUM DIALYSATE SERUM 
TIME REAL NONLIN REAL NONLIN REAL 
0.30 1.90 1.89 0.29 0.48 7.76 
0.50 0.85 0.74 
0.53 1.16 1.20 5.26 
0.77 0.96 0.93 0.94 0.85 3.97 
1.00 0.86 0.83 0.94 0.88 3.44 
1.50 0.76 0.75 0.83 0.86 3.70 
2.02 0.72 0.72 0.76 0.83 2.95 
3.00 0.69 0.67 2.19 
3.03 0.76 0.77 
4.00 0.67 0.72 
4.07 0.55 0.62 2.70 
5.78 0.64 0.63 
6.03 0.50 0.53 2.07 
6.70 0.52 0.51 0.35 2.23 
7.18 0.50 0.49 0.41 2.34 
8.18 0.43 0.45 0.43 1.87 
10.00 0.45 
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10.18 0.36 0.39 1. 68 
14.50 0.33 
14.53 0.29 0.28 1.43 
18.88 0.24 0.20 0.21 1.09 
23.33 0.23 0.15 0.64 
23.47 0.21 
Phenytoin Serum and Dialysate Data with NONLIN84 Predicted 
Values. 
Patient #5 FREE DRUG LEVELS TOTAL DRUG LEVELS 
SERUM DIALYSATE SERUM 
TIME REAL NONLIN REAL NONLIN REAL 
0.28 1.83 2.00 7.18 
0.30 0.32 0.25 
0.53 1.91 1. 62 0.60 0.46 7.01 
0.78 1. 37 1.40 0.69 0.61 5.04 
1.18 1.26 1.20 0.77 0.73 4.60 
1.50 0.77 0.77 
1.53 1.17 1.11 4.81 
2.02 0.75 0.79 3.66 
2.05 0.93 1. 06 
3.00 0.73 0.78 
3.05 0.96 1. 01 4.30 
4.02 0.70 0.76 
4.07 0.83 0.98 4.15 
5.83 0.66 o. 72 
6.17 0.88 0.92 3.56 
6.83 1. 29 0.90 0.28 3.83 
7.27 0.76 0.89 0.44 2.78 
8.27 0.77 0.87 0.47 3.17 
10.00 0.49 
10.32 0.75 0.82 2.93 
14.75 0.74 0.72 0.46 3.13 
19.35 0.62 0.63 0.41 2.18 
23.18 0.44 
23.35 0.65 0.56 2.52 
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Phenytoin Serum and Dialysate Data with NONLIN84 Predicted 
Values. 
Patient #6 FREE DRUG LEVELS TOTAL DRUG LEVELS 
SERUM DIALYSATE SERUM 
TIME REAL NONLIN REAL NONLIN REAL 
0.28 1. 09 1. 09 0.25 0.21 6.81 
0.48 0.37 0.40 
0.53 0.94 0.94 5.97 
0.75 0.54 0.53 
0.87 0.78 0.85 5.42 
1. 00 0.60 0.59 
1. 07 0.94 0.82 5.08 
1.55 0.59 0.63 
1.67 o. 77 0.77 4.79 
2.02 0.61 0.63 
2.07 0.71 0.75 4.81 
3.03 0.71 0.73 0.61 0.61 4.66 
4.02 0.68 0.70 0.63 0.59 4.56 
5.78 1.40 4.25 
6.00 0.64 0.65 
6.53 2.44 3.80 
7.53 0.68 0.62 3.79 
7.70 3.42 
8.37 0.55 0.60 0.49 3.31 
10.22 0.60 0.56 0.46 2.29 
14.50 0.38 2.18 
14.65 0.48 0.48 
19.27 0.26 1.86 
19.37 0.39 0.40 
23.00 0.30 
190 
APPENDIX D 
Coefficients of Variance for the Fitted Phenytoin 
Parameters. 
jPatient jPatient !Patient !Patient !Patient !Patient 
I 1 I 2 I 3 I 4 I 5 I 6 -----1--------1--------1--------1--------1--------1-------
Vc I 0.06 I o.04 I o.o7 I o.oa I o.o9 I 0.06 -----1--------1--------1--------1--------1--------1-------
Alphal 0.10 I o.o9 I 0.13 I 0.12 I o.24 I 0.13 -----1--------1--------1--------1--------1--------1-------
Beta I o.24 I o.09 I 0.25 I 0.16 I 0.29 I 0.11 -----1--------1--------1--------1---- .---1--------1-------
K21 I 0.12 I o.o9 I 0.13 I 0.10 I 0.24 I 0.13 -----1--------1--------1--------1--------1--------1-------
Vp I o.o5 I o.o9 I o.o7 I 0.06 I 0.15 I 0.15 
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Vancomycin data Patient #1 Vancomycin data 
Pt #2 episode l 
TIME DIALYSATE SERUM TIME DIALYSATE SERUM 
(hrs (mg/1) (mg/1) (hrs) (mg/1) (mg/1) 
o.oo 50 o.oo 55 
0.50 36 0.17 0 
0.58 5.3 0.33 2.1 
0.92 6.2 0.50 48 
1.00 33 0.58 4.4 
1. 08 7 1. 00 41 
1.42 8.9 1. 08 6.4 
1.50 29 2.00 39 
2.00 32 2.08 9 
2.42 12 4.00 33 
4.00 32 4.08 11.8 
4.42 14.3 4.75 3.8 
5.95 26 4.92 2.3 
14.50 11.2 5.33 3.7 
15.25 2.3 5.67 4.4 
15.42 2.7 6.00 34 
15.92 3.8 6.67 6.2 
16.92 5.7 8.67 10.4 
17.75 23 18.00 25 
18.92 8.6 18.75 18.2 
23.75 8.3 23.00 9.2 
29.17 8 23.67 2.3 
29.75 21 23.83 2.9 
39.50 9.9 24.00 3.8 
40.63 2.2 24.50 4.6 
40.72 2 25.50 6.5 
40.80 2.7 27.50 9.7 
40.88 2.7 30.00 12.7 20 
41. 05 3.6 33.75 11.5 
41.55 3.9 43.42 8.7 
42.00 21 47.42 7.9 
42.55 5.3 54.00. 21 
66.50 5.6 57.25 8.5 
71. 75 17 67.25 11.5 
89.75 15 71.93 5.9 
95.67 1.1 72.82 1. 2 
95.83 1.5 72.98 1.5 
96.33 1.8 73.23 1.9 
96.83 2.1 73.73 3.2 
97.83 3.7 74.73 4.6 
100.42 5.2 76.73 6.2 
115.58 4.6 78.00 18 
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Observed vancomycin concentrations. 
Vancomycin data Pt #1 Vancomycin data 
Pt #2 episode 1 
TIME DIALYSATE SERUM TIME DIALYSATE 
(hrs (mg/1) (mg/1) (hrs) (mg/1) 
124.75 14 80.92 5.5 
148.75 10 91. 08 
172.58 12 96.50 4.8 
173.00 3.1 100.08 5.4 
102.00 
104.50 4.5 
115.00 5.9 
119.83 3.3 
124.00 4.1 
126.00 
128.25 2.5 
139.25 5.8 
144.00 4 
144.50 
144.67 
144.92 
145.42 1.1 
146.45 1.8 
148.42 3 
148.50 
Vancomycin data Vancomycin data 
Pt #2 episode 2 Pt #2 episode 3 
TIME DIALYSATE SERUM TIME DIALYSATE 
(hrs) (mg/1) (mg/1) (hrs) (mg/1) 
0.00 o.oo 
0.17 0.9 0.17 2 
0.33 2.8 0.33 3.8 
0.50 47 0.50 
0.58 3.9 0.58 6.9 
1. 00 38 1. 00 
1. 08 6.9 1.08 10.5 
2.00 37 2.00 
2.08 12 2.08 14.7 
4.08 15 37 4.00 
6.00 39 4.08 17 
11.25 16 4.33 
15.92 13 4.67 
16.67 3.3 5.00 
16.83 3.9 5.32 1. 6 
SERUM 
(mg/1) 
16 
11 
11 
SERUM 
(mg/1) 
61 
56 
45 
37 
35 
33 
32 
33 
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Observed vancomycin concentrations. 
Vancomycin data Vancomycin data 
Pt #2 episode 2 Pt #2 episode 3 
TIME DIALYSATE 
(hrs (mg/1) 
17.08 4.9 
17.58 6.1 
18.00 
18.58 8.9 
20.58 12.5 
25.08 12 
30.00 
33.92 14 
35.12 1.8 
35.28 2.6 
35.53 3.3 
36.03 4.4 
37.03 6.4 
39.03 8.6 
42.92 7.4 
46.92 6.4 
54.00 
58.42 11.5 
63.13 7 
67.92 7 
71.92 5.8 
78.00 
82.17 8.5 
82.83 
83.00 1.3 
83.25 1.8 
83.75 2.5 
84.75 3.3 
86.75 5.4 
134.42 
13.67 
134.92 l 
135.42 1.4 
136.42 2 
138.00 17 
138.42 3.2 
SERUM 
(mg/1) 
29 
25 
24 
21 
DIALYSATE 
(mg/1) 
TIME 
(hrs) 
5.33 
5.48 
5.67 
5.73 
6.00 
6.23 
6.33 
7.23 
9.23 
17.87 
18.00 
18.33 
18.50 
18.75 
19.25 
20.25 
22.25 
26.82 
30.00 
30.92 
3.7 
5.2 
8.4 
11. 2 
16.5 
16.l 
2 
3 
4.9 
6.4 
8.9 
13 
11.8 
11. 3 
SERUM 
(mg/1) 
33 
34 
31 
32 
26 
27 
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Observed vancomycin 
Vancomycin data Pt #3 
TIME DIALYSATE SERUM 
(hrs) (mg/1) (mg/1) 
o.oo 6.6 
1.00 32 
1.08 7.5 
1. 25 9.4 
1.50 10.9 
2.00 12 23 
3.00 15.3 
5.00 17.1 
6.00 21 
8.12 23 
10.25 17.6 
11.12 4.4 
11.28 5.5 
11.53 5.7 
12.03 7.5 
13.03 11.4 
15.03 13.7 
16.38 3 
16.55 4.6 
16.80 5.7 
17.30 7.9 
18.30 10.5 
20.00 16 
20.30 12.6 
31.92 14.3 
32.00 17 
37.17 11.9 
37.78 2.5 
37.95 4.3 
38.20 4.9 
38.70 6 
39.70 8.5 
41. 70 11.2 
44.02 16 
46.35 9.9 
56.33 12.3 
57.02 2.1 
57.18 3.1 
57.43 4 
57.93 5.3 
58.93 7.2 
60.93 11 
concentrations. 
Vancomycin data 
TIME DIALYSATE 
(hrs) (mg/1) 
0.00 
0 .17. 2.7 
0.33 3.9 
0.42 
0.58 5.2 
0.92 
1. 08 7.7 
1. 92 
2.08 10.1 
4.25 11.9 
4.42 
5.92 
17.92 11.4 
18.42 3.1 
18.58 
18.67 3.9 
19.92 5.6 
20.33 6.7 
22.33 8.4 
44.92 10.4 
Pt #4 
SERUM 
(mg/1) 
39 
32 
30 
28 
24 
23 
18 
16 
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Observed vancomycin concentrations. 
Vancomycin data Pt #3 
TIME DIALYSATE SERUM 
(hrs) (mg/1) (mg/1) 
68.00 14 
68. 50 9 
72.50 8.7 
88. 75 9 
92.67 5.4 
98.17 6.3 
102. 00 13 
102.83 7.9 
114.50 8.3 
120.50 5.3 
124.50 5.8 
126.25 9.5 
128.50 
140.17 7.1 
140.50 1.3 
140.67 1.8 
140.92 2.1 
141.42 2.5 
142.42 3.4 
144.42 4.3 
145.58 5.8 
Vancomycin data Pt #5 
TIME DIALYSATE SERUM 
(hrs) (mg/1) (mg/1) 
o.oo 66 
0.50 54 
0.58 
0.75 3.9 
1. 00 5.6 38 
1. 50 8.4 
2.00 43 
2.50 13 
4.00 39 
4.50 15 
6.00 30 
15.17 13 
16.12 
16.28 
16.53 3.4 
18.00 25 
18.03 10.1 
20.23 25 
195 
196 
APPENDIX E (cont.) 
Observed vancomycin concentrations. 
Vancomycin data Pt #5 
TIME DIALYSATE SERUM 
(hrs) (mg/1) (mg/1) 
20.57 27 
20.90 29 
21.23 20 
21. 67 
23.37 16 
30.00 18 
37.17 5.2 
41.95 13.5 
46.58 13.3 
51.25 10.1 
54.00 16 
61. 08 13.6 
66.42 11.4 
71.00 10.5 
75.33 10.1 
78.00 11 
85.00 11 
90.00 9.4 
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APPENDIX F 
NONLIN76 Subroutine DEFUNC for Procainamide and 
N-acetylprocainamide during CAPO 
//STEPl EXEC FORTXCLG 
//FORT.SYSIN DD * 
C 
SUBROUTINE PLOTS(X) 
ENTRY PLOT(X) 
ENTRY AXIS(X) 
ENTRY SYMBOL(X) 
ENTRY WHERE(X) 
ENTRY DATE(X) 
RETURN 
END 
SUBROUTINE DFUNC(F,P,CON,VAL,X,I,J,ISPEC,XVEC,Y,W,NOBS) 
IMPLICIT REAL*8 (A-H,0-Z) 
DOUBLE PRECISION P(l) ,VAL(l),F,CON(l),Y(l),W(l) ,X,XVEC(l) 
DIMENSION ISPEC(l) ,NOBS(l) 
C ***** ENTER MAIN PROGRAM LINES***** 
XK12 P(l) 
XK13 P(2) 
XK21 P(3) 
XK30 P(4) 
XKlO P(5) 
XKA P(6) 
XOFVP = P(7) 
XOFVN = P(8) 
B = XK13 + XK21 + XK12 + XKlO 
C = (XK13 + XKlO) * XK21 
XLAMl = (B + ((B**2.)-4.*C)**.5)/ 2.0 
XLAM2 = (B - ((B**2.)-4.*C)**.5)/ 2.0 
ElCHCK = XKA * X 
IF(ElCHCK .LT. 150.) El DEXP (-ElCHCK) 
IF(ElCHCK .GE. 150.) El 0.0 
E2CHCK = (XLAMl * X) 
IF(E2CHCK .LT. 150.) E2 DEXP (-E2CHCK) 
IF(E2CHCK .GE. 150.) E2 0.0 
E3CHCK = (XLAM2 * X) 
IF(E3CHCK .LT. 150.) E3 DEXP (-E3CHCK) 
IF(E3CHCK .GE. 150.) E3 0.0 
E4CHCK = (XK30 * X) 
IF(E4CHCK .LT. 150.) E4 DEXP (-E4CHCK) 
IF(E4CHCK .GE. 150.) E4 0.0 
AP ((XK21 - XKA) * XKA) /((XLAMl - XKA)*(XLAM2-XKA)) 
BP ((XK21 - XLAMl)* XKA)/((XKA-XLAMl)*(XLAM2-XLAMl)) 
CP ((XK21 - XLAM2)* XKA)/((XKA-XLAM2)*(XLAM1-XLAM2)) 
DP ((XK21 - XK30) * XKA)/((XLAM1-XK30)*(XLAM2-XK30)) 
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NONLIN76 Subroutine DEFUNC for Procainamide and 
N-acetylprocainamide during CAPO. 
GO TO (10,20) ,J 
10 F = ((AP * El) + (BP * E2) + (CP * E3)) * XOFVP 
GO TO 30 
20 F = ((DP/(XKA - XK30))*E4 + (AP/(XK30 - XKA))*El + 
C(BP/(XK30 - XLAMl))*E2 + (CP/(XK30 - XLAM2))*E3) * 
C(XK13 * XOFVN) 
30 IF(ISPEC(8) .NE.9)RETURN 
WRITE(6,40)XLAM1,XLAM2 
40 FORMAT('OLAMBDA 1 = ',F8.5,' 1/HR'/' LAMBDA 2 
C' ,F8.5, 1 1/HR') 
RETURN 
END 
//LKED.SUB DD DSN=VCU.STATPGMS,DISP=SHR 
//LKED.SYSIN DD * 
ENTRY MAIN 
INCLUDE SUB(NONLN1,NONLN2,MISC) 
//GO.FT03F001 DD UNIT=SYSSQ,SPACE=(l200, (100,100)) 
//GO.PLOTTAPE DD DUMMY 
//GO.SYSIN DD * 
(input is found on the next page) 
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NOtUN76 Subroutine DEFUIC for Procainanide and 
N-acetylprocainamide during CAPO (input). 
000001 PROC-NAPA CAPO #1 W. II. IIT=I 
30 8 2 0 0 12 11 0 0 
.001 .001 
0.015 0.055 0.027 0.0026 0.006 2. 748 12.4 12.4 
0.001 0.001 0.001 0.0001 0.0001 0.01 2.0 2.0 
0.9 0.9 0.9 0.9 0.09 5.0 30.0 30.0 
2.3 2.4 3.3 2. 7 2.5 2.0 I. 7 1.2 
0.82 0.62 0.33 0.24 
0.15 0.24 0.4 0.57 0.81 1.0 1.3 1.5 
1. 7 1.6 1.5 
0.5 1.0 2.0 4.0 6.0 10.0 14.0 24.0 
34.03 50.75 73.31 95;78· 
1.0 2.0 4.0 6.0 10.0 14.0 24.0 34.83 
50.75 73.31 95. 78 
122101 PT 11 REOOtE USING UlST 
000001 PROC-NAPA CAPO 12 B. M. WT=! 
30 8 2 0 0 10 9 0 0 
0.001 .001 
0.04 0.124 0.039 0.0046 0.014 0.485 12.4 12.4 
0.001 0.100 0.030 0.0001 0.0091 0.01 2.0 2.0 
0.9 0.9 0.9 0.02 0.09 5.0 30.0 30.0 
0.11 0.48 o. 91 1.9 1.8 1.3 0.89 .47 
0.2 0.12 
0.18 0.59 0.8 1.2 1.5 I. 7 1.5 1.4 
1.2 
0.5 1.0 2. 0 4.0 6.0 10.0 14.0 24. 
48.0 72.0 
2.0 4.0 6.0 10.0 H.O 24.0 48.0 72. 
96. 
122101 PT 12 REOOtE USING UlST 
000001 PROC-NAPA CAPO 13 R.11. WT=! 
30 B 2 0 0 12 12 0 0 
0.001 .001 
0.015 0.071 0.023 0.0018 0.008 2.392 12.4 12.4 
0.001 0.055 0.021 0.0011 0.0061 0.01 2.0 2.0 
o. 9 0.9 0.9 0.011 0.09 5.0 30.0 30.0 
3.0 3.9 3.8 3.1 3.0 2. 4 2.0 1.6 
0.91 0.48 0.31 0.20 
0.29 0.47 0.68 0.99 1.2 1.3 1.5 1.a 
2.2 2.1 2.1 2.0 
0.5 1.0 2.0 4.0 6.0 8.0 10.0 14.0 
24.0 36.0 48.0 72.0 
0.5 1.0 2.00 4.0 6.0 B.O 10.0 14.0 
24.0 36.0 48.0 72.0 
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APPENDIX F <cont. l 
NON.JN76 Subroutine DEFUIC for Procaina111ide and 
N-acetylprocainuide during CAPO (input). 
122101 PT 13 REDONE USJN6 LAST 
000001 PROC-NAPA CAPO 14 A. B. IIT=I 
30 a 2 0 0 11 11 0 0 
0.001 .001 
0.026 0.069 0.038 0.0075 0.008 3.311 12.4 12.4 
0.001 0.001 0.001 0.0001 0.0001 0.01 2.0 2.0 
0.9 0.9 0.9 0.9 0.09 5 .. 0 30.0 30.0 
2.4 2.4 2.0 1.5 1.6 1.3 I.I .65 
0.43 0.28 0.17 
0.28 0.41 0.53 0.64 o. 76 0.88 1.0 1.3 
1.2 1.2 1.0 
1.0 2.0 4.0 6.0 8.0 10.0 14.0 24. 
36.0 48.0 72.17 
2. 0 4.0 6.0 8.0 10.0 14.0 24.0 36. 
48.0 72.17 96. 
122101 PT 14 RElJ(JJI( USJN6 LAST 
000001 PROC-NAPA CAPO 15 0. J. IIT=l 
30 8 2 I 0 0 11 12 0 0 
0.001 .001 
0.073 0.165 0.108 0.0089 0.019 3.432 12.4 12.4 
0.001 0.100 0.095 0.0001 0.0161 0.01 2.0 2.0 
0.9 0.9 0.9 0.9 0.09 5.0 30.0 30.0 
3. 7 4.5 3.1 2 .. 5 1.9 I. 7 1. 3 .95 
0.5 0.26 0.2 
0.53 1.2 1.5 1.9 2.2 2.5 2. 7 2.8 
3.2 2.9 2 .. 5 2.1 
0.5 1.0 2.0 4.0 6.0 8.0 10.0 14. 
24.0 36.0 -18.0 
0.5 1.0 2. 0 4.0 6.0 8.0 10.0 14. 
24.0 36.0 48.0 72.0 
122101 PT 15 REDONE US ING LAST 
000001 PROC-NAPA CAPO 16 W. S. IIT=l 
30 8 2 1 0 0 12 14 0 0 
0.001 .001 
o. 012 0.082 0.043 0.0119 0.009 2.595 12.4 12.4 
0.001 0.067 0.036 0.0001 0.0080 0.01 2.0 2.0 
0.9 0.9 0.9 0.024 0.09 9.0 30.0 30.0 
3.8 4.8 4.5 4.4 3. 7 3.4 2.2 2.0 
0.81 0.36 0.23 0.10 
0.44 0.9 1.2 1.8 1.8 2.1 2.4 3.2 
3.2 2.6 2.5 1.7 1.5 1.0 
0.67 1.17 2.17 3.17 4.17 6.17 10.17 14.17 
24.17 36.17 48.25 72.17 
0.67 1.17 2.17 3.17 4.17 6.17 10.17 14.17 
24.17 36.17 48.25 72.17 96.17 120.17 
122101 PT 16 IEOOIE USING LAST 
9 
II 
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APPENDIX G 
NONLIN84 Subroutine for Fitting Phenytoin Serum and 
Dialysate Data During CAPO 
TITLE 
PATIENT 1 SIMULTANEOUS FIT OF 2 COMPARTMENT PHENYTOIN INFUSION 
MODEL 
TEMP 
REMARK ASSIGN CONSTANTS AND PARAMETERS 
XKO = CON(l) 
TINF = CON(2) 
VC = P(l) 
XLAMl = P(2) 
XLAM2 = P(J) 
XK21 = P(4) 
VP = P(S) 
REMARK ASSIGN CALCULATED VARIABLES 
XKlO = (XLAM1*XLAM2)/XK21 
XK12 = XLAMl + XLAM2 - XK21 - XKlO 
TAU = MIN (TINF,X) 
DC XKO/VC 
DP = (XKO/VP) 
El = DEXP (XLAMl*TAU) 
EJ = DEXP (XLAM2*TAU) 
CHCK2 = (XLAMl*X) 
CHCK4 = (XLAM2*X) 
E2CHCK = MIN (CHCK2,50) 
E4CHCK = MIN (CHCK4,50) 
E2 = DEXP (-E2CHCK) 
E4 = DEXP (-E4CHCK) 
XL2 = -XLAM1*(XLAM2 - XLAMl) 
RT2 = -XLAM2*(XLAM1 - XLAM2) 
END 
FUNCl 
XLl (1-El)*(XK21-XLAM1)*E2 
RTl = (1-E3)*(XK21-XLAM2)*E4 
F = ((XL1/XL2) + (RT1/RT2))*DC 
END 
FUNC2 
XLFTl = (1-El)*XK12*E2 
RGHTl = (1-E3)*XK12*E4 
F = ((XLFT1/XL2) + (RGHT1/RT2))*DP 
END 
SECO 
REMARK CALCULATE SECONDARY PARAMETERS 
REMARK******************************* 
THALF = 0.693/XLAM2 
S(l) = THALF 
Rl = DC*((DEXP(-XLAM1*TINF)-l)*(XK21 - XLAM1))/XL2 
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APPENDIX G (cont.) 
NONLIN84 Subroutine for Fitting Phenytoin Serum and 
Dialysate Data During CAPO 
S(2) = Rl 
R2 = OC*((OEXP(-XLAM2*TINF)-l)*(XK21 - XLAM2))/RT2 
S(3) = R2 
Al = (Rl * XKO * TINF * XLAMl)/(XKO*(l - OEXP(-XLAMl*TINF))) 
S(4) = Al 
A2 = (R2 * XKO * TINF * XLAM2)/(XKO*(l - DEXP(-XLAM2*TINF))) 
S(5) = A2 
AUC = (Al / XLAMl) + (A2 / XLAM2) 
S(6) AUC 
AUMC = (Al / XLAM1**2.0) + (A2 / XLAM2**2.0) 
S(7) = AUMC 
XMRT = (AUMC/AUC) + (TINF*0.5) 
VDSS =((XKO*TINF*AUMC)/(AUC*AUC))-((XKO*TINF**2.0)/(AUC*2.0)) 
S(8) = VOSS 
TBC = VDSS/XMRT 
S(9) = TBC 
VOBETA = (XKO*TINF)/(AUC*XLAM2) 
S(lO) = VOBETA 
REMARK S(l2) XKlO 
REMARK S(l3) = XK12 
END 
EOM 
NFUN 2 
NOBS 14,8 
NPAR 5 
LOWER 1,1,0.008,0.01,1 
UPPER 500,8,0.09,8,1500 
INIT 130.39,6.6,0.05,1.14,15 
NSEC 10 
NCON 2 
CONS 1472, .25 
CONV 0.000001 
DATA 
0.27,3.31 
0.5,1.54 
0.75,1.27 
1. 0, 1.18 
1.5,0.76 
3.0,0.76 
4.0,0.73 
6.02,0.75 
6.85,0.67 
7.35,0.63 
8.35,0.59 
10.35,0.69 
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NONLIN84 Subroutine for Fitting Phenytoin Serum and 
Dialysate Data During CAPO. 
14.88,0.58 
19.75,0.56 
23.75,0.49 
0.25,2.6 
0.75,8.l 
2.0,8.8 
4.0,7.6 
BEGIN 
NEWP 0,1 
TITLE 
PATIENT #2 FOR 2 COMPARTMENT PHENYTOIN DATA 
NOBS 16,9 
LOWER l,l,0.001,0.0l,l 
UPPER 500,10,0.9,10,700 
INIT 220.65,2.6,0.07,l.48,ll.8 
CONS 1084.3,.23 
DATA 
0.28,1.25 
0.52, 1. 00 
0.75,0.90 
1.00,0.92 
1.50,0.79 
2.00,0.11 
3.00,0.69 
4.00,0.67 
6.02,0.62 
6.70,0.56 
7.25,0.53 
8.22,0.53 
10.20,0.45 
14.32,0.40 
17.53,0.32 
22.50,0.26 
0.25,0.09 
0.52,0.32 
0.75,0.44 
1. 00, 0.58 
1.50,0.64 
2.00,0.66 
3.00,0.56 
4.00,0.64 
5.85,0.61 
BEGIN 
NEWP 0,1 
TITLE 
PATIENT #3 FOR 2 COMPARTMENT PHENYTOIN DATA 
204 
APPENDIX G (cont.) 
NONLIN84 Subroutine for Fitting Phenytoin Serum and 
Dialysate Data During CAPO. 
NOBS 
INIT 
CONS 
DATA 
16,9 
130.74,6.5,0.04,6.21,12.3 
1104,.25 
0.27,2.20 
0.50,1.26 
0.75,1.03 
1. oo, 0.88 
1.50,0.89 
2.00,0.82 
3.00,0.75 
4.00,0.73 
6.00,0.70 
6.85,0.64 
7.33,0.68 
8.40,0.67 
10.33,0.60 
14.77,0.51 
19.00,0.45 
23.00,0.41 
0.27,0.18 
0.50,0.44 
0.75,0.44 
1.00,0.78 
1.50,0.89 
2.00,0.80 
3.00,0.76 
4.00,0.77 
5.85,0.73 
BEGIN 
NEWP 0,1 
TITLE 
PATIENT #4 FOR 2 COMPARTMENT PHENYTOIN DATA 
NOBS 16,9 
INIT 189.88,3.7,0.07,3.25,30 
CONS 1012, • 25 
DATA 
0.30,1.90 
0.53,1.16 
0.77,0.96 
1.00,0.86 
1.50,0.76 
2.02,0.72 
3.00,0.69 
4.07,0.55 
6.03,0.50 
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NONLIN84 Subroutine for Fitting Phenytoin Serum and 
Dialysate Data During CAPO. 
6.70,0.52 
7.18,0.50 
8.18,0.43 
10.18,0.36 
14.53,0.29 
18.88,0.24 
23.33,0.23 
0.30,0.29 
0.50,0.85 
0.77,0.94 
1.00,0.94 
1.50,0.83 
2.02,0.76 
3.03,0.76 
4.00,0.67 
5.78,0.64 
BEGIN 
NEWP O,l 
TITLE 
PATIENT #5 FOR 2 COMPARTMENT PHENYTOIN DATA 
NOBS 16,9 
INIT 189.88,1.8,0.03,l.l,130.l 
CONS 1380,.25 
DATA 
0.28,1.83 
0.53,1.91 
0.78,1.37 
1.18,1.26 
1. 53, 1.17 
2.05,0.93 
3.05,0.96 
4.07,0.83 
6.17,0.88 
6.83,1.29 
7.27,0.76 
8.27,0.77 
10.'32, o. 75 
14.75,0.74 
19.35,0.62 
23.35,0.65 
0.30,0.32 
0.53,0.60 
0.78,0.69 
1.18, o. 77 
1.50, o. 77 
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NONLIN84 Subroutine for Fitting Phenytoin Serum and 
Dialysate Data During CAPO. 
2.02,0.75 
3.00,0.73 
4.02,0.70 
5.83,0.66 
BEGIN 
NEWP 0,1 
TITLE 
PATIENT #5 FOR 2 COMPARTMENT PHENYTOIN DATA 
NOBS 15,8 
INIT 248.21,3.6,0.05,1.92,116.2 
CONS 1380,. 25 
DATA 
0.28,1.09 
0.53,0.94 
0.87,0.78 
1.07,0.94 
1.67,0.77 
2.07,0.71 
3.03,0.71 
4.02,0.68 
6.00,0.64 
7.53,0.68 
8.37,0.55 
10.22,0.60 
14.65,0.48 
19.37,0.39 
0.28,0.25 
0.48,0.37 
0.75,0.54 
1. 00, o. 60 
1.55,0.59 
2.02,0.61 
3.03,0.61 
4.02,0.63 
BEGIN 
FINISH 
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NONLIN84 Subroutine for Fitting a Closed Compartment 
Model to Vancomycin during CAPO. 
TITLE 
VANCOMYCIN CLOSED COMPARTMENT FIT OF SERUM AND DIALYSIS 
MODEL 
TEMP 
REMARK ASSIGN CONSTANTS AND PARAMETERS 
XO = CON(l) 
SLOPE = P(l) 
CSS = P(2) 
VP = P(3) 
K12 = CSS*VP*SLOPE/XO 
K21 = SLOPE - K12 
VC = XO*K21/(CSS*SLOPE) 
CHCK2 = (SLOPE*X) 
E2CHCK = MIN (CHCK2,50) 
E2 = DEXP (-E2CHCK) 
CO = XO/VC 
SERINT = (CO*K12)/SLOPE 
END 
FUNCl 
F = (SERINT * E2) + CSS 
END 
FUNC2 
F = CSS - (CSS * E2) 
END 
SECO 
REMARK CALCULATE SECONDARY PARAMETERS 
REMARK******************************* 
THALF = 0.693/SLOPE 
S(l) THALF 
S(2) = CO 
S(3) = K12 
5(4) = K21 
VC = (K21 * XO)/(CSS * SLOPE) 
S(5) = VC 
VP = (K12 * XO)/(CSS * SLOPE) 
5(6) = VP 
CLMAX = VC*Kl2 
S(7) = CLMAX 
END 
EOM 
NFUN 2 
NOBS 
NPAR 
INIT 
NSEC 
5,5 
3 
.6032,32,33.66 
7 
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NONLIN84 Subroutine for Fitting a Closed Compartment 
Model to Vancomycin during CAPO. 
NCON 1 
CONS 1000 
CONV 0.000001 
DATA 
0 55 
0.5 48 
1. 0 41 
2.0 39 
4.0 33 
.33 2.1 
.58 4.4 
1.08 6.4 
2.08 9.0 
4. 08 11. 8 
BEGIN 
NEWP 
INIT 
NOBS 
CONS 
DATA 
0,1 
.1268,37,14 
4,6 
.5 
1.0 
2.0 
4.08 
.17 
.33 
.58 
1. 08 
2.08 
4.08 
BEGIN 
1000 
47 
38 
37 
37 
0.9 
2.8 
3.9 
6.9 
12 
15 
0,1 
.695,33,24.26 
1000 
NEWP 
INIT 
CONS 
NOBS 6,6 
DATA 
0 61 
0.5 
1 
2 
4 
4.33 
0.17 
0.33 
0.58 
1.08 
56 
45 
37 
35 
33 
2 
3.8 
6.9 
10.5 
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NONLIN84 Subroutine for Fitting a Closed Compartment 
Model to Vancomycin during CAPO. 
2.08 14.7 
4.08 17 
BEGIN 
NEWP 0,1 
INIT .153,33,23.86 
NOBS 7,6 
DATA 
0 50 
0.5 36 
1 33 
1. 5 29 
2 32 
4 32 
5.95 26 
0.58 5.3 
0.92 6.2 
1.08 7.0 
1.42 8.9 
2.42 12 
4.42 14.3 
BEGIN 
NEWP 0,1 
INIT .148,30,25.09 
NOBS 6,5 
DATA 
0 66 
0.5 54 
1 38 
2 43 
4 39 
6 30 
0.75 3.9 
1 5.6 
1.5 8.4 
2.5 13 
4.5 15 
BEGIN 
NEWP 0,1 
INIT .145,23,26.87 
NOBS 6,6 
DATA 
0 39 
0.42 32 
0.92 30 
1.92 28 
4.42 24 
5.92 23 
0.17 2.7 
0.33 3.9 
0.58 5.2 
1. 08 7. 7 
2.08 10.1 
4.25 11.9 
BEGIN 
FINISH 
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APPENDIX I 
NONLIN84 Subroutine for Open Compartment Analysis of 
the CAPD Vancomycin Data. 
Convergence is only achieved for the last two data sets. 
TITLE 
VANCOMYCIN OPEN MODEL FIT OF FIRST DIALYSATE 
MODEL 
TEMP 
REMARK ASSIGN CONSTANTS AND PARAMETERS 
XKO = CON(l) 
A =  P(l) 
B = P(2) 
XLAMl = P(3) 
XLAM2 = P(4) 
VP = P(5) 
REMARK ASSIGN CALCULATED VARIABLES 
XK21 = ((A*XLAM2)+(B*XLAM1))/(A+B) 
XKlO = (XLAM1*XLAM2)/XK21 
XK12 = XLAMl + XLAM2 - XK21 - XK10 
VC = XKO/ (A+B) 
DP = XKO/VP 
CHCK2 = (XLAM1*X) 
CHCK4 = (XLAM2*X) 
E2CHCK = MIN (CHCK2,50) 
E4CHCK = MIN (CHCK4,50) 
E2 = DEXP (-E2CHCK) 
E4 = DEXP (-E4CHCK) 
XL2 = (XLAM2 - XLAM1) 
RT2 = (XLAMl - XLAM2) 
END 
FUNCl 
F = (A*E2) + (B*E4) 
END 
FUNC2 
XLFTl = XK12*E2 
RGHT1 = XK12*E4 
F = ((XLFT1/XL2) + (RGHT1/RT2))*DP 
END 
SECO 
REMARK CALCULATE SECONDARY PARAMETERS 
REMARK******************************* 
THALF = 0.693/XLAM2 
S(1) THALF 
XK21 ((A*XLAM2)+(B*XLAM1))/(A+B) 
S (2) XK21 
XK10 (XLAM1*XLAM2)/XK21 
S (3) XK10 
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NONLIN84 Subroutine for Open Compartment Analysis of 
the CAPO Vancomycin Data. 
XK12 = XLAMl + XLAM2 - XK21 - XKlO 
S(4) = XK12 
VC = XKO/ (A+B) 
S(5) = VC 
AUC = (A / XLAMl) + (B / XLAM2) 
S(6) = AUC 
TBC = XKO/AUC 
S(7) = TBC 
VDBETA = TBC/XLAM2 
S(8) = VDBETA 
END 
EOM 
NFUN 2 
NOBS 5,5 
NPAR 5 
LOWER 0,0,.000001,o,o 
UPPER 100,100,10,10,200 
INIT 10.43,44.57,1.45,0.0739,20 
NSEC 8 
NCON 1 
CONS 1000 
CONV 0.000001 
DATA 
0 55 
0.5 48 
1. 0 41 
2.0 39 
4.0 33 
0.33 2.1 
0.58 4.4 
1.08 6.4 
2.08 9.0 
4.08 11.8 
BEGIN 
NEWP 0,1 
INIT 23.35,40.35,1.19,0.0416,20 
NOBS 6, 6 
DATA 
0 61 
0.5 56 
1 45 
2 37 
4 35 
4.33 33 
0.17 2 
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NONLIN84 Subroutine for Open Compartment Analysis of 
the CAPO Vancomycin Data. 
0.33 3.8 
0.58 6.9 
1.08 10.5 
2.08 14.7 
4.08 17 
BEGIN 
NEWP 0,1 
INIT 16.69,33.31,3.28,0.0329,20 
NOBS 7,6 
DATA 
0 
0.5 
1 
1.5 
2 
4 
5.95 
0.58 
0.92 
1. 08 
1.42 
2.42 
4.42 
BEGIN 
NEWP 
INIT 
NOBS 
DATA 
0 
0.5 
1 
2 
4 
6 
0.75 
1 
1.5 
2.5 
4.5 
BEGIN 
NEWP 
INIT 
NOBS 
DATA 
0 
50 
36 
33 
29 
32 
32 
26 
5.3 
6.2 
7.0 
8.9 
12 
14.3 
0,1 
21.79,44.21,1.38,0.0532,20 
6,5 
66 
54 
38 
43 
39 
30 
3.9 
5.6 
8.4 
13 
15 
0,1 
7.78,31.22,3.94,0.0544,20 
6,6 
39 
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NONLIN84 Subroutine for Open Compartment Analysis of 
the CAPD Vancomycin Data. 
0.42 32 
0.92 30 
1. 92 28 
4.42 24 
5.92 23 
0.17 2.7 
0.33 3.9 
0.58 5.2 
1. 08 7. 7 
2.08 10.1 
4.25 11.9 
BEGIN 
FINISH 
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Exapmle of the Error Message Encountered in the Open Model 
Fits of the Vancomycin Data from Patients 1, 2a, and 2c. 
%MTH-F-FLOOVEMAT, floating overflow in math library 
user PC 00030308 
%TRACE-F-TRACEBACK, symbolic stack dump follows 
module name routine name line rel PC abs PC 
0006FAC8 0006FAC8 
0007C932 0007C932 
ERFDW ERFDW 56 00000128 00030308 
above condition handler called with exception 000004BC: 
%SYSTEM-F-FLTDIV F, arithmetic fault, floating divide by 
zero at PC=0007CSFA, 
PS 
L=03C00004 
----- end of exception message 
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Procainamide Simulation 
THIS IS A 2 COMPARTMENT ORAL ABSORPTION SIMULATION PROGRAM 
*THAT SIMULATES PROCAINAMIDE AND N-ACETYLPROCAINAMIDE. * 
*SINCE FLOWS CONNECT THE COMPARTMENTS, YOU MUST REMEMBER 
*THAT FLOW (J) IS EQUAL TO THE MICRO RATE CONSTANT (K) TIMES 
*THE CONCENTRATION (C) AND THAT THE UNITS OF FLOW ARE AMOUNT 
*PER TIME SO THAT THE UNITS OF THE RATE CONSTANT MUST BE 
*VOLUME PER TIME. THIS MEANS THAT SINCE WE USUALLY SPEAK OF 
*THERATE CONSTANTS AS RECIPROCAL TIME, WE MUST MULTIPLY OUR 
*RATE CONSTANT TIMES THE VOLUME OF THE COMPARTMENT THAT THE 
*FLOW IS COMMING FROM. I DO THIS BY CREATING A 'G' ELEMENT 
*FOR THE MICRO RATE CONSTANT THAT IS A POLY (2). IT 
*DEPENDS ON THE CONCENTRATION OF THE DEPENDENT CAPACITOR AND 
*AN INDEPENDENT VOLTAGE SOURCE THAT SPECIFIES THE VOLUME OF 
*THAT COMPARTMENT. THE MODEL ASSUMES THAT PROCAINAMIDE IS 
*DISTRIBUTED INTO 2 COMPARTMENTS WHILE NAPA DISTRIBUTED INTO 
*A SINGLE COMPARTMENT. METABOLISM OF PROCAINAMIDE TO NAPA IS 
*ASSUMED TO BE FIRST ORDER. THE PERITONEUM IS REPRESENTED AS 
*A TERMINAL COMPARTMENT. SEE BELOW. * 
************************************************************ 
RINFl 1 0 1E25 
RINF2 2 0 1E25 
RINF3 3 0 1E25 
RINF4 4 0 1E25 
RINFS 5 0 1E25 
RINF6 6 0 1E25 
RMETl 10 0 1E25 
RMET3 30 O 1E25 
RMET4 40 0 1E25 
* 
*VCENTRAL WILL CONTAIN THE VOLUME OF THE CENTRAL COMPARTMENT * 
VCENTRAL 4 0 100 
* 
*VPERIFER WILL CONTAIN THE VOLUME OF THE PERIFERAL 
*COMPARTMENT.* * 
VPERIFER 5 0 80 * 
*VMETONE WILL CONTAIN THE VOLUME OF THE METABOLITE'S 1ST 
*COMPARTMENT* * 
VMETONE 40 0 111 
* 
*IDOSE WILL CONTAIN THE DOSING REGIMEN. IN THIS CASE, THE 
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Procainamide Simulation 
*DOSING REGIMEN CONSISTED OF 650MG X F(.85) x S(.87) = 451MG 
*EVERY 12 HRS. FOR A SINGLE DOSE SIMULATION THE LAST TERM 
*IN THE PARENTHESIS IS SET TO THE LENGTH OF THE SIMULATION.* 
* 
IDOSE O 6 PULSE(O 45100 0 lU lU .01 12) * 
*CAPACITORS 1-3 AND 10 WILL CONTAIN INITIAL CONDITIONS FOR 
*EACH SET OF DOSES. THIS IS NECESSARY BECAUSE WHEN THE 
*DOSING INTERVAL IS MUCH SMALLER THEN THE LENGTH OF THE 
*SIMULATION, SPICE2 WILL IGNORE THE DOSING REGIMEN 
*COMPLETELY. * 
CCENTRAL 1 0 100 IC=l.89 
CPERIFER 2 0 80 IC=2.514 
CORINE 3 0 1 IC=l00.5 
CDOSE 6 0 1 IC=O 
CMETONE 10 0 111 IC=3.070 
CMURINE 30 0 1 IC=70.56 * 
*THE INITIAL CONDITION OF THE CENTRAL COMPARTMENT WILL BE 
*ZERO SINCE NO DRUG EXISTS IN THE CENTRAL COMPARTMENT AT 
*TIME ZERO. * * 
*THE LAST NUMBER IN THE G ELEMENT DESCRIPTION IS THE VALUE 
*OF THE MICRO RATE CONSTANT. * 
GKA 6 1 6 0 2.098 
GK12 1 2 POLY(2) 1 0 4 0 0 0 0 0 0.0607 
GK21 2 1 POLY(2) 2 0 5 0 0 0 0 0 0.0656 
GKURINE 1 3 POLY(2) 1 0 4 0 0 0 0 0 0.0152 
GKMURINE 10 30 POLY(2) 10 0 40 0 0 0 0 0 0.0162 
GKMFORM 1 10 POLY(2) 1 0 4 0 0 0 0 0 0.0622 
.TRAN 1 48 0 0.1 UIC 
.PRINT TRAN V(l) V(2) V(3) V(6) V(lO) V(30) 
.PLOT TRAN V(l) V(2) V(3) V(6) V(lO) V(30) 
.OPTIONS NOPAGE NUMDGT=4 LIMPTS=5000 ITL1=5000 ITL3=1000 
+ITL4=2000 ITL5=0 PIVTOL=l.OE-20 NODE 
.END 
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APPENDIX L 
Two compartment closed model where Ve = 10 liters and Vp 2 
liters. Bolus dose (Co) of 100mg into compartment c 
THIS IS A 2 COMPARTMENT CLOSED MODEL IV BOLUS SIMULATION 
*SINCE FLOWS CONNECT THE COMPARTMENTS, YOU MUST REMEMBER 
*THAT FLOW (J) IS EQUAL TO THE MICRO RATE CONSTANT (K) TIMES 
*THE CONCENTRATION (C) AND THAT THE UNITS OF FLOW ARE AMOUNT 
*PER TIME SO THAT THE UNITS OF THE RATE CONSTANT MUST BE 
*VOLUME PER TIME. THIS MEANS THAT SINCE WE USUALLY SPEAK OF 
*THE RATE CONSTANTS AS RECIPROCAL TIME, WE MUST MULTIPLY OUR 
*RATE CONSTANT TIMES THE VOLUME OF THE COMPARTMENT THAT THE 
*FLOW IS COMMING FROM. I DO THIS BY CREATING A 'G' ELEMENT 
*FOR THE MICRO RATE CONSTANT THAT IS A POLY (2). IT 
*DEPENDS ON THE CONCENTRATION OF THE DEPENDENT CAPACITOR AND 
*AN INDEPENDENT VOLTAGE SOURCE THAT SPECIFIES THE VOLUME OF 
*THAT COMPARTMENT. IN ORDER TO USE THE .ALTER STATEMENT TO 
*CHANGE THE VALUE OF THE RATE CONSTANTS, THE G ELEMENTS ARE 
*3RD ORDER POLYNOMIALS THAT ALSO DEPEND ON A VOLTAGE SOURSE 
*THAT CONTAINS THE VALUE OF THE MICRO RATE CONSTANT. THE 
*.ALTER SECTION ALTERS THE VALUE OF THE VOLTAGE ELEMENT SO 
*THAT IN ONE RUN MANY SIMULATIONS CAN BE PERFORMED. SEE 
*BELOW. 
************************************************************ 
RINFl 1 0 1El9 
RINF2 2 0 1El9 
RINF4 4 0 1El9 
RINFS 5 0 1El9 
RINF6 6 0 1El9 
RINF7 7 0 1El9 
RINFlO 10 O 1El9 these are resistors that provide ground 
RINF20 20 O 1El9 for the network. 
RINF30 30 0 1El9 
RINF130 130 0 1El9 * 
*VCENTRAL WILL CONTAIN THE VOLUME OF THE CENTRAL COMPARTMENT 
VCENTRAL 4 0 10 * 
*VPERIFER WILL CONTAIN THE VOLUME OF THE PERIFERAL 
*COMPARTMENT.* 
VPERIFER 5 0 2 
* 
*VAM12 FOLLOWS THE FLOW DUE TO Kl2 
VAM12 1 10 0 * 
*VAM21 FOLLOWS THE FLOW DUE TO K21 
VAM21 2 20 0 * 
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APPENDIX L (cont.) 
Two compartment closed model where Ve = 10 liters and Vp = 2 
liters. Bolus dose (Co) of 100mg into compartment C 
*HNET IS A CURRENT CONTROLLED VOLTAGE SOURCE THAT CALCULATES 
*NET FLOW.IN THE MODEL. 
HNET 30 0 POLY(2) VAM12 VAM21 0 -1 1 * 
*THE NEXT TWO LINES CALCULATE CLEARANCE BE DIVIDING THE 
*CONCENTRATION IN COMPARTMENT C BY THE NET FLOW IN THE 
*MODEL. * 
GNUMER O 130 30 0 1 
GDENOM 130 0 POLY(2) 130 0 1 0 0 0 0 0 1 
* 
*THESE CAPACITORS STORE THE CURRENT (MG/HR) THAT IS BROUGHT 
*TO THEM. THE CAPACITOR FOR THE CENTRAL COMPARTMENT 
*(CCENTRAL) STARTS AT A CONCENTRATION OF 10 MG/L (DUE TO A 
*100 MG BOLUS). 
* 
CCENTRAL 1 0 10 IC=lO 
CPERIFER 2 0 2 IC=O * 
*THE G ELEMENT DEPENDS ON THE CONCENTRATION IN THE 
*ORIGINATING COMPARTMENT, THE VOLUME OF THAT COMPARTMENT, 
*AND THE VOLTAGE SOURCE THAT CONTAINS THE VALUE OF THE RATE 
*CONSTANT. 
* 
GK12 10 2 POLY(3) 1 0 4 0 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 
VK12 6 0 0.05775 
GK21 20 1 POLY(3) 2 0 5 0 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 
VK21 7 0 0.05775 
.TRAN 10 90 UIC 
.PRINT TRAN V(l) V(2) V{l30) I(VAM12) I(VAM21) V(30) 
.OPTIONS NOPAGE NUMDGT=5 LIMPTS=5000 ITL1=5000 ITL3=1000 
+ITL4=2000 ITL5=0 PIVTOL=l.OE-30 
.ALTER 
VK12 6 0 0.01155 
VK21 7 0 0.05775 
.ALTER 
VK12 6 0 0.05775 
VK21 7 0 0.01155 
.ALTER 
VK12 6 0 0.03 
VK21 7 0 0.05775 
.ALTER 
VK12 6 0 0.05775 
VK21 7 0 0.03 
.END 
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APPENDIX M 
Two compartment closed model where Ve = 10 liters and Vp 2 
liters. Bolus dose (Po} of 100mg into compartment P. 
THIS IS A 2 COMPARTMENT CLOSED MODEL IV BOLUS SIMULATION 
*SINCE FLOWS CONNECT THE COMPARTMENTS, YOU MUST REMEMBER 
*THAT FLOW (J} IS EQUAL TO THE MICRO RATE CONSTANT (K} TIMES 
*THE CONCENTRATION (C) AND THAT THE UNITS OF FLOW ARE AMOUNT 
*PER TIME SO THAT THE UNITS OF THE RATE CONSTANT MUST BE 
*VOLUME PER TIME. THIS MEANS THAT SINCE WE USUALLY SPEAK OF 
*THE RATE CONSTANTS AS RECIPROCAL TIME, WE MUST MULTIPLY OUR 
*RATE CONSTANT TIMES THE VOLUME OF THE COMPARTMENT THAT THE 
*FLOW IS COMMING FROM. I DO THIS BY CREATING A 'G' ELEMENT 
*FOR THE MICRO RATE CONSTANT THAT IS A POLY (2). IT 
*DEPENDS ON THE CONCENTRATION OF THE DEPENDENT CAPACITOR AND 
*AN INDEPENDENT VOLTAGE SOURCE THAT SPECIFIES THE VOLUME OF 
*THAT COMPARTMENT. IN ORDER TO USE THE .ALTER STATEMENT TO 
*CHANGE THE VALUE OF THE RATE CONSTANTS, THE G ELEMENTS ARE 
*3RD ORDER POLYNOMIALS THAT ALSO DEPEND ON A VOLTAGE SOURSE 
*THAT CONTAINS THE VALUE OF THE MICRO RATE CONSTANT. THE 
*.ALTER SECTIOIN ALTERS THE VALUE OF THE VOLTAGE ELEMENT SO 
*THAT IN ONE RUN MANY SIMULATIONS CAN BE PERFORMED. SEE 
*BELOW. 
************************************************************ 
RINFl 1 0 1El9 
RINF2 2 0 1El9 
RINF4 4 0 1El9 
RINF5 5 0 1El9 
RINF6 6 0 1El9 
RINF7 7 0 1El9 
RINFlO 10 0 1El9 these are resistors that provide ground 
RINF20 20 0 1El9 for the network. 
RINF30 30 0 1El9 
RINF130 130 0 1El9 
* 
*VCENTRAL WILL CONTAIN THE VOLUME OF THE CENTRAL COMPARTMENT 
VCENTRAL 4 0 10 
* 
*VPERIFER WILL CONTAIN THE VOLUME OF THE PERIFERAL 
*COMPARTMENT.* 
VPERIFER 5 0 2 * 
*VAM12 FOLLOWS THE FLOW DUE TO Kl2 
VAM12 1 10 0 * 
*VAM21 FOLLOWS THE FLOW DUE TO K21 
VAM21 2 20 0 
* 
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APPENDIX M (cont.) 
Two compartment closed model where Ve = 10 liters and Vp = 2 
liters. Bolus dose (Po) of 100mg into compartment P. 
*HNET IS A CURRENT CONTROLLED VOLTAGE SOURCE THAT CALCULATES 
*NET FLOW IN THE MODEL. 
HNET 30 0 POLY(2) VAM12 VAM21 0 1 -1 * 
*THE NEXT TWO LINES CALCULATE CLEARANCE BE DIVIDING THE 
*CONCENTRATION IN COMPARTMENT C BY THE NET FLOW IN THE 
*MODEL. * 
GNUMER O 130 30 0 1 
GDENOM 130 0 POLY(2) 130 0 2 0 0 0 0 0 1 * 
*THESE CAPACITORS STORE THE CURRENT (MG/HR) THAT IS BROUGHT 
*TO THEM. THE CAPACITOR FOR THE CENTRAL COMPARTMENT 
*(CPERIFER) STARTS AT A CONCENTRATION OF 50 MG/L (DUE TO A 
*100 MG BOLUS) . * 
CCENTRAL 1 0 10 IC=O 
CPERIFER 2 0 2 IC=5.0 * 
*THE G ELEMENT DEPENDS ON THE CONCENTRATION IN THE 
*ORIGINATING COMPARTMENT, THE VOLUME OF THAT COMPARTMENT, 
*AND THE VOLTAGE SOURCE THAT CONTAINS THE VALUE OF THE RATE 
*CONSTANT. 
* 
GK12 10 2 POLY(3) 1 0 4 0 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 
VK12 6 0 0.05775 
GK21 20 1 POLY(3) 2 0 5 0 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 
VK21 7 0 0.05775 
.TRAN 10 90 UIC 
.PRINT TRAN V(l) V(2) V(l30) I(VAM12) I(VAM21) V(30) 
.OPTIONS NOPAGE NUMDGT=5 LIMPTS=5000 ITL1=5000 ITL3=1000 
+ITL4=2000 ITL5=0 PIVTOL=l.OE-30 
.ALTER 
VK12 6 0 0.01155 
VK21 7 0 0.05775 
.ALTER 
VK12 6 0 0.05775 
VK21 7 0 0.01155 
.ALTER 
VK12 6 0 0.03 
VK21 7 0 0.05775 
.ALTER 
VK12 6 0 0.05775 
VK21 7 0 0.03 
.END 
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APPENDIX N 
Two compartment closed model where Ve = 10 liters and Vp 
10 liters. Bolus dose (Co) of 100mg into compartment C. 
THIS IS A 2 COMPARTMENT CLOSED MODEL IV BOLUS SIMULATION 
*SINCE FLOWS CONNECT THE COMPARTMENTS, YOU MUST l'IBMEMBER 
*THAT FLOW (J) IS EQUAL TO THE MICRO RATE CONSTANT (K) TIMES 
*THE CONCENTRATION (C) AND THAT THE UNITS OF FLOW ARE AMOUNT 
*PER TIME SO THAT THE UNITS OF THE RATE CONSTANT MUST BE 
*VOLUME PER TIME. THIS MEANS THAT SINCE WE USUALLY SPEAK OF 
*THE RATE CONSTANTS AS RECIPROCAL TIME, WE MUST MULTIPLY OUR 
*RATE CONSTANT TIMES THE VOLUME OF THE COMPARTMENT THAT THE 
*FLOW IS COMMING FROM. I DO THIS BY CREATING A 'G' ELEMENT 
*FOR THE MICRO RATE CONSTANT THAT IS A POLY (2). IT 
*DEPENDS ON THE CONCENTRATION OF THE DEPENDENT CAPACITOR AND 
*AN INDEPENDENT VOLTAGE SOURCE THAT SPECIFIES THE VOLUME OF 
*THAT COMPARTMENT. IN ORDER TO USE THE .ALTER STATEMENT TO 
*CHANGE THE VALUE OF THE RATE CONSTANTS, THE G ELEMENTS ARE 
*3RD ORDER POLYNOMIALS THAT ALSO DEPEND ON A VOLTAGE SOURSE 
*THAT CONTAINS THE VALUE OF THE MICRO RATE CONSTANT. THE 
*.ALTER SECTIOIN ALTERS THE VALUE OF THE VOLTAGE ELEMENT SO 
*THAT IN ONE RUN MANY SIMULATIONS CAN BE PERFORMED. SEE 
* BELOW. * 
*********************************************************** 
RINFl 1 0 1El9 
RINF2 2 0 1El9 
RINF4 4 0 1El9 
RINF5 5 0 1El9 
RINF6 6 0 1El9 
RINF7 7 0 1El9 
RINFlO 10 o 1El9 these are resistors that provide ground 
RINF20 20 o 1El9 for the network. 
RINF30 30 0 1El9 
RINF130 130 0 1El9 
* 
*VCENTRAL WILL CONTAIN THE VOLUME OF THE CENTRAL COMPARTMENT 
VCENTRAL 4 0 10 * 
*VPERIFER WILL CONTAIN THE VOLUME OF THE PERIFERAL 
*COMPARTMENT.* 
VPERIFER 5 0 10 * 
*VAM12 FOLLOWS THE FLOW DUE TO Kl2 
VAM12 1 10 0 * 
*VAM21 FOLLOWS THE FLOW DUE TO K21 
VAM21 2 20 0 * 
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APPENDIX N (cont.) 
Two compartment closed model where Ve = 10 liters and Vp = 
10 liters. Bolus dose (Co) of 100mg into compartment c. 
*HNET IS A CURRENT CONTROLLED VOLTAGE SOURCE THAT CALCULATES 
*NET FLOW IN THE MODEL. 
HNET 30 0 POLY(2) VAM12 VAM21 0 -1 1 
*THE NEXT TWO LINES CALCULATE CLEARANCE BE DIVIDING THE 
*CONCENTRATION IN COMPARTMENT C BY THE NET FLOW IN THE 
*MODEL. * 
GNUMER o. 130 30 0 1 
GDENOM 130 0 POLY(2) 130 0 1 0 0 0 0 0 1 * 
*THESE CAPACITORS STORE THE CURRENT (MG/HR) THAT IS BROUGHT 
*TO THEM. THE CAPACITOR FOR THE CENTRAL COMPARTMENT 
*(CCENTRAL) STARTS AT A CONCENTRATION OF 10 MG/L (DUE TO A 
*100 MG BOLUS) . 
* 
CCENTRAL 1 0 10 IC=lO 
CPERIFER 2 0 2 IC=O * 
*THE G ELEMENT DEPENDS ON THE CONCENTRATION IN THE 
*ORIGINATING COMPARTMENT, THE VOLUME OF THAT COMPARTMENT, 
*AND THE VOLTAGE SOURCE THAT CONTAINS THE VALUE OF THE RATE 
*CONSTANT. 
* 
GK12 10 2 POLY(3) 1 0 4 0 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 
VK12 6 0 0. 05775 
GK21 20 1 POLY(3) 2 0 5 0 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 
VK21 7 0 0.05775 
.TRAN 10 90 UIC 
.PRINT TRAN V(l) V(2) V(l30) I(VAM12) I(VAM21) V(30) 
.OPTIONS NOPAGE NUMDGT=5 LIMPTS=5000 ITL1=5000 ITL3=1000 
+ITL4=2000 ITL5=0 PIVTOL=l.OE-30 
.ALTER 
VK12 6 0 0.01155 
VK21 7 0 0.05775 
.ALTER 
VK12 6 0 0.05775 
VK21 7 0 0.01155 
.ALTER 
VK12 6 0 0.03 
VK21 7 0 0.05775 
.ALTER 
VK12 6 0 0. 05775 
VK21 7 0 0.03 
.END 
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APPENDIX 0 
Two compartment closed model where Ve = 10 liters and Vp 
changes. Bolus dose (Co) of 100mg into compartment C 
THIS IS A 2 COMPARTMENT CLOSED MODEL IV BOLUS SIMULATION 
*SINCE FLOWS CONNECT THE COMPARTMENTS, YOU MUST REMEMBER 
*THAT FLOW (J) IS EQUAL TO THE MICRO RATE CONSTANT (K) TIMES 
*THE CONCENTRATION (C) AND THAT THE UNITS OF FLOW ARE AMOUNT 
*PER TIME SO THAT THE UNITS OF THE RATE CONSTANT MUST BE 
*VOLUME PER TIME. THIS MEANS THAT SINCE WE USUALLY SPEAK OF 
*THE RATE CONSTANTS AS RECIPROCAL TIME, WE MUST MULTIPLY OUR 
*RATE CONSTANT TIMES THE VOLUME OF THE COMPARTMENT THAT THE 
*FLOW IS COMMING FROM. I DO THIS BY CREATING A 'G' ELEMENT 
*FOR THE MICRO RATE CONSTANT THAT IS A POLY (2). IT 
*DEPENDS ON THE CONCENTRATION OF THE DEPENDENT CAPACITOR AND 
*AN INDEPENDENT VOLTAGE SOURCE THAT SPECIFIES THE VOLUME OF 
*THAT COMPARTMENT. IN ORDER TO USE THE .ALTER STATEMENT TO 
*CHANGE THE VALUE OF THE RATE CONSTANTS, THE G ELEMENTS ARE 
*3RD ORDER POLYNOMIALS THAT ALSO DEPEND ON A VOLTAGE SOURSE 
*THAT CONTAINS THE VALUE OF THE MICRO RATE CONSTANT. THE 
*.ALTER SECTION ALTERS THE VALUE OF THE VOLTAGE ELEMENT SO 
*THAT IN ONE RUN MANY SIMULATIONS CAN BE PERFORMED. SEE 
*BELOW. * 
*********************************************************** 
RINFl 1 0 1El9 
RINF2 2 0 1El9 
RINF4 4 0 1El9 
RINF5 5 0 1El9 
RINF6 6 0 1El9 
RINF7 7 o 1El9 the resistor section provides a ground for 
RINFS 8 o 1El9 the network. 
RINF9 9 0 1El9 
RINFlO 10 0 1El9 
RINF12 12 0 1El9 
RINF14 14 0 1El9 
RINF15 15 0 1El9 
RINF16 16 0 1E19 
RINF17 17 0 1El9 
RINF20 20 0 1El9 
RINF30 30 0 1El9 
RINFlOO 100 0 1El9 
RINF130 130 0 1El9 * 
*VCENTRAL WILL CONTAIN THE VOLUME OF THE CENTRAL COMPARTMENT 
VCENTRAL 4 0 10 * 
*CAVITY WILL CONTAIN THE VOLUME OF THE PERIFERAL 
*COMPARTMENT.* 
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APPENDIX O (cont.) 
Two compartment closed model where Ve = 10 liters and Vp 
changes. Bolus dose (Co) of 100mg into compartment C 
*VPERIFER 5 0 2 IS NOT USED 
* 
*VAM12 AND VAM21 FOLLOW THE FLOW OF DRUG DUE TO ITS 
*RESPECTIVE RATE CONSTANT. * 
VAM12 1 10 0 
VAM21 2 20 0 * 
*HNET PROVIDES NET FLOW OF DRUG IN THE MODEL. * 
HNET 30 0 POLY(2) VAM12 VAM21 0 -1 1 
* 
*********************************************************** 
*CLEARANCE DURING THE PROCESS IS FOUND BY DIVIDING NET FLOW 
*BETWEEN THE COMPARTMENTS BY THE CONCENTRATION IN THE 
*CENTRAL COMPARTMENT. V(l30) CONTAINS CLEARANCE. 
*********************************************************** 
* 
GNUMER O 130 30 0 1 
GDENOM 130 0 POLY(2) 130 0 1 0 0 0 0 0 1 * 
*CCENTRAL CONTAINS THE CONCENTRATION IN THE C COMPARTMENT. 
*CPERIFER CONTAINS THE AMOUNT OF DRUG IN COMPARTMENT P. 
CCENTRAL 1 0 10 IC=lO 
CPERIFER 2 0 1 IC=O * 
* 
************************************************************ 
*THE CONCENTRATION IN THE PERIPHERAL COMPARTMENT IS EQUAL TO 
*THE AMOUNT IN THE PERIPHERAL COMPARTMENT V(2) DIVIDED BY 
*THE VOLUME IN THE PERIPHERAL COMPARTMENT V(lOO). THE 
*CONCENTRATION ITSELF WILL BE FOUND IN V(S). 
************************************************************ 
GAMNT O 5 2 0 1 
GVOL 5 0 POLY(2) 5 0 100 0 0 0 0 0 1 * 
*THE G ELEMENT DEPENDS ON THE CONCENTRATION IN THE 
*ORIGINATING COMPARTMENT, THE VOLUME OF THAT COMPARTMENT, 
*AND THE VOLTAGE ,SOURCE THAT CONTAINS THE VALUE OF THE RATE 
*CONSTANT * 
GK12 
VK12 
GK21 
VK21 
10 2 POLY(3) 1 0 
6 0 0.05775 
20 1 POLY(2) 
7 0 0.05775 
4 0 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 
2 0 7 0 0 0 0 0 1 
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APPENDIX O (cont.) 
Two compartment closed model where Ve = 10 liters and Vp 
changes. Bolus dose (Co) of 100mg into compartment c 
* 
************************************************************ 
*THIS SECTION ALLOWS THE VOLUME OF THE PERIPHERAL 
*COMPARTMENT TO CHANGE BY ALLOWING INFLOW AND OUTFLOW 
************************************************************ 
* 
*VZEROULTR IS USED TO RESET CVOLULTRA TO ZERO BEFORE THE 
*NEXT TIME THAT THE VOLUME OF P WILL UNDERGO A PERIOD OF 
*CHANGE. * 
VZEROULTR 9 15 0 * 
*VFOPPOCLK IS USED WITH HZEROULTR TO RESET VOLUME ADDED TO 
*P. 
VFOPPOCLK 16 0 PULSE (1 0 90 lU lU 0.1 90.100002) * 
*VULTRAFIL MEASURES THE RATE OF CHANGE IN VOLUME OF P. 
VULTRAFIL 8 100 0 
* 
*THIS IS THE CAPACITOR SECTION. CAVITY CONTAINS THE VOLUME 
*OF COMPARTMENT P. CVOLULTRA CONTAINS THE VOLUME BY WHICH P 
*WILL CHANGES. CULTRZERO IS THE VOLUME THAT IS INFUSED INTO 
*P. * 
CAVITY 100 0 1 IC=2 
CVOLULTRA 9 0 1 IC=O 
CULTRZERO 12 0 1 IC=O * 
************************************************************ 
*IZINCLCK IS A CLOCK THAT ALLOWS FOR 610ML OF FLUID TO ENTER 
*P. GALPHA IS THE FIRST ORDER RATE CONSTANT THAT DESCRIBES 
*FLOW INTO P. VALFACLCK TURNS FLOW ON IMMEDIATELY IT OFF 
*AFTER 90 HRS. FLOW RATE (U) = Z X ALFA X (EXP(-ALFA x T)). 
*Z IS THE TOTAL AMOUNT OF VOLUME ATTRIBUTED TO FLOW. Z x 
*ALFA IS EQUAL TO THE INITIAL FLOW RATE WHEN THE PROCESS 
*BEGINS. 
************************************************************ 
* 
VALFACLCK 17 0 PULSE(O 1 0 lU lU 90.0 90.000002) 
IZINCLCK O 12 PULSE (0 6.4 0 lU lU 0.1 90.000002) 
GALPHA 12 8 POLY(2) 12 0 17 0 0 0 0 0 1.8 
* 
HCONVERT 14 0 VULTRAFIL 1 
FCONVERT O 9 VULTRAFIL 1 * 
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APPENDIX O (cont.) 
Two compartment closed model where Ve = 10 liters and Vp 
changes. Bolus dose (Co) of 100mg into compartment C 
*ILOOSEVOL WILL ALLOW FOR SOME OF THE VOLUME TO DUMP 
* 
ILOOSEVOL 100 90 PULSE(O 0.00606 0 lU lU 90 90.000002) 
R90 90 0 1 * 
*HZEROULTR USES VFOPPOCLK WHICH IS A CLOCK OPPOSITE TO 
*VCLOCK AND VZEROULTR TO ALLOW CVOLULTRA MEASURE VOLUME OF 
*FLUID ADDED AND RESET IT TO ZERO BEFORE THE NEXT FLOW 
*PERIOD.* * 
HZEROULTR 15 0 POLY(2) VFOPPOCLK VZEROULTR O O O O 1E25 
.TRAN 10 90 UIC 
.PRINT TRAN V(l) V(5) V(130) V(lOO) I(VAM12) I(VAM21) V(30) 
.PLOT TRAN V(lOO) 
.OPTIONS NOPAGE NUMDGT=5 LIMPTS=5000 ITL1=5000 ITL3=1000 
+ITL4=2000 ITL5=0 PIVTOL=l.OE-30 
.ALTER 
VK12 6 0 0.01155 
VK21 7 0 0.05775 
.ALTER 
VK12 6 0 0.05775 
VK21 7 0 0.01155 
.ALTER 
VK12 6 0 0.03 
VK21 7 0 0.05775 
.ALTER 
VK12 6 0 0.05775 
VK21 7 0 0.03 
.END 
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APPENDIX P 
Two compartment closed model where Ve = 10 liters and Vp 
changes. Bolus dose (Po) of 100mg into compartment P. 
THIS IS A 2 COMPARTMENT CLOSED MODEL IV BOLUS SIMULATION 
*SINCE FLOWS CONNECT THE COMPARTMENTS, YOU MUST REMEMBER 
*THAT FLOW (J) IS EQUAL TO THE MICRO RATE CONSTANT (K) TIMES 
*THE CONCENTRATION (C) AND THAT THE UNITS OF FLOW ARE AMOUNT 
*PER TIME SO THAT THE UNITS OF THE RATE CONSTANT MUST BE 
*VOLUME PER TIME. THIS MEANS THAT SINCE WE USUALLY SPEAK OF 
*THE RATE CONSTANTS AS RECIPROCAL TIME, WE MUST MULTIPLY OUR 
*RATE CONSTANT TIMES THE VOLUME OF THE COMPARTMENT THAT THE 
*FLOW IS COMMING FROM. I DO THIS BY CREATING A 'G' ELEMENT 
*FOR THE MICRO RATE CONSTANT THAT IS A POLY (2). IT 
*DEPENDS ON THE CONCENTRATION OF THE DEPENDENT CAPACITOR AND 
*AN INDEPENDENT VOLTAGE SOURCE THAT SPECIFIES THE VOLUME OF 
*THAT COMPARTMENT. IN ORDER TO USE THE .ALTER STATEMENT TO 
*CHANGE THE VALUE OF THE RATE CONSTANTS, THE G ELEMENTS ARE 
*3RD ORDER POLYNOMIALS THAT ALSO DEPEND ON A VOLTAGE SOURSE 
*THAT CONTAINS THE VALUE OF THE MICRO RATE CONSTANT. THE 
*.ALTER SECTIOIN ALTERS THE VALUE OF THE VOLTAGE ELEMENT SO 
*THAT IN ONE RUN MANY SIMULATIONS CAN BE PERFORMED. SEE 
*BELOW. * 
************************************************************ 
RINFl 1 0 1E19 
RINF2 2 0 1E19 
RINF4 4 0 1E19 
RINF5 5 0 1El9 
RINF6 6 0 1El9 
RINF7 7 O 1El9 the resistor section provides a ground for 
RINF8 8 O 1El9 the network. 
RINF9 9 0 1El9 
RINFlO 10 0 1El9 
RINF12 12 0 1E19 
RINF14 14 0 1El9 
RINF15 15 0 1El9 
RINF16 16 0 1E19 
RINF17 17 0 1El9 
RINF20 20 O 1El9 
RINF30 30 0 1El9 
RINFlOO 100 0 1El9 
RINF130 130 0 1El9 * 
*VCENTRAL WILL CONTAIN THE VOLUME OF THE CENTRAL 
*COMPARTMENT.* 
VCENTRAL 4 0 10 * 
*CAVITY WILL CONTAIN THE VOLUME OF THE.PERIFERAL 
*COMPARTMENT.* 
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APPENDIX p (cont.) 
Two compartment closed model where Ve = 10 liters and Vp 
changes. Bolus dose (Po) of 100mg into compartment P. 
*VPERIFER 5 0 2 IS NOT USED * 
*VAM12 AND VAM21 FOLLOW THE FLOW OF DRUG DUE TO ITS 
*RESPECTIVE RATE CONSTANT. * 
VAM12 1 10 0 
VAM21 2 20 0 * 
*HNET PROVIDES NET FLOW OF DRUG IN THE MODEL. * 
HNET 30 0 POLY(2) VAM12 VAM21 0 1 -1 * 
* 
************************************************************ 
*CLEARANCE DURING THE PROCESS IS FOUND BY DIVIDING NET FLOW 
*BETWEEN THE COMPARTMENTS BY THE CONCENTRATION IN THE 
*PERIPHERAL COMPARTMENT. V(130) CONTAINS CLEARANCE. 
************************************************************ * 
GNUMER O 130 30 0 l 
GDENOM 130 0 POLY(2) 130 0 5 0 0 0 0 0 l * 
*CCENTRAL CONTAINS THE CONCENTRATION IN THE C COMPARTMENT. 
*CPERIFER CONTAINS THE AMOUNT OF DRUG IN COMPARTMENT P. * 
CCENTRAL l O 10 IC=O 
CPERIFER 2 0 l IC=50 
* 
************************************************************ 
*THE CONCENTRATION IN THE PERIPHERAL COMPARTMENT IS EQUAL TO 
*THE AMOUNT IN THE PERIPHERAL COMPARTMENT V(2) DIVIDED BY 
*THE VOLUME IN THE PERIPHERAL COMPARTMENT V(lOO). THE 
* CONCENTRATION ITSELF WILL BE FOUND IN V(5). 
************************************************************ 
GAMNT O 5 2 0 1 
GVOL 5 0 POLY(2) 5 0 100 0 0 0 0 0 l 
* 
*THE G ELEMENT DEPENDS ON THE CONCENTRATION IN THE 
*ORIGINATING COMPARTMENT, THE VOLUME OF THAT COMPARTMENT, 
*AND THE VOLTAGE SOURCE THAT CONTAINS THE VALUE OF THE RATE 
*CONSTANT. 
* 
GK12 
VK12 
GK2l 
VK21 
10 2 POLY(3) l 0 
6 0 0.05775 
20 l POLY(2) 
7 0 0.05775 
4 0 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 
2 0 7 0 0 0 0 0 l 
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APPENDIX p (cont.) 
Two compartment closed model where Ve = 10 liters and Vp 
changes. Bolus dose (Po) of 100mg into compartment P. 
* 
************************************************************ 
*THIS SECTION ALLOWS THE VOLUME OF THE PERIPHERAL 
*COMPARTMENT TO CHANGE BY ALLOWING INFLOW AND OUTFLOW 
************************************************************* 
*VZEROULTR IS USED TO RESET CVOLULTRA TO ZERO BEFORE THE 
*NEXT TIME THAT THE VOLUME OF P WILL UNDERGO A PERIOD OF 
*CHANGE. 
* 
VZEROULTR 9 15 0 
* 
*VFOPPOCLK IS USED WITH HZEROULTR TO RESET VOLUME ADDED TO 
*P. 
VFOPPOCLK 16 0 PULSE (1 0 90 lU lU 0.1 90.100002) * 
*VULTRAFIL MEASURES THE RATE OF CHANGE IN VOLUME OF P. 
VULTRAFIL 8 100 0 * 
*THIS IS THE CAPACITOR SECTION. CAVITY CONTAINS THE VOLUME 
*OF COMPARTMENT P. CVOLULTRA CONTAINS THE VOLUME BY WHICH P 
*WILL CHANGES. CULTRZERO IS THE VOLUME THAT IS INFUSED INTO 
*P. 
* 
CAVITY 100 0 1 IC=2 
CVOLULTRA 9 0 1 IC=O 
CULTRZERO 12 0 1 IC=O * 
************************************************************ 
*IZINCLCK IS A CLOCK THAT ALLOWS FOR 610ML OF FLUID TO ENTER 
*P. GALPHA IS THE FIRST ORDER RATE CONSTANT THAT DESCRIBES 
*FLOW INTO P. VALFACLCK TURNS FLOW ON IMMEDIATELY IT OFF 
*AFTER 90 HRS. FLOW RATE (U) = Z x ALFA x (EXP(-ALFA x T)). 
*Z IS THE TOTAL AMOUNT OF VOLUME ATTRIBUTED TO FLOW. Z x 
*ALFA IS EQUAL TO THE INITIAL FLOW RATE WHEN THE PROCESS 
*BEGINS. 
************************************************************ * 
VALFACLCK 17 0 PULSE(O 1 0 lU lU 90.0 90.000002) 
IZINCLCK O 12 PULSE (0 6.4 0 lU lU 0.1 90.000002) 
GALPHA 12 8 POLY(2) 12 0 17 0 0 0 0 0 1.8 * 
HCONVERT 14 0 VULTRAFIL 1 
FCONVERT O 9 VULTRAFIL 1 * 
*ILOOSEVOL WILL ALLOW FOR SOME OF THE VOLUME TO DUMP 
* 
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APPENDIX P (cont.) 
Two compartment closed model where Ve = 10 liters and Vp 
changes. Bolus dose (Po) of 100mg into compartment P. 
ILOOSEVOL 100 90 PULSE(O 0.00606 0 lU lU 90 90.000002) 
R90 90 0 1 * 
*HZEROULTR USES VFOPPOCLK WHICH IS A CLOCK OPPOSITE TO 
*VCLOCK AND VZEROULTR 
*TO ALLOW CVOLULTRA MEASURE VOLUME OF FLUID ADDED AND RESET 
*IT TO ZERO BEFORE THE NEXT FLOW PERIOD.* 
* 
HZEROULTR 15 0 POLY(2) VFOPPOCLK VZEROULTR O O O O 1E25 
.TRAN 10 90 UIC 
.PRINT TRAN V(l) V(5) V{l30) V(lOO) I(VAM12) I(VAM21) V(30) 
.PLOT TRAN V(lOO) 
.OPTIONS NOPAGE NUMDGT=5 LIMPTS=5000 ITL1=5000 ITL3=1000 
+ITL4=2000 ITL5=0 PIVTOL=l.OE-30 
.ALTER 
VK12 6 0 0.01155 
VK21 7 0 0.05775 
.ALTER 
VK12 6 0 0.05775 
VK21 7 0 0.01155 
.ALTER 
VK12 6 0 0.03 
VK21 7 0 0.05775 
.ALTER 
VK12 6 0 0.05775 
VK21 7 0 0.03 
.END 
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APPENDIX Q 
Two compartment open model where Ve = 10 liters and Vp = 2. 
Bolus dose (Po) of 100mg into compartment C. The micro-rate 
constant for outflow (KlO) is decreased in each simulation 
to see how KlO effects the closed model characteristics. 
THIS IS A 2 COMPARTMENT CLOSED MODEL IV BOLUS SIMULATION 
*SINCE FLOWS CONNECT THE COMPARTMENTS, YOU MUST REMEMBER 
*THAT FLOW (J) IS EQUAL TO THE MICRO RATE CONSTANT (K) TIMES 
*THE CONCENTRATION (C) AND THAT THE UNITS OF FLOW ARE AMOUNT 
*PER TIME SO THAT THE UNITS OF THE RATE CONSTANT MUST BE 
*VOLUME PER TIME. THIS MEANS THAT SINCE WE USUALLY SPEAK OF 
*THE RATE CONSTANTS AS RECIPROCAL TIME, WE MUST MULTIPLY OUR 
*RATE CONSTANT TIMES THE VOLUME OF THE COMPARTMENT THAT THE 
*FLOW IS COMMING FROM. I DO THIS BY CREATING A 'G' ELEMENT 
*FOR THE MICRO RATE CONSTANT THAT IS A POLY (2). IT 
*DEPENDS ON THE CONCENTRATION OF THE DEPENDENT CAPACITOR AND 
*AN INDEPENDENT VOLTAGE SOURCE THAT SPECIFIES THE VOLUME OF 
*THAT COMPARTMENT. IN ORDER TO USE THE .ALTER STATEMENT TO 
*CHANGE THE VALUE OF THE RATE CONSTANTS, THE G ELEMENTS ARE 
*3RD ORDER POLYNOMIALS THAT ALSO DEPEND ON A VOLTAGE SOURSE 
*THAT CONTAINS THE VALUE OF THE MICRO RATE CONSTANT. THE 
*.ALTER SECTIOIN ALTERS THE VALUE OF THE VOLTAGE ELEMENT SO 
*THAT IN ONE RUN MANY SIMULATIONS CAN BE PERFORMED. KlO IS 
*VARIED. SEE BELOW.* 
************************************************************ 
RINFl 1 0 1El9 
RINF2 2 o 1El9 the resistor section provides groun for 
RINF4 4 o 1El9 the network. 
RINF5 5 0 1El9 
RINF6 6 0 1El9 
RINF7 7 0 1El9 
RINF9 9 0 1El9 
RINFlO 10 0 1El9 
RINF20 20 0 1El9 
RINF30 30 0 1El9 
RINF130 130 0 1El9 
* 
*VCENTRAL WILL CONTAIN THE VOLUME OF THE CENTRAL 
*COMPARTMENT.* 
VCENTRAL 4 0 10 * 
*VPERIFER WILL CONTAIN THE VOLUME OF THE PERIFERAL 
*COMPARTMENT.* 
VPERIFER 5 0 2 * 
*VAM12 FOLLOWS THE FLOW DUE TO Kl2 
VAM12 1 10 0 
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APPENDIX Q (cont.) 
Two compartment open model where Ve = 10 liters and Vp = 2. 
Bolus dose (Po) of 100mg into compartment c. The micro-rate 
constant for outflow (KlO) is decreased in each simulation 
to see how KlO effects the closed model characteristics. 
* 
*VAM21 FOLLOWS THE FLOW DUE TO K21 
VAM21 2 20 0 
*HNET IS A CURRENT CONTROLLED VOLTAGE SOURCE THAT CALCULATES 
*NET 
*FLOW IN THE MODEL EXCLUDING KlO. 
HNET 30 0 POLY(2) VAM12 VAM21 0 -1 1 * 
*THE NEXT TWO LINES CALCULATE CLEARANCE BE DIVIDING THE 
*CONCENTRATION IN COMPARTMENT C BY THE NET FLOW BETWEEN THE 
*COMPARTMENTS. THIS CLEARANCE WILL BE COMPARED TO OPEN MODEL 
*CLEARANCE. * 
GNUMER O 130 30 0 1 
GDENOM 130 0 POLY(2) 130 0 1 0 0 0 0 0 1 * 
*THESE CAPACITORS STORE THE CURRENT (MG/HR) THAT IS BROUGHT 
*TO THEM. THE CAPACITOR FOR THE CENTRAL COMPARTMENT 
*(CCENTRAL) STARTS AT A CONCENTRATION OF 10 MG/L (DUE TO A 
*100 MG BOLUS) . * 
CCENTRAL 1 0 10 IC=lO 
CPERIFER 2 0 2 IC=O * 
*THE G ELEMENT DEPENDS ON THE CONCENTRATION IN THE 
*ORIGINATING COMPARTMENT, THE VOLUME OF THAT COMPARTMENT, 
*AND THE VOLTAGE SOURCE THAT CONTAINS THE VALUE OF THE RATE 
*CONSTANT * 
GK12 10 2 POLY(3) 1 0 4 0 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 
VK12 6 0 0.05775 
GK21 20 1 POLY(3) 2 0 5 0 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 
VK21 7 0 0.05775 
GK10 1 0 POLY(3) 1 0 4 0 9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 
VKlO 9 0 0.6 
.TRAN 10 90 UIC 
.PRINT TRAN V(l) V(2) V(l30) I(VAM12) I(VAM21) V(30) 
.OPTIONS NOPAGE NUMDGT=5 LIMPTS=5000 ITL1=5000 ITL3=1000 
+ITL4=2000 ITL5=0 PIVTOL=l.OE-30 
.ALTER 
VKlO 9 0 0.12 
.ALTER 
VKlO 9 0 0.06 
234 
APPENDIX Q (cont.) 
Two compartment open model where Ve = 10 liters and Vp = 2. 
Bolus dose (Po) of 100mg into compartment c. The micro-rate 
constant for outflow (KlO) is decreased in each simulation 
to see how KlO effects the closed model characteristics • 
• ALTER 
VKlO 9 0 0.03 
.ALTER 
VKlO 9 0 0.006 
.ALTER 
VK12 6 0 0.01155 
VK21 7 0 0.05775 
.ALTER 
VK12 6 0 0.01155 
VK21 7 0 0.05775 
VKlO 9 0 0.12 
.ALTER 
VK12 6 0 0.01155 
VK21 7 O 0.05775 
VKlO 9 0 0.06 
.ALTER 
VK12 6 0 0.01155 
VK21 7 0 0.05775 
VKlO 9 0 0.03 
.ALTER 
VK12 6 0 0.01155 
VK21 7 0 0.05775 
VKlO 9 0 0.006 
.ALTER 
VK12 6 0 0.05775 
VK21 7 0 0. 01155 
.ALTER 
VKlO 9 0 0.12 
VK12 6 0 0.05775 
VK21 7 O 0.01155 
.ALTER 
VKlO 9 0 0.06 
VK12 6 0 0.05775 
VK21 7 0 0.01155 
.ALTER 
VKlO 9 0 0.03 
VK12 6 0 0.05775 
VK21 7 0 0.01155 
.ALTER 
VKlO 9 0 0.006 
VK12 6 0 0.05775 
VK21 7 0 0.01155 
.END 
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APPENDIX R 
Two compartment open model where the models from the above 
simulation that fit well to a closed compartment model are 
here used to simulate multiple dose. A bolus dose (Co) of 
100mg into compartment c and 10 subsequent 100mg bolus doses 
are administered 90 hours apart. 
THIS rs A 2 COMPARTMENT CLOSED MODEL IV BOLUS SIMULATION . 
*SINCE FLOWS CONNECT THE COMPARTMENTS, YOU MUST REMEMBER 
*THAT FLOW (J) rs EQUAL TO THE MICRO RATE CONSTANT (K) TIMES 
*THE CONCENTRATION (C) AND THAT THE UNITS OF FLOW ARE AMOUNT 
*PER TIME SO THAT THE UNITS OF THE RATE CONSTANT MUST BE 
*VOLUME PER TIME. THIS MEANS THAT SINCE WE USUALLY SPEAK OF 
*THE RATE CONSTANTS AS RECIPROCAL TIME, WE MUST MULTIPLY OUR 
*RATE CONSTANT TIMES THE VOLUME OF THE COMPARTMENT THAT THE 
*FLOW IS COMMING FROM. I DO THIS BY CREATING A 'G' ELEMENT 
*FOR THE MICRO RATE CONSTANT THAT rs A POLY (2). IT 
*DEPENDS ON THE CONCENTRATION OF THE DEPENDENT CAPACITOR AND 
*AN INDEPENDENT VOLTAGE SOURCE THAT SPECIFIES THE VOLUME OF 
*THAT COMPARTMENT. IN ORDER TO USE THE .ALTER STATEMENT TO 
*CHANGE THE VALUE OF THE RATE CONSTANTS, THE G ELEMENTS ARE 
*3RD ORDER POLYNOMIALS THAT ALSO DEPEND ON A VOLTAGE SOURSE 
*THAT CONTAINS THE VALUE OF THE MICRO RATE CONSTANT. THE 
*.ALTER SECTIOIN ALTERS THE VALUE OF THE VOLTAGE ELEMENT SO 
*THAT IN ONE RUN MANY SIMULATIONS CAN BE PERFORMED. K10 rs 
*VARIED. SEE BELOW.* 
************************************************************ 
RINF1 1 0 1E19 
RINF2 2 0 1E19 
RINF4 4 0 1El9 
RINFS 5 0 1E19 
RINF6 6 0 1E19 
RINF7 7 0 1E19 
RINF9 9 0 1E19 
RINFlO 10 0 1E19 
RINF20 20 0 1E19 
RINF30 30 0 1E19 
RINF40 40 0 1E19 
RINF130 130 0 1E19 
* 
*VCENTRAL WILL CONTAIN THE VOLUME OF THE CENTRAL 
*COMPARTMENT.* 
VCENTRAL 4 0 10 * 
*VPERIFER WILL CONTAIN THE VOLUME OF THE PERIFERAL 
*COMPARTMENT.* 
VPERIFER 5 0 2 
* 
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APPENDIX R (cont.) 
Two compartment open model where the models from the above 
simulation that fit well to a closed compartment model are 
here used to simulate multiple dose. A bolus dose (Co) of 
100mg into compartment C and 10 subsequent 100mg bolus doses 
are administered 90 hours apart. 
*VAM12 FOLLOWS THE FLOW DUE TO K12 
VAM12 1 10 0 * 
*VAM21 FOLLOWS THE FLOW DUE TO K21 
VAM21 2 20 0 * 
*HNET IS A CURRENT CONTROLLED VOLTAGE SOURCE THAT CALCULATES 
*NET FLOW IN THE MODEL EXCLUDING K10. 
HNET 30 0 POLY(2) VAM12 VAM21 0 -1 1 * 
*THE NEXT TWO LINES CALCULATE CLEARANCE BE DIVIDING THE 
*CONCENTRATION IN COMPARTMENT C BY THE NET FLOW BETWEEN THE 
*COMPARTMENTS. THIS CLEARANCE WILL BE COMPARED TO OPEN MODEL 
*CLEARANCE. * 
GNUMER O 130 30 0 1 
GDENOM 130 0 POLY(2) 130 0 1 0 0 0 0 0 1 * 
*THESE CAPACITORS STORE THE CURRENT (MG/HR) THAT IS BROUGHT 
*TO THEM. THE CAPACITOR FOR THE CENTRAL COMPARTMENT 
*(CCENTRAL) STARTS AT A CONCENTRATION OF 10 MG/L (DUE TO A 
*100 MG BOLUS). * 
CCENTRAL 1 0 10 IC=lO 
CPERIFER 2 0 2 IC=O * 
*THE FOLLOWING IS A CLOCK WHICH ALLOWS MULTIPLE BOLUS 
*DOSES. A PULSE FUNCTION IS USED WHERE THE LENGTH OF THE 
*CYCLE DETERMINES THE NUMBER OF DOSES. THE INITIAL CONDITION 
*OF THE CENTRAL COMPARTMENT IS 10 MG/L. 
* 
IMULTI 40 1 PULSE(O 100 88.99997 .00001 .00001 1 90.) * 
*THE G ELEMENT DEPENDS ON THE CONCENTRATION IN THE 
*ORIGINATING COMPARTMENT, THE VOLUME OF THAT COMPARTMENT, 
*AND THE VOLTAGE SOURCE THAT CONTAINS THE VALUE OF THE RATE 
*CONSTANT 
* 
GK12 10 2 POLY(3) 1 0 4 0 6 0 0 0 0 0 0 0 0 O O O O O O O 1 
VK12 6 0 0.01155 
GK21 20 1 POLY(3) 2 0 5 0 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 
VK21 7 0 0.05775 
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APPENDIX R (cont.) 
Two compartment open model where the models from the above 
simulation that fit well to a closed compartment model are 
here used to simulate multiple dose. A bolus dose (Co) of 
100mg into compartment C and 10 subsequent 100mg bolus doses 
are administered 90 hours apart. 
GKlO 1 0 POLY(3) 1 0 4 0 9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 
VKlO 9 0 0.0012 
.TRAN 30 900 UIC 
.PRINT TRAN V(l) V(2) V(9) V(40) 
.PLOT TRAN V(l) V(2) 
.OPTIONS NOPAGE NUMDGT=5 LIMPTS=5000 ITL1=5000 ITL3=1000 
+ITL4=2000 ITL5=0 PIVTOL=l.OE-30 
.ALTER 
VK12 6 0 0.05775 
VK21 7 0 0.01155 
VKlO 9 0 0.0012 
.ALTER 
VK12 6 0 0. 05775 
VK21 7 0 0.01155 
VKlO 9 0 0.006 
.END 
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APPENDIX S 
Two compartment closed model where the closed compartment 
fitted parameters generated from NONLIN84 are used to 
simulate concentrations in c and in P during multiple doses. 
A bolus dose (Co) of 100mg into compartment c and 10 
subsequent 100mg bolus doses are administered 90 hours 
apart. Since in this run of simulations volume terms as well 
as rate constants are altered, the .ALTER statement can not 
be used. Therefore each simulation was run seperately. In 
the three runs only the values of the parameters are 
different so in this listing ***** will represent where the 
approriate value should be inserted. The values for the 
parameters used are as follows: 
RUN 1 RUN 2 RUN 3 
Ve = 9.865 9.859 9.966 
Vp = 2.892 2.324 2.065 
Kl2= 0.01707 0.07014 0.06017 
K21= 0.05794 0.01185 0.01160 
THIS IS A 2 COMPARTMENT CLOSED MODEL IV BOLUS SIMULATION 
*SINCE FLOWS CONNECT THE COMPARTMENTS, YOU MUST REMEMBER 
*THAT FLOW (J) IS EQUAL TO THE MICRO RATE CONSTANT (K) TIMES 
*THE CONCENTRATION (C) AND THAT THE UNITS OF FLOW ARE AMOUNT 
*PER TIME SO THAT THE UNITS OF THE RATE CONSTANT MUST BE 
*VOLUME PER TIME. THIS MEANS THAT SINCE WE USUALLY SPEAK OF 
*THE RATE CONSTANTS AS RECIPROCAL TIME, WE MUST MULTIPLY OUR 
*RATE CONSTANT TIMES THE VOLUME OF THE COMPARTMENT THAT THE 
*FLOW IS COMMING FROM. I DO THIS BY CREATING A 'G' ELEMENT 
*FOR THE MICRO RATE CONSTANT THAT IS A POLY (2). IT 
*DEPENDS ON THE CONCENTRATION OF THE DEPENDENT CAPACITOR AND 
*AN INDEPENDENT VOLTAGE SOURCE THAT SPECIFIES THE VOLUME OF 
*THAT COMPARTMENT. IN ORDER TO USE THE .ALTER STATEMENT TO 
*CHANGE THE VALUE OF THE RATE CONSTANTS, THE G ELEMENTS ARE 
*3RD ORDER POLYNOMIALS THAT ALSO DEPEND ON A VOLTAGE SOURSE 
*THAT CONTAINS THE VALUE OF THE MICRO RATE CONSTANT. THE 
*.ALTER SECTIOIN ALTERS THE VALUE OF THE VOLTAGE ELEMENT SO 
*THAT IN ONE RUN MANY SIMULATIONS CAN BE PERFORMED. KlO IS 
*DELETED,SEE BELOW.* 
************************************************************ 
RINFl 1 0 1El9 
RINF2 2 0 1El9 
RINF4 4 0 1El9 
RINF5 5 0 1El9 
RINF6 6 0 1El9 
RINF7 7 0 1El9 
RINFlO 10 0 1El9 
RINF20 20 0 1El9 
RINF30 30 0 1E19 
RINF40 40 0 1E19 
RINF130 130 0 1E19 
APPENDIX s (cont.) 
*VCENTRAL WILL CONTAIN THE VOLUME OF THE CENTRAL 
*COMPARTMENT.* 
VCENTRAL 4 0 ***** * 
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*VPERIFER WILL CONTAIN THE VOLUME OF THE PERIFERAL 
*COMPARTMENT.* 
VPERIFER 5 0 ***** * 
*VAM12 FOLLOWS THE FLOW DUE TO K12 
VAM12 1 10 0 * 
*VAM21 FOLLOWS THE FLOW DUE TO K21 
VAM21 2 20 0 * 
*HNET IS A CURRENT CONTROLLED VOLTAGE SOURCE THAT CALCULATES 
*NET 
*FLOW IN THE MODEL EXCLUDING KlO. 
HNET 30 0 POLY(2) VAM12 VAM21 0 -1 1 * 
*THE NEXT TWO LINES CALCULATE CLEARANCE BE DIVIDING THE 
*CONCENTRATION IN COMPARTMENT C BY THE NET FLOW BETWEEN THE 
*COMPARTMENTS. THIS CLEARANCE WILL BE COMPARED TO OPEN MODEL 
*CLEARANCE. * 
GNUMER O 130 30 0 1 
GDENOM 130 0 POLY(2) 130 0 1 0 0 0 0 0 1 * 
*THESE CAPACITORS STORE THE CURRENT (MG/HR) THAT IS BROUGHT 
*TO THEM. THE CAPACITOR FOR THE CENTRAL COMPARTMENT 
*(CCENTRAL) STARTS AT A CONCENTRATION OF 10 MG/L (DUE TO A 
*100 MG BOLUS). * 
CCENTRAL 1 0 ***** IC=lO 
CPERIFER 2 0 ***** IC=O * 
*THE FOLLOWING IS A CLOCK WHICH ALLOWS MULTIPLE BOLUS 
*DOSES. A PULSE FUNCTION IS USED WHERE THE LENGTH OF THE 
*CYCLE DETERMINES THE NUMBER OF DOSES. THE INITIAL CONDITION 
*OF THE CENTRAL COMPARTMENT IS 10 MG/L. 
* 
IMULTI 40 1 PULSE(O 100 88.99997 .00001 .00001 1 90.) 
* 
*THE G ELEMENT DEPENDS ON THE CONCENTRATION IN THE 
*ORIGINATING COMPARTMENT, THE VOLUME OF THAT COMPARTMENT, 
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*AND THE VOLTAGE SOURCE THAT CONTAINS THE VALUE OF THE RATE 
*CONSTANT. 
* 
GK12 10 2 POLY(3) 1 0 4 0 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 
VK12 6 0 ******* 
GK21 20 1 POLY(3) 2 0 5 0 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 
VK21 7 0 ******* 
.TRAN 30 900 UIC 
.PRINT TRAN V(l) V(2) 
.PLOT TRAN V(l) V(2) 
.OPTIONS NOPAGE NUMDGT=5 LIMPTS=5000 ITL1=5000 ITL3=1000 
+ITL4=2000 ITL5=0 PIVTOL=l.OE-30 
.END 
241 
APPENDIX T 
This NONLIN84 subroutine is used to fit data from a 
simulated two compartment open model to a two compartment 
closed model. 
TITLE 
CLOSED COMPARTMENT TEST OF OPEN MODEL WITH VARYING·KlO 
MODEL 
TEMP 
REMARK ASSIGN CONSTANTS AND PARAMETERS 
CO = CON(l) 
VC = P(l) 
XK12 = P(2) 
XK21 = P(3) 
VP = P(4) 
REMARK ASSIGN CALCULATED VARIABLES 
XLAMl = XK12 + XK21 
DC= CO/VC 
DP= CO/VP 
CHCK2 = (XLAMl*X) 
E2CHCK = MIN (CHCK2,50) 
E2 = DEXP (-E2CHCK) 
END 
FUNCl 
F = (DC/XLAM1)*((XK12*E2)+XK21) 
END 
FUNC2 
F = (DP*XK12/XLAM1)*(1 - E2) 
END 
SECO 
REMARK CALCULATE SECONDARY PARAMETERS 
REMARK******************************* 
THALF = 0.693/XLAMl 
S(l) = THALF 
CLMAX = VC*XK12 
5(2) = CLMAX 
END 
EOM 
NOPLOTS 
NFUN 2 
NOBS 10,10 
NPAR 4 
INIT 10,0.05775,0.01155,2 
NSEC 2 
NCON 1 
CONS 100 
CONV 0.000001 
DATA 
0 10 
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APPENDIX T (cont.) 
This subroutine is used to fit data from a simulated two 
compartment open model to a two compartment closed model. 
10 5.5022 
20 3.3507 
30 2.3239 
40 1. 8281 
50 1.5871 
60 1. 4654 
70 1.4013 
80 1. 3642 
90 1. 3401 
0 0.000070 
10 20.248 
20 29.715 
30 34.017 
40 35.881 
50 36.578 
60 36.731 
70 36.622 
80 36.393 
90 36.108 
BEGIN 
NEWP 0,1 
INIT 10,0.05775,0.01155,2 
DATA 
0 10 
10 5.6672 
20 3.5444 
30 2.508 
40 1. 998 
50 1. 7468 
60 1. 6202 
70 1. 5551 
80 1.5196 
90 1.4986 
0 0.000067 
10 20.528 
20 30.47 
30 35.207 
40 37.423 
50 38.4 
60 38.782 
70 38.87 
80 38.817 
90 38.695 
BEGIN 
NEWP 0,1 
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APPENDIX T (cont.) 
This subroutine is used to fit data from a simulated two 
compartment open model to a two compartment closed model. 
INIT 10,0.05775,0.01155,2 
DATA 
0 10 
10 5.7233 
20 3.6114 
30 2.5729 
40 2.0586 
50 1.8044 
60 1. 6764 
70 1.6112 
80 1. 5765 
90 1. 5569 
0 0.000066 
10 20.623 
20 30.727 
30 35.617 
40 37.96 
50 39.039 
60 39.506 
70 39.667 
80 39.682 
90 39.623 
BEGIN 
NEWP 0,1 
INIT 10,0.05775,0.01155,2 
DATA 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
0 
10 
20 
30 
40 
50 
60 
70 
80 
10 
5.7403 
3.6318 
2 .5927 
2. 0772 
1. 8221 
1. 6937 
1. 6286 
1.5942 
1.575 
0.000066 
20.651 
30.805 
35.742 
38.123 
39.234 
39.727 
39.912 
39.947 
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APPENDIX T (cont.) 
This subroutine is used to fit data from a simulated two 
compartment open model to a two compartment closed model. 
90 39.908 
BEGIN 
NEWP 0,1 
INIT 10,0.05775,0.01155,2 
DATA 
0 10 
10 5.7573 
20 3.6523 
30 2.6126 
40 2.0959 
50 1.8401 
60 1. 7113 
70 1.6462 
80 1. 612 
90 1. 5934 
0 0.000065 
10 20.68 
20 30.884 
30 35.867 
40 38.287 
50 39.43 
60 39.95 
70 40.159 
80 40.215 
90 40.196 
BEGIN 
NEWP 0,1 
INIT 10,0.05775,0.01155,2 
DATA 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
0 
10 
20 
30 
40 
50 
10 
5.7686 
3.666 
2.626 
2.1086 
1. 8521 
1. 7231 
1.658 
1. 6241 
1. 6058 
0.000065 
20.699 
30.936 
35.951 
38.398 
39.562 
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APPENDIX T (cont.) 
This subroutine is used to fit data from a simulated two 
compartment open model to a two compartment closed model. 
60 40.1 
70 40.324 
80 40.396 
90 40.39 
BEGIN 
NEWP 0,1 
INIT 10,0.01155,0.05775,2 
DATA 
0 9.9988 
10 0.029975 
20 0.006998 
30 0.003960 
40 0.002249 
50 0.001276 
60 0.000725 
70 0.000411 
80 0.000233 
90 0.000132 
0 0.000122 
10 0.588 
20 0.33519 
30 0.19032 
40 0.1081 
50 0 •. 061335 
60 0.034855 
70 0.019767 
80 0.011237 
90 0.006372 
BEGIN 
NEWP 0,1 
INIT 10,0.01155,0.05775,2 
DATA 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
0 
10 
20 
10 
6.8121 
4.8904 
3.6501 
2.7944 
2.1758 
1. 7104 
1. 3532 
1. 0741 
0.85433 
0.000018 
3.555 
4.4933 
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APPENDIX T (cont.) 
This subroutine is used to fit data from a simulated two 
compartment open model to a two compartment closed model. 
30 4.3521 
40 3.8288 
50 3.2198 
60 2.6452 
70 2.1462 
80 1. 7286 
90 1. 3867 
BEGIN 
NEWP 0,1 
INIT 10,0.01155,0.05775,2 
DATA 
0 10 
10 8.6383 
20 7.786 
30 7.1961 
40 6.7433 
50 6.3668 
60 6.0347 
70 5.732 
80 5.4502 
90 5.1852 
0 0.000014 
10 4.0308 
20 5.8375 
30 6.5442 
40 6.7191 
50 6.637 
60 6.4377 
70 6.1873 
80 5.9192 
90 5.6492 
BEGIN 
-NEWP 0, 1 
INIT 10,0.01155,0.05775,2 
DATA 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
10 
8.8989 
8.2537 
7.8394 
7.5416 
7.3045 
7.0994 
6.9125 
6.7366 
6.5683 
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APPENDIX T (cont.) 
This subroutine is used to fit data from a simulated two 
compartment open model to a two compartment closed model. 
0 0.000013 
10 4.0961 
20 6.0396 
30 6.9058 
40 7.2422 
50 7.3149 
60 7.2605 
70 7.1444 
80 7.0001 
90 6.8438 
BEGIN 
NEWP 0,1 
INIT 10,0.01155,0.05775,2 
DATA 
0 10 
10 8.9875 
20 8.4158 
30 8.0667 
40 7.8288 
50 7.6479 
60 7.496 
70 7.3598 
80 7.2322 
90 7.1101 
0 0.000013 
10 4.1182 
20 6.1089 
30 7.0317 
40 7.4271 
50 7.5582 
60 7.5606 
70 7.4991 
80 7.4071 
90 7.3009 
BEGIN 
NEWP 0,1 
INIT 10,0.01155,0.05775,2 
DATA 
0 
10 
20 
30 
40 
50 
60 
10 
9.0143 
8.4651 
8.1362 
7.9171 
7.7541 
7.6194 
248 
APPENDIX T (cont.) 
This subroutine is used to fit data from a simulated two 
compartment open model to a two compartment closed model. 
70 7.4997 
80 7.3882 
90 7.2814 
0 0.000013 
10 4.1248 
20 6.1299 
30 7.0701 
40 7.4836 
50 7.6331 
60 7.6534 
70 7.6093 
80 7.5342 
90 7.4444 
BEGIN 
NEWP 0,1 
INIT 10,0.01155,0.05775,2 
DATA 
0 10 
10 9.0411 
20 8.5147 
30 8.2063 
40 8.0065 
50 7.8618 
60 7.7448 
70 7.6424 
80 7.5476 
90 7.4571 
0 0.000013 
10 4.1315 
20 6.1509 
30 7.1086 
40 7.5407 
50 7.7087 
60 7.7474 
70 7.7213 
80 7.6637 
90 7.5909 
BEGIN 
NEWP 0,1 
INIT 10,0.01155,0.05775,2 
DATA 
0 
10 
20 
30 
10 
9.0591 
8.5479 
8.2533 
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APPENDIX T (cont.) 
This subroutine is used to fit data from a simulated two 
compartment open model to a two compartment closed model. 
40 8.0666 
50 7.9345 
60 7.8297 
70 7.7391 
80 7.6558 
90 7.5766 
0 0.000013 
10 4.1359 
20 6.165 
30 7.1345 
40 7.579 
50 7.7596 
60 7.8108 
70 7.7969 
80 7.7514 
90 7.6903 
BEGIN 
FINISH 
APPENDIX U 
Single dose procainamide simulation data. 
TIME 
hrs 
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
Proc. 
mg/1 
0 
3.607 
3.615 
3.227 
2.853 
2.531 
2.256 
2.022 
1.821 
1.649 
1.501 
1.373 
1.263 
1.167 
1.084 
1.01 
0.9474 
0.8912 
0.8402 
0.7949 
0.7542 
0.7177 
0.6845 
0.6544 
0.6268 
0.6015 
0.578 
0.5563 
0.5359 
0.517 
0.4991 
0.4822 
0.4662 
0.4511 
0.4366 
0.4228 
0.4096 
0.397 
0.3849 
0.3732 
0.362 
0.3512 
0.3408 
0.3307 
Napa 
mg/1 
0 
0.1386 
0.3413 
0.5262 
0.6866 
0.8248 
0.9444 
1. 048 
1.138 
1.216 
1. 284 
1.343 
1.394 
1.439 
1.479 
1.513 
1. 543 
1.568 
1. 591 
1.611 
1.629 
1.643 
1.656 
1. 667 
1. 676 
1. 683 
1.689 
1. 693 
1. 696 
1. 698 
1.699 
1.699 
1.698 
1. 696 
1.694 
1.69 
1. 686 
1. 682 
1. 677 
1.671 
1. 664 
1.657 
1. 65 
1. 642 
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APPENDIX U (cont.) 
Single dose procainamide simulation data. 
TIME Proc. 
hrs mg/1 
44 0.3209 
45 0.3115 
46 0.3024 
47 0.2936 
48 0.285 
49 0.2768 
50 0.2687 
51 0.261 
52 0.2534 
53 0.2461 
54 0.239 
55 0.2321 
56 0.2254 
57 0.219 
58 0.2126 
59 0.2065 
60 0.2006 
61 0.1948 
62 0.1892 
63 0.1838 
64 0.1785 
65 0.1734 
66 0.1684 
67 0.1636 
68 0.1589 
69 0.1543 
70 0.1499 
71 0.1456 
72 0.1414 
73 0.1374 
74 0.1334 
75 0.1296 
76 0.1259 
77 0.1223 
78 0.1188 
79 0.1154 
80 0.1121 
81 0.1089 
82 0.1057 
83 0.1027 
84 0.09976 
85 0.09691 
86 0.09412 
87 0.09143 
Napa 
mg/1 
1. 634 
1.625 
1.616 
1. 607 
1.597 
1.587 
1. 577 
1.566 
1. 555 
1.544 
1.533 
1. 521 
1. 509 
1.498 
1.485 
1.473 
1.461 
1.448 
1.436 
1. 423 
1.41 
1. 397 
1. 384 
1. 371 
1. 358 
1.345 
1.332 
1. 319 
1.306 
1.292 
1.279 
1.266 
1.253 
1. 24 
1.226 
1. 213 
1.2 
1.187 
1.174 
1.161 
1.148 
1.135 
1.122 
1.109 
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APPENDIX U (cont.) 
Single dose procainamide simulation data. 
TIME Proc. Napa 
hrs mg/1 mg/1 
88 0.08881 1.096 
89 0.08626 1.083 
90 0.08379 1.071 
91 0.08139 1.058 
92 0.07905 1.045 
93 0.07679 1.033 
94 0.07458 1.021 
95 0.07245 1.008 
96 0.07037 0.996 
97 0.06835 0.9839 
98 0.06639 0.9718 
99 0.06449 0.9598 
100 0.06262 0.9479 
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APPENDIX V 
Multiple dose procainamide simulation data. 
TIME Proc. Napa 
hrs. mg/1 mg/1 
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
0 
3.614 
3.612 
3.228 
2.855 
2.533 
2.258 
2.023 
1.822 
1.65 
1.502 
1. 374 
1.264 
4.782 
4.696 
4.239 
3.802 
3.423 
3.097 
2.817 
2.576 
2.367 
2.186 
2.029 
1.891 
5.384 
5.273 
4.795 
4.338 
3.94 
3.596 
3.299 
3.042 
2.818 
2.623 
2.451 
2.3 
5.781 
5.659 
5.168 
4.7 
4.291 
3.937 
0 
0.1377 
0.3406 
0.5254 
0.6858 
0.8243 
0.944 
1. 048 
1.137 
1.216 
1.283 
1.343 
1.394 
1.577 
1.819 
2.039 
2.229 
2.394 
2.536 
2.66 
2.767 
2.859 
2.94 
3.01 
3.07 
3.26 
3.508 
3.732 
3.925 
4.092 
4.235 
4.359 
4.465 
4.556 
4.633 
4.7 
4.756 
4.942 
5.184 
5.402 
5.589 
5.749 
5.885 
253 
APPENDIX V (cont.) 
Multiple dose procainamide simulation data. 
TIME Proc. Napa 
hrs. mg/1 mg/1 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
66 
67 
68 
69 
70 
71 
72 
73 
74 
75 
76 
77 
78 
79 
80 
81 
82 
83 
84 
85 
3.63 
3.363 
3.13 
2.926 
2.745 
2.585 
6.06 
5.928 
5.429 
4.954 
4.537 
4.176 
3.863 
3.589 
3.349 
3.138 
2.952 
2.786 
6.253 
6.117 
5.613 
5.132 
4. 711 
4.345 
4.026 
3.748 
3.504 
3.288 
3.098 
2.928 
6.391 
6.251 
5.743 
5.258 
4.833 
4.464 
4.142 
3.86 
3.613 
3.394 
3.2 
3.028 
6.487 
6.001 
6.098 
6.181 
6.25 
6.307 
6.353 
6.529 
6.761 
6.968 
7 .145 
7.293 
7.418 
7.522 
7.608 
7.678 
7.735 
7.78 
7.814 
7.977 
8.197 
8.391 
8.555 
8.691 
8.802 
8.893 
8.966 
9.024 
9.067 
9.099 
9.12 
9 •. 27 
9.476 
9.657 
9.808 
9.93 
10.03 
10.11 
10.17 
10.21 
10.24 
10.26 
10.27 
10.4 
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APPENDIX V (cont.) 
Multiple dose procainamide simulation data. 
TIME Proc. Napa 
hrs. mg/1 mg/1 
86 
87 
88 
89 
90 
91 
92 
93 
94 
95 
96 
97 
98 
99 
100 
101 
102 
103 
104 
105 
106 
107 
108 
109 
110 
111 
112 
113 
114 
115 
116 
117 
118 
119 
120 
121 
122 
123 
124 
125 
126 
127 
128 
6.345 
5.835 
5.347 
4.92 
4.548 
4.223 
3.939 
3.689 
3.469 
3.273 
3.098 
6.558 
6.411 
5.899 
5.41 
4.98 
4.607 
4.281 
3.995 
3.744 
3.521 
3.324 
3.148 
6.605 
6.458 
5.945 
5.454 
5.023 
4.648 
4.321 
4.034 
3.782 
3.559 
3.36 
3.183 
6.638 
6.491 
5.977 
5.485 
5.054 
4.678 
4.35 
4.062 
10.6 
10.77 
10.9 
11. 01 
11.1 
11.16 
11. 21 
11.24 
11.26 
11.27 
11.26 
11.39 
11.57 
11.73 
11.85 
11.95 
12.02 
12.08 
12.11 
12.13 
12 .14 
12.14 
12.12 
12.23 
12.4 
12.55 
12.66 
12.75 
12.82 
12.86 
12.88 
12.89 
12.89 
12.88 
12.85 
12.95 
13.12 
13.25 
13.36 
13.43 
13.49 
13.52 
13.54 
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APPENDIX V (cont.) 
Multiple dose procainamide simulation data. 
TIME Proc. Napa 
hrs. mg/1 mg/1 
129 
130 
131 
132 
133 
134 
135 
136 
137 
138 
139 
140 
141 
142 
143 
144 
145 
146 
147 
148 
149 
150 
151 
152 
153 
154 
155 
156 
157 
158 
159 
160 
161 
162 
163 
164 
165 
166 
167 
168 
169 
170 
171 
3.809 
3.585 
3.386 
3.207 
6.662 
6.514 
5.999 
5.507 
5.075 
4.699 
4.37 
4.082 
3.828 
3.603 
3.403 
3.225 
6.68 
6.531 
6.016 
5.523 
5.09 
4.713 
4.384 
4.096 
3.841 
3.616 
3.416 
3.237 
6.691 
6.543 
6.027 
5.534 
5.101 
4.724 
4.394 
4.105 
3.851 
3.626 
3.425 
3.246 
6.702 
6.551 
6.035 
13.54 
13.53 
13.5 
13.47 
13.57 
13.72 
13.85 
13.94 
14.01 
14.06 
14.08 
14.09 
14.09 
14.07 
14.03 
13.99 
14.08 
14.22 
14.34 
14.43 
14.5 
14.53 
14.55 
14.56 
14.54 
14.52 
14.48 
14.43 
14.51 
14.65 
14.76 
14.85 
14.9 
14.94 
14.95 
14.95 
14.93 
14.9 
14.85 
14.8 
14.87 
15.01 
15.12 
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APPENDIX V (cont.) 
Multiple dose procainamide simulation data. 
TIME Proc. Napa 
hrs. mg/1 mg/1 
172 
173 
174 
175 
176 
177 
178 
179 
180 
181 
182 
183 
184 
185 
186 
187 
188 
189 
190 
191 
192 
193 
194 
195 
196 
197 
198 
199 
200 
201 
202 
203 
204 
205 
206 
207 
208 
209 
210 
211 
212 
213 
214 
5.542 
5.108 
4.731 
4.401 
4.112 
3.858 
3.632 
3.431 
3.252 
6.706 
6.557 
6.04 
5.547 
5.114 
4.736 
4.406 
4.117 
3.862 
3.637 
3.436 
3.256 
6.71 
6.56 
6.044 
5.551 
5.117 
4.74 
4.41 
4.12 
3.865 
3.64 
3.439 
3.259 
6. 713 
6.563 
6.047 
5.553 
5.12 
4.742 
4.412 
4.123 
3.868 
3.642 
15.19 
15.25 
15.27 
15.28 
15.27 
15.25 
15.21 
15.16 
15.11 
15.18 
15.31 
15.41 
15.48 
15.53 
15.56 
15.56 
15.55 
15.52 
15.48 
15.42 
15.36 
15.43 
15.55 
15.65 
15.72 
15.77 
15.79 
15.79 
15.77 
15.74 
15.69 
15.64 
15.57 
15.64 
15.76 
15.86 
15.92 
15.96 
15.98 
15.98 
15.96 
15.93 
15.88 
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APPENDIX V (cont.) 
Multiple dose procainamide simulation data. 
TIME Proc. Napa 
hrs. mg/1 mg/1 
215 
216 
217 
218 
219 
220 
221 
222 
223 
224 
225 
226 
227 
228 
229 
230 
231 
232 
233 
234 
235 
236 
237 
238 
239 
240 
3.441 
3.261 
6.717 
6.566 
6.049 
5.555 
5.122 
4.744 
4.414 
4 .125 
3.869 
3.644 
3.443 
3.263 
6.717 
6.567 
6.05 
5.557 
5.123 
4.745 
4.415 
4.126 
3.871 
3.645 
3.444 
3.264 
15.82 
15.75 
15.81 
15.93 
16.03 
16.09 
16.13 
16.14 
16.14 
16.12 
16.08 
16.03 
15.97 
15.9 
15.96 
16.07 
16.17 
16.23 
16.27 
16.28 
16.27 
16.25 
16.21 
16.16 
16.09 
16.02 
258 
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APPENDIX W 
Closed compartment simulations. 
Dose into C = 100 mg, Ve = 10 liters, Vp = 2 liters 
Kl2 = 0.05775 K21 = 0.05775 
TIME Cc Cp Clearance Kl2 K21 Net 
flow flow flow 
0.00000 10.00000 0.00011 0. 57750 5.77500 0.00001 5.77500 
10.00000 6.57650 17.11800 0.27647 3.79790 1. 97710 1. 82080 
20.00000 5.49410 22.52900 0.10382 3.17280 2.60220 0.57070 
30.00000 5.15530 24.22300 0.03479 2.97720 2.79780 0.17939 
40.00000 5.04850 24.75700 0.01111 2.91550 2.85950 0.0567 
50.00000 5.01530 24.92400 0.00352 2.89630 2.87870 0.0166 
60.00000 5.00480 24.97600 0.00110 2.89030 2.88470 0.00552 
70.00000 5.00150 24.99200 0.00035 2.88840 2.88660 0.00174 
80.00000 5.00050 24.99800 0.00011 2.88780 2. 88720 0.00054 
90.00000 5.00010 24.99900 0.00003 2.88760 2.88740 0. 00017 
Kl2 = 0.05775 K21 0.01155 
TIME Cc Cp Clearance Kl2 K21 Net 
flow flow flow 
0.00000 10.00000 0.00()06 0.57750 5.77500 0.00000 5.77500 
10.00000 5.83720 20.81400 0.49482 3.37100 0.48080 2.89020 
20.00000 3.74950 31. 25200 0.38475 2.16540 0.72193 1. 44340 
30.00000 2.70810 36.46000 0.26627 1.56390 0.84222 0.72168 
40.00000 2.18620 39.06900 0.16467 1.26260 0.90249 0.36007 
50.00000 1. 92670 40.36700 0.09347 1.11260 0.93247 0.18017 
60.00000 1. 79640 41. 01800 0.05003 1.03740 0.94752 0.08988 
70.00000 1. 73160 41. 34200 0.02597 0.99998 0.95500 0.04497 
80.00000 1. 69910 41. 50500 0.01321 0.98121 0.95876 0.02245 
90.00000 1. 68280 41. 58600 0.00666 0.97184 0.96063 0.01121 
Kl2 = 0.03 K21 = 0.05775 
TIME Cc Cp Clearance Kl2 K21 Net 
flow flow flow 
0.00000 10.00000 0.00004 0.30000 3.00000 0.00000 3.00000 
10.00000 8.00410 9.97930 0.15589 2.40120 1. 15260 1. 24860 
20.00000 7.17140 14.14300 0.07220 2.15140 1. 63350 0.51794 
30.00000 6.82650 15.86800 0.03152 2.04790 1. 83270 0.21521 
40.00000 6.68280 16.58600 0.01334 2.00480 1. 91570 0.08913 
50.00000 6.62350 16.88300 0.00560 1.98700 1.95000 0.03708 
60.00000 6.59870 17.00700 0.00233 1.97960 1. 96430 0.01535 
70.00000 6.58850 17.05800 0.00097 1. 97650 1. 97020 0.00639 
80.00000 6.58420 17.07900 0.00040 1.97530 1.97260 0.00265 
90.00000 6.58240 17.08800 0.00017 1.97470 1. 97360 0.00110 
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APPENDIX W (cont.) 
Closed compartment simulations. 
Dose into c = 100 mg, Ve = 10 liters, Vp = 2 liters 
Kl2 = 0.05775 K21 = 0.03 
TIME Cc Cp Clearance Kl2 K21 Net 
flow flow flow 
0.00000 10.00000 0.00008 0.57750 5.77500 0.00000 5.77500 
10.00000 6.15800 19.21000 0.38986 3.55620 1.15260 2.40360 
20.00000 4.55500 27.22500 0.21873 2.63050 1. 63350 0.99703 
30.00000 3.89090 30.54500 0.10641 2.24700 1. 83270 0.41429 
40.00000 3.61430 31. 92800 0.04747 2.08730 1. 91570 0.17157 
50.00000 3.50020 32.49900 0.02039 2.02130 1.95000 0.07139 
60.00000 3.45250 32.73800 0.00856 1. 99380 1. 96430 0.02955 
70.00000 3.43280 32.83600 0.00358 1.98250 1. 97020 0.01230 
80.00000 3.42460 32.87700 0.00149 1. 97770 1. 97260 0.00510 
90.00000 3.42120 32.89400 0.00062 1. 97570 1. 97360 0.00211 
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APPENDIX X 
Closed compartment simulations. 
Dose into P = 100 mg, Ve = 10 liters, Vp 2 liters 
K12 = 0.05775, K21 = 0.05775 
TIME Cc Cp Clearance K12 K21 Net 
flow flow flow 
0.00000 0.00002 50.00000 0.11550 0.00001 5.77500 5.77500 
10.00000 3.42350 32.88200 0.05529 1.97710 3.79790 1. 82080 
20.00000 4.50590 27.47100 0.02076 2.60220 3.17280 0.57070 
30.00000 4.84470 25.77700 0.00696 2.79780 2. 97720 0.17939 
40.00000 4.95150 25.24300 0.00222 2.85950 2.91550 0.05607 
50.00000 4.98470 25.07600 0.00070 2.87870 2.89630 0.01766 
60.00000 4.99520 25.02400 0.00022 2.88470 2.89030 0.00552 
70.00000 4.99850 25.00800 0.00007 2.88660 2.88840 0.00174 
80.00000 4.99950 25.00200 0.00002 2.88720 2.88780 0.00054 
90.00000 4.99990 25.00100 0.00001 2.88740 2.88760 0.00017 
K12 = 0.01155, K21 = 0.05775 
TIME Cc Cp Clearance K12 K21 Net 
flow flow flow 
0.00000 0.00001 50.00000 0.11550 0.00000 5. 77500 5.77500 
10.00000 4.16280 29.18600 0.09897 0.48080 3.37100 2.89020 
20.00000 6.25050 18.74800 0.07695 0.72193 2.16540 1. 44340 
30.00000 7.29190 13.54000 0.05325 0.84222 1. 56390 0.72168 
40.00000 7.81380 10.93100 0.03293 0.90249 1. 26260 0.36007 
50.00000 8.07330 9.63330 0.01869 0.93247 1.11260 0.18017 
60.00000 8.20360 8.98180 0.01001 0.94752 1.03740 0.08988 
70.00000 8.26840 8.65780 0.00519 0.95500 0.99998 0.04497 
80.00000 8.30090 8.49530 0.00264 0.95876 0.98121 0.02245 
90.00000 8.31720 8.41420 0.00133 0.96063 0.97184 0.01121 
K12 = 0.05775, K21 = 0.01155 
TIME Cc Cp Clearance K12 K21 Net 
flow flow flow 
0.00000 0.00000 50.00000 0.02310 0.00000 1.15500 1.15500 
10.00000 0.83255 45.83700 0.01261 0.48080 1. 05880 0.57804 
20.00000 1. 25010 43.75000 0.00660 0.72193 1. Ol.060 0.28869 
30.00000 1. 45840 42.70800 0.00338 0.84222 0.98656 0.14434 
40.00000 1.56280 42.18600 0. 00171 0.90249 0.97450 0.07201 
50.00000 1. 61470 41. 92700 0.00086 0.93247 0.96851 0.03603 
60.00000 1. 64070 41. 79600 0.00043 0.94752 0.96550 0.01798 
70.00000 1. 65370 41. 73200 0.00022 0.95500 0.96400 0.00899 
80.00000 1. 66020 41.69900 0.00011 0.95876 0.96325 0.00449 
90.00000 1. 66340 41.68300 0.00005 0.96063 0.96287 0.00224 
APPENDIX X (cont.) 
Closed compartment simulations. 
Dose into P = 100 mg, Ve = 10 liters, Vp 
TIME 
0.00000 
10.00000 
20.00000 
30.00000 
40.00000 
50.00000 
60.00000 
70.00000 
80.00000 
90.00000 
TIME 
0.00000 
10.00000 
20.00000 
30.00000 
40.00000 
50.00000 
60.00000 
70.00000 
80.00000 
90.00000 
Cc 
0.00002 
3.84200 
5.44500 
6.10910 
6.38570 
6.49980 
6.54750 
6. 56720 
6.57540 
6.57880 
Cc 
0.00001 
1. 99590 
2.82860 
3.17350 
3.31720 
3.37650 
3.40130 
3. 41150 
3.41580 
3.41760 
Kl2 = 0.03, K21 = 0.05775 
Cp Clearance Kl2 
50.00000 
30.79000 
22.77500 
19.45500 
18. 07200 
17.50100 
17.26200 
17.16400 
17.12300 
17.10600 
0.11550 
0.07797 
0.04375 
0.02128 
0.00949 
0.00408 
0. 00171 
0.00072 
0.00030 
0.00012 
Kl2 = 0.05775, K21 
Cp Clearance 
50.00000 0.06000 
40.02100 0.03118 
35.85700 0.01444 
34.13200 0.00630 
33.41400 0.00267 
33.11700 0.00112 
32.99300 0.00047 
32.94200 0.00019 
32.92100 0.00008 
32.91200 0.00003 
flow 
0.00000 
1.15260 
1. 63350 
1. 83270 
1. 91570 
1. 95000 
1. 96430 
1. 97020 
1. 97260 
1. 97360 
= 0.03 
Kl2 flow 
0.00000 
1.15260 
1. 63350 
1. 83270 
1. 91570 
1. 95000 
1. 96430 
1. 97020 
1.97260 
1. 97360 
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2 liters 
K21 
flow 
5.77500 
3.55620 
2.63050 
2.24700 
2.08730 
2.02130 
2.99380 
1. 98250 
1. 97770 
1. 97570 
Net 
flow 
5.77500 
2.40360 
0.99703 
0.41429 
0.17157 
0.07139 
0.02955 
0.01230 
0.00510 
o. 00211 
K21 flow Net flow 
3.00000 3.00000 
2.40120 1.24860 
2.15140 0.51794 
2.04790 0.21521 
2.00480 0.08913 
1. 98700 0. 03708 
1. 97960 0. 01535 
1. 97650 0. 00639 
1. 97530 0. 00265 
1.97470 0.00110 
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Closed compartment simulations. 
Dose into C = 100 mg, Ve = 10 liters, Vp 10 liters. 
K12 = 0.05775, K21 = 0.05775 
TIME Cc Cp Clearance K12 K21 Net 
flow flow flow 
0.00000 10.00000 0.00002 0.57750 5.77500 0.00001 5.77500 
10.00000 6.57650 3.42350 0.27647 3.79790 1. 97710 1. 82080 
20.00000 5.49410 4.50590 0.10382 3.17280 2.60220 0.57070 
30.00000 5.15530 4.84470 0.03479 2.97720 2.79780 0.17939 
40.00000 5.04850 4.95150 0. 01111 2.91550 2.85950 0.05607 
50.00000 5.01530 4.98470 0.00352 2.89630 2.87870 0.01766 
60.00000 5.00480 4.99520 0.00110 2.89030 2.88470 0.00552 
70.00000 5.00150 4.99850 0.00035 2.88840 2.88660 0.00174 
80.00000 5.00050 4.99950 0.00011 2.88780 2.88720 0.00054 
90.00000 5.00010 4.99990 0.00003 2.88760 2.88740 0.00017 
K12 = 0.01155, K21 = 0.05775 
TIME Cc Cp Clearance K12 K21 Net 
flow flow flow 
0.00000 10.00000 0.00000 0.11550 1.15500 0.00000 1.15500 
10.00000 9.16740 0. 83255 0.06304 1.05880 0.48080 0.57804 
20.00000 8.74990 1.25010 0. 03299 1.01060 0.72193 0.28869 
30.00000 8.54160 1. 45840 0.01690 0.98656 0.84222 0.14434 
40.00000 8.43720 1.56280 0.00854 0.97450 0.90249 o. 07201 
50.00000 8.38530 1. 61470 0.00430 0.96851 0.93247 0.03603 
60.00000 8.35930 1. 64070 0.00215 0.96550 0.94752 0.01798 
70.00000 8.34630 1. 65370 0.00108 0.96400 0.95500 0.00899 
80.00000 8.33980 1. 66020 0.00054 0.96325 0.95876 0.00449 
90.00000 8.33660 1. 66340 0.00027 0.96287 0.96063 0.00224 
K12 = 0.05775, K21 = 0.01155 
TIME Cc Cp Clearance K12 K21 Net 
flow flow flow 
0.00000 10.00000 0.00001 0.57750 5.77500 0.00000 5.77500 
10.00000 5.83720 4.16280 0.49482 3.37100 0.48080 2.89020 
20.00000 3.74950 6.25050 0.38475 2.16540 0.72193 1.44340 
30.00000 2.70810 7.29190 0.26627 1. 56390 0.84222 0.72168 
40.00000 2.18620 7.81380 0.16467 1. 26260 0.90249 0.36007 
50.00000 1. 92670 8.07330 0.09347 1.11260 0.93247 0.18017 
60.00000 1. 79640 8.20360 0.05003 1.03740 0.94752 0.08988 
70.00000 1. 73160 8.26840 0.02597 0.99998 0.95500 0.04497 
80.00000 1. 69910 8.30090 0.01321 0.98121 0.95876 0.02245 
90.00000 1. 68280 8.31720 0.00666 0.97184 0.96063 0.01121 
APPENDIX Y (cont.) 
Closed compartment simulations. 
Dose into C = 100 mg, Ve = 10 liters, Vp 
TIME 
0.00000 
10.00000 
20.00000 
30.00000 
40.00000 
50.00000 
60.00000 
70.00000 
80.00000 
90.00000 
TIME 
0.00000 
10.00000 
20.00000 
30.00000 
40.00000 
50.00000 
60.00000 
70.00000 
80.00000 
90.00000 
Cc 
10.00000 
8.00410 
7.17140 
6.82650 
6.68280 
6.62350 
6.59870 
6.58850 
6.58420 
6.58240 
Cc 
10.00000 
6.15800 
4.55500 
3.89090 
3.61430 
3.50020 
3.45250 
3.43280 
3.42460 
3.42120 
K12 = 0.03, K21 = 0.057775 
cp Clearance K12 
0.00001 
1. 99590 
2.82860 
3.17350 
3.31720 
3.37650 
3.40130 
3.41150 
3.41580 
3.41760 
0.30000 
0.15589 
0.07220 
0.03152 
0.01334 
0.00560 
0.00233 
0.00097 
0.00040 
0.00017 
K12 = 0.05775, K21 
Cp Clearance 
0.00002 
3.84200 
5.44500 
6.10910 
6.38570 
6.49980 
6.54750 
6.56720 
6.57540 
6.57880 
0.57750 
0.38986 
0.21873 
0.10641 
0.04747 
0.02039 
0.00856 
0.00358 
0.00149 
0.00062 
flow 
3.00000 
2.40120 
2.15140 
2.04790 
2.00480 
1. 98700 
1.97960 
1. 97650 
1.97530 
1.97470 
= 0.03 
Kl2 
flow 
5.77500 
3.55620 
2.63050 
2.24700 
2.08730 
2. 02130 
1. 99380 
1. 98250 
1.9'7770 
1. 97570 
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10 liters. 
K21 
flow 
0.00000 
1.15260 
1. 63350 
1. 83270 
1. 91570 
1.95000 
1. 96430 
1. 97020 
1. 97260 
1. 97360 
K21 
flow 
0.00000 
1.15260 
1. 63350 
1.83270 
1. 91570 
1. 95000 
1. 96430 
1.97020 
1. 97260 
1. 97360 
Net 
flow 
3.00000 
1. 24860 
0.51794 
0.21521 
0.08913 
0. 03708 
0.01535 
0.00639 
0.00265 
0.00110 
Net 
flow 
5.77500 
2.40360 
0.99703 
0.41429 
0.17157 
0.07139 
0.02955 
0.01230 
0.00510 
0.00211 
265 
APPENDIX Z 
Closed compartment simulations. 
Dose into c 100 mg, Ve = 10 liters and Vp changes. 
Kl2 = 0.05775, K21 = 0.05775 
TIME Cc Cp Clearance Vp K12 flow K21 flow Net fl 
0.00000 10.00000 0.00000 0.57750 2.00000 5.77500 0.00000 5.7750 
10.00000 6.57540 13.27700 0.27670 2.57940 3.79730 1. 97770 1. 8196 
20.00000 5.49520 17.88500 0.10408 2.51880 3.17350 2.60150 0.5719 
30.00000 5.15610 19.70500 0.03496 2.45820 2. 97770 2.79730 0.1803 
40.00000 5.04880 20.65100 0. 01116 2.39760 2.91570 2.85930 0.0563 
50.00000 5.01540 21. 32200 0.00353 2.33700 2.89640 2.87860 0. 0177 
60.00000 5.00480 21.94300 0.00111 2.27640 2.89030 2.88470 0.0055 
70.00000 5.00150 22.55800 0.00034 2.21580 2.88840 2.88660 0. 0017 
80.00000 5.00050 23.19800 0.00010 2.15520 2.88780 2.88720 0.0005 
90.00000 5.00010 23.87000 0.00003 2.09460 2.88760 2.88740 0.0001 
Kl2 = 0.01155, K21 = 0.05775 
TIME Cc Cp Clearance Vp K12 flow K21 flow Net flo 
0.00000 10.00000 0.00000 0.11550 2.00000 1.15500 0.00000 1.1550 
10.00000 9.16680 3.23010 0.06301 2.57940 1.05880 0.48116 0.5776 
20.00000 8.75000 4.96290 0.03299 2.51880 1.01060 0.72190 0.2887 
30.00000 8.54190 5.93190 0.01691 2.45820 0.98658 0.84208 0.1445 
40.00000 8.43740 6.51750 0.00854 2.39760 0.97452 0.90242 0.0721 
50.00000 8.38540 6.90900 0.00430 2.33700 0.96851 0.93244 0.0360 
60.00000 8.35930 7.20740 0.00215 2.27640 0.96550 0.94749 0.0180 
70.00000 8.34630 7.46310 0.00107 2.21580 0.96400 0.95500 0.0090 
80.00000 8.33980 7.70310 0.00053 2.15520 0.96325 0.95875 0.0044 
90.00000 8.33660 7.94150 0.00029 2.09460 0.96287 0.96063 0.0022 
TIME K12 = 0.05775, K21 = 0.01155 
0.00000 Cc Cp Clearance Vp K12 flow K21 flow Net flo 
10.00000 . 10. 00000 0.00000 0.57750 2.00000 5.77500 0.00000 5. 7750 
20.00000 5.83410 16.15100 0.49501 2.57940 3.36920 0.48116 2.8881 
30.00000 3.74980 24.81400 0.38495 2.51880 2.16550 o. 72190 1. 4436 
40.00000 2.70930 29.65900 0.26644 2.45820 1. 56460 0.84208 0.7225 
50.00000 2.18690 32.58700 0.16481 2.39760 1. 26290 0.90242 0.3605 
60.00000 1. 92690 34.54500 0.09354 2.33700 1.11280 0.93244 0.1803 
70.00000 1.79660 36.03700 0.05011 2.27640 1. 03750 0.94749 0.0900 
80.00000 1. 73160 37.31600 0.02598 2.21580 
1. 00000 0.95500 0.0450 
90.00000 1. 69910 38.51600 
0.01323 2.15520 0.98124 0.95875 0.0224 
1. 68290 39.70700 0.00666 2.09460 0.97185 0.96063 0. 0112 
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APPENDIX Z 
Closed compartment simulations. 
Dose into C 100 mg, Ve = 10 liters and Vp changes. 
K12 =· 0.05775, K21 = 0.05775 
TIME Cc Cp Clearance Vp K12 flow K21 flow Net flow 
0.00000 10.0000 0.00000 0.57750 2.00000 5.77500 0.00000 5.77500 
10.00000 6.5754 13. 27700 0.27670 2.57940 3.79730 1. 97770 1. 81960 
20.00000 5.4952 17.88500 0.10408 2.51880 3.17350 2.60150 0.57198 
30.00000 5.1561 19.70500 0.03496 2.45820 2.97770 2.79730 0.18033 
40.00000 5.0488 20.65100 0.01116 2.39760 2.91570 2.85930 0.05636 
50.00000 5.0154 21. 32200 0.00353 2.33700 2.89640 2.87860 0.01774 
60.00000 5.0048 21. 94300 0.00111 2.27640 2.89030 2.88470 0.00555 
70.00000 5.0015 22.55300 0.00034 2.21580 2.88840 2.88660 0.00174 
80.00000 5.0005 23.19800 0.00010 2.15520 2.88780 2.88720 0.00054 
90.00000 5.0001 23.87000 0.00003 2.09460 2.88760 2.88740 0.00017 
Kl2 = 0.01155, K21 = 0.05775 
TIME Cc Cp Clearance Vp Kl2 flow K21 flow Net flow 
0.00000 10.0000 0.00000 0.11550 2.00000 1.15500 0.00000 1.15500 
10.00000 9.1668 3.23010 0.06301 2.57940 1. 05880 0.48116 0.57761 
20.00000 8.7500 4.96290 0.03299 2.51880 1. 01060 0.72190 0.28872 
30.00000 8.5419 5.93190 0.01691 2.45820 0.98658 0.84208 0.14450 
40.00000 8.4374 6.51750 0.00854 2.39760 0.97452 0.90242 0.07210 
50.00000 8.3854 6.90900 0.00430 2.33700 0.96851 0.93244 0.03606 
60.00000 8.3593 7.20740 0.00215 2.27640 0.96550 0.94749 0.01801 
70.00000 8.3463 7.46310 0.00107 2.21580 0.96400 0.95500 0.00900 
80.00000 8.3398 7.70310 0.00053 2.15520 0.96325 0.95875 .0.00449 
90.00000 8.3366 7.94150 0.00029 2.09460 0.96287 0.96063 0.00224 
Kl2 = 0.05775, K21 = 0.01155 
TIME Cc Cp Clearance Vp Kl2 flow K21 flow Net flow 
0.00000 10.0000 0.00000 0.57750 2.00000 5.77500 0.00000 5.77500 
10.00000 5.8341 16.15100 0.49501 2.57940 3.36920 0.48116 2.88810 
20.00000 3.7498 24. 81400 0.38495 2.51880 2.16550 0.72190 1. 44360 
30.00000 2.7093 29.65900 0.26644 2.45820 1.56460 0.84208 0. 72252 
40.00000 2.1869 32.58700 0.16481 2.39760 1. 26290 0.90242 0.36050 
50.00000 1. 9269 34.54500 0.09354 2.33700 1.11280 0.93244 0.18033 
60.00000 1. 7966 36.03700 0.05011 2.27640 1. 03750 0.94749 o·. 09004 
70.00000 1. 7316 37.31600 0.02598 2.21580 1.00000 0.95500 0.04504 
80.00000 1. 6991 38.51600 0.01323 2.15520 0.98124 0.95875 0.02248 
90.00000 1.6829 39.70700 0.00666 2.09460 0.97185 0.96063 0.01121 
TIME 
0.00000 
10.00000 
20.00000 
30.00000 
40.00000 
50.00000 
60.00000 
70.00000 
80.00000 
90.00000 
TIME 
0.00000 
10.00000 
20.00000 
30.00000 
40.00000 
50.00000 
60.00000 
70.00000 
80.00000 
90.00000 
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Closed compartment simulations. 
Dose into C = 100 mg, Ve = 10 liters and Vp changes. 
Cc 
10.0000 
8.0029 
7.1718 
6.8270 
6.6830 
6.6235 
6.5988 
6.5885 
6.5842 
6.5824 
Cc 
10.0000 
6.1550 
4.5557 
3.8920 
3.6148 
3.5003 
3.4526 
3.4328 
3.4246 
3.4212 
Kl2 = 0.03, K21 = 0.05775 
Clearance Vp Kl2 flow 
0.30000 2.00000 3.00000 
0.15588 2.57940 2.40090 
0.07226 2.51880 2.15150 
0.03159 2.45820 2.04810 
0.01336 2.39760 2.00490 
0.00560 2.33700 1.98710 
0.00233 2.27640 1.97960 
0.00091 2.21580 1.97650 
0.00040 2.15520 1.97530 
0.00016 2.09460 1.97470 
Cp 
0.00000 
7.74260 
11. 22800 
12.90800 
13.83500 
14.44800 
14.94100 
15.39600 
15.84900 
16.31600 
Kl2 
Cp 
0.00000 
14.90400 
21. 61500 
24.84800 
26.63200 
27.81200 
28.76200 
29.63800 
30.50900 
31. 40800 
= 0.05775, K21 = 
Clearance Vp 
0.57750 2.00000 
0.39011 2.57940 
0.21896 2.51880 
0.10662 2.45820 
0.04757 2.39760 
0.02043 2.33700 
0.00858 2.27640 
0.00358 2.21580 
0.00149 2.15520 
0.00061 2.09460 
0.03 
K12 flow 
5.77500 
3.55480 
2.63090 
2.24760 
2.08750 
2.02140 
1. 99390 
1.98250 
1. 97770 
1. 97580 
K21 flow 
0.00000 
1.15330 
1. 63330 
1. 83240 
1. 91560 
1. 94990 
1. 96420 
1. 97010 
1.97260 
1. 97360 
K21 flow 
0.00000 
1.15330 
1. 63330 
1. 83240 
1. 91560 
1. 94990 
1. 96420 
1.97010 
1. 97260 
1. 97360 
Net flow 
3.00000 
1.24750 
0.51826 
0.21572 
0.08934 
0.03715 
0.01540 
0.00639 
0.00265 
0.00109 
Net flow 
5.77500 
2.40150 
0.99765 
0.41525 
0.17198 
0.07152 
0.02965 
0.01231 
0.00511 
0.00211 
TIME 
0.00000 
10.00000 
20.00000 
30.00000 
40.00000 
50.00000 
60.00000 
70.00000 
80.00000 
90.00000 
TIME 
0.00000 
10.00000 
20.00000 
30.00000 
40.00000 
50.00000 
60.00000 
70.00000 
80.00000 
90.00000 
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APPENDIX Z (cont.) 
Closed compartment simulations. 
Dose into C = 100 mg, Ve = 10 liters and Vp changes. 
Kl2 = 0.03, K21 = 0.05775 
cc cp Clearance Vp Kl2 flow 
10.00000 0.00000 0.30000 2.00000 3.00000 
8.00290 7.74260 0.15588 2.57940 2.40090 
7.17180 11.22800 0.07226 2.51880 2.15150 
6.82700 12.90800 0.03159 2.45820 2.04810 
6.68300 13.83500 0.01336 2.39760 2.00490 
6.62350 14.44800 0.00560 2.33700 1.98710 
6.59880 _ 14.94100 0.00233 2.27640 1.97960 
6.58850 15.39600 0.00091 2.21580 1.97650 
6.58420 15.84900 0.00040 2.15520 1.97530 
6.58240 16.31600 0.00016 2.09460 1.97470 
Cc 
10.00000 
6.15560 
4.55570 
3. 89200 
3.61480 
3.50030 
3.45260 
3.43280 
3.42460 
3.42120 
Kl2 = 0.05775, K21 = 0.03 
Cp Clearance Vp Kl2 flow 
0.00000 0.57750 2.00000 5.77500 
14.90400 0.39011 2.57940 3.55480 
21.61500 0.21896 2.51880 2.63090 
24.84800 0.10662 2.45820 2.24760 
26.63200 0.04757 2.39760 2.08750 
27.81200 0.02043 2.33700 2.02140 
28.76200 0.00858 2.27640 1.99390 
29.63800 0.00358 2.21580 1.98250 
30.50900 0.00149 2.15520 1.97770 
31.40800 0.00061 2.09460 1.97580 
K21 flow 
0.00000 
1.15330 
1. 63330 
1. 83240 
1. 91560 
1. 94990 
1. 96420 
1. 97010 
1. 97260 
1. 97360 
K21 flow 
0.00000 
1.15330 
1. 63330 
1. 83240 
1. 91560 
1. 94990 
1. 96420 
1. 97010 
1. 97260 
1. 97360 
Net flo 
3.0000 
1.2475 
0.5182 
0.2157 
0.0893 
0. 0371 
0.0154 
0.0063 
0.0026 
0.0010 
Net flo 
5.7750 
2.4015 
0.9976 
0.4152 
0 .171� 
0.071!i 
0.029� 
0.012� 
0.0051 
0.002:j. 
267 
APPENDIX AA 
Two compartment open model simulations with decreasing K10 
Kl2 0.01155, K21 = 0.05775, 
K10 = 0.6 
TIME 
0.00000 
10.00000 
20.00000 
30.00000 
40.00000 
50.00000 
60.00000 
70.00000 
80.00000 
90.00000 
Cc 
9.99880 
0.02998 
0.00700 
0.00396 
0.00225 
0.00128 
0.00073 
0.00041 
0.00023 
0.00013 
K10 = 0.03 
TIME Cc 
0.00000 
10.00000 
20.00000 
30.00000 
40.00000 
50.00000 
60.00000 
70.00000 
80.00000 
90.00000 
10.00000 
6.81210 
4.89040 
3.65010 
2.79440 
2.17580 
1.71040 
1. 35320 
1. 07410 
0.85433 
K10 = 0.006 
TIME Cc 
0.00000 
10.00000 
20.00000 
30.00000 
40.00000 
50.00000 
60.00000 
70.00000 
80.00000 
90.00000 
10.00000 
8.63830 
7.78600 
7.19610 
6.74330 
6.36680 
6.03470 
5.73200 
5.45020 
5.18520 
Cp 
0.00012 
0.58800 
0.33519 
0.19032 
0.10810 
0.06134 
0.03486 
0.01977 
0.01124 
0.00637 
Cp 
0.00002 
3.55500 
4.49330 
4.35210 
3.82880 
3.21980 
2.64520 
2.14620 
1. 72860 
1. 38670 
Cp 
0.00001 
4.03080 
5.83750 
6.54420 
6.71910 
6.63700 
6.43770 
6.18730 
5.91920 
5.64920 
Clearance K12 
flow 
-0.11550 1.15490 
2.19180 0.00346 
5.41680 0.0008:L 
5.43450 0.00046 
5.43450 0.00026 
5.43450 O.OOO:L5 
5.43450 0.00008 
5.43450 0.00005 
5.43450 0.00003 
5.43450 0.00002 
Clearance Kl2 
flow 
-0.11550 1.15500 
-0.05511 0.78679 
-0.00932 0.56484 
0.02227 0.42158 
0.04276 0.32276 
0.05544 0.25130 
0.06313 0.19755 
0.06769 0.15629 
0.07039 0.12406 
0.07197 0.09868 
Clearance Kl2 
flow 
-0.11550 1.15500 
-0.06157 0.99773 
-0.02889 0.89928 
-0.01046 0.83115 
-0.00042 0.77886 
0.00490 0.73536 
0.00771 0.69701 
0.00917 0.66204 
0.00994 0.62950 
0.01034 0.59889 
K21 
flow 
0.00001 
0.06791 
o. 03872 
0.02198 
0.01249 
0.00708 
0.00403 
0.00228 
0.00130 
0.00074 
K21 
flow 
0.00000 
0.41060 
0.51897 
0.50267 
0.44222 
0.37189 
0.30553 
0.24788 
0.19966 
0.16016 
K21 
flow 
0.00000 
0.46556 
0.67423 
0.75585 
0.77605 
0.76658 
0.74355 
0.71463 
0.68366 
0.65248 
Net 
flow 
-1.15480 
0.06445 
0.03791 
0.02152 
0,01223 
0.00694 
0.00394 
0.00224 
0.00127 
0.00072 
Net 
flow 
-1.15500 
-0.37620 
-0.04586 
0.08108 
0.11946 
0.12058 
0.10798 
0.09159 
0.07560 
0.06148 
Net 
flow 
-1.15500 
-0.53217 
-0.22504 
-0.07530 
-0.00281 
0.03121 
0.04655 
0.05259 
0.05417 
0.05359 
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APPENDIX AA (cont.) 
Two compartment open model simulations with decreasing K10 
K12 0.01155, K21 = 0.05775, 
KlO = 0.003 
TIME Cc 
0.00000 
10.00000 
20.00000 
30.00000 
40.00000 
50.00000 
60.00000 
70.00000 
80.00000 
90.00000 
10.00000 
8.89890 
8.25370 
7.83940 
7.54160 
7.30450 
7.09940 
6.91250 
6.73660 
6.56830 
KlO = 0.002 
TIME Cc 
0.00000 
10.00000 
20.00000 
30.00000 
40.00000 
50.00000 
60.00000 
70.00000 
80.00000 
90.00000 
10.00000 
8.98750 
8.41580 
8.06670 
7.82880 
7.64790 
7.49600 
7.35980 
7.23220 
7 .11010 
KlO = 0.0017 
TIME Cc 
0.00000 
10.00000 
20.00000 
30.00000 
40.00000 
50.00000 
60.00000 
70.00000 
80.00000 
90.00000 
10.00000 
9.01430 
8.46510 
8.13620 
7.91710 
7.75410 
7.61940 
7.49970 
7.38820 
7.28140 
Cp 
0.00001 
4.09610 
6.03960 
6.90580 
7.24220 
7.31490 
7.26050 
7.14440 
7.00010 
6.84380 
Cp 
0.00001 
4,11820 
6.10890 
7.03170 
7.42710 
7.55820 
7.56060 
7.49910 
7.40710 
7.30090 
Cp 
0.00001 
4.12480 
6.12990 
7.07010 
7.48360 
7.63310 
7.65340 
7.60930 
7.53420 
7.44440 
Clearance K12 
flow 
-0.11550 1.15500 
-0.06231 1.02780 
-0.03098 0.95330 
-0.01375 0.90546 
-0.00459 0.87106 
0.00016 0.84367 
0.00262 0.81998 
0.00387 0.79839 
0.00452 0.77808 
0.00485 0.75864 
Clearance K12 
flow 
-0.11550 1.15500 
-o. 06256 1. 03810 
-0.03166 0.97203 
-0.01482 0.93170 
-0.00593 0.90423 
-0.00135 0.88333 
0.00100 0.86579 
0.00219 0.85005 
0.00279 0.83532 
0.00310 0.82121 
Clearance K12 
flow 
-0.11550 1.15500 
-o. 06260 1. 04120 
-0.03186 0.97772 
-0.01513 0.93973 
-0.00632 0.91443 
-0.00180 0.89560 
0.00052 0.88004 
0.00169 0.86621 
0.00228 0.85333 
0.00258 0.84101 
K21 
flow 
0.00000 
0.47310 
0.69757 
0.79762 
0.83647 
0.84487 
0.83859 
0.82518 
0.80851 
0.79046 
K21 
flow 
0.00000 
0.47565 
0.70558 
0.81217 
0.85783 
0.87298 
0.87325 
0.86614 
0.85552 
0.84326 
K21 
flow 
0.00000 
0.47642 
0.70800 
0.81659 
0.86436 
0.88162 
0.88397 
0.87887 
0.87020 
0.85983 
Net 
flow 
-1.15500 
-0.55473 
-0.25573 
-0.10783 
-0.03459 
0.00119 
0.01861 
0.02678 
0.03043 
0.03183 
Net 
flow 
-1.15500 
-0.56241 
-0.26645 
-0.11954 
-0.04640 
-0.01035 
0.00747 
0.01609 
0.02020 
0.02204 
Net 
flow 
-1.15500 
-0.56473 
-0.26972 
-0.12314 
-0.05007 
-0.01398 
0.00393 
0.01266 
0.01687 
0.01882 
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APPENDIX AA (cont.) 
Two compartment open model simulations with decreasing KlO 
Kl2 0.01155, K21 = 0.05775, 
KlO = 0.0014 
TIME Cc 
0.00000 
10.00000 
20.00000 
30.00000 
40.00000 
50.00000 
60.00000 
70.00000 
80.00000 
90.00000 
10.00000 
9. 04110 
8.51470 
8.20630 
8.00650 
7.86180 
7.74480 
7.64240 
7.54760 
7.45710 
KlO = 0.0012 
TIME Cc 
0.00000 
10.00000 
20.00000 
30.00000 
40.00000 
50.00000 
60.00000 
70.00000 
80.00000 
90.00000 
10.00000 
9.05910 
8.54790 
8.25330 
8.06660 
7.93450 
7.82970 
7.73910 
7.65580 
7.57660 
Cp 
0.00001 
4.13150 
6.15090 
7.10860 
7.54070 
7.70870 
7.74740 
7. 72130 
7.66370 
7.59090 
Cp 
0.00001 
4.13590 
6.16500 
7.13450 
7.57900 
7.75960 
7.81080 
7.79690 
7.75140 
7.69030 
Clearance Kl2 
flow 
-0.11550 1.15500 
-0.06270 1.04430 
-0.03206 0.98345 
-0.01545 0.94783 
-0.00672 0.92475 
-0.00225 0.90804 
0.00004 0.89453 
0.00119 0.88270 
0.00178 0.87174 
0.00207 0.86129 
Clearance Kl2 
flow 
-0.11550 1.15500 
-0.06275 1.04630 
-0.03219 0.98728 
-0.01566 0.95326 
-0.00698 0.93169 
-0.00254 0.91643 
-0.00028 0.90433 
0.00086 0.89386 
0.00144 0.88425 
0.00173 0.87510 
K21 
flow 
0.00000 
0.47719 
0.71043 
0.82104 
0.87095 
0.89036 
0.89483 
0.89180 
0.88516 
0.87675 
K21 
flow 
0.00000 
0.47770 
0.71206 
0.82403 
0.87537 
0.89624 
0.90215 
0.90054 
0.89529 
0.88824 
Net 
flow 
-1.15500 
-0.56706 
-0.27301 
-0.12678 
-0.05380 
-0.01768 
0.00030 
0.00911 
0.01342 
0.01546 
Net 
flow 
-1.15500 
-0.56862 
-0.27522 
-0.12923 
-0.05632 
-0.02020 
-0.00218 
, 0. 00668 
0.01104 
0.01314 
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APPENDIX AA (cont.) 
Two compartment open model simulations with decreasing K10 
K12 0.05775, K21 = 0.01155 
K10 = 0.6 
TIME 
0.00000 
10.00000 
20.00000 
30.00000 
40.00000 
50.00000 
60.00000 
70.00000 
80.00000 
90.00000 
Cc 
9.99860 
0.02568 
0.01289 
0.01160 
0.01044 
0.00940 
0.00846 
0.00761 
0.00685 
0.00617 
K10 = 0.03 
TIME Cc 
0.00000 
10.00000 
20.00000 
30.00000 
40.00000 
50.00000 
60.00000 
70.00000 
80.00000 
90.00000 
10.00000 
4.34440 
2.14660 
1. 28890 
0.94245 
0.79445 
0. 72203 
0.67954 
0.64889 
0.62333 
K10 = 0.006 
TIME Cc 
0.00000 
10.00000 
20.00000 
30.00000 
40.00000 
50.00000 
60.00000 
70.00000 
80.00000 
90.00000 
10.00000 
5.50220 
3.35070 
2.32390 
1. 82810 
1. 58710 
1. 46540 
1. 40130 
1. 36420 
1. 34010 
Cp 
0.00061 
4.00450 
3.60930 
3.24880 
2.92440 
2.63240 
2.36950 
2.13300 
1. 91990 
1. 72820 
Cp 
0.00009 
18.19100 
24.55700 
26.36500 
26.45900 
25.91100 
25.14100 
24.30500 
23.46200 
22.63600 
Cp 
0.00007 
20.24800 
29.71500 
34.01700 
35.88100 
36.57800 
36.73100 
36.62200 
36.39300 
36.10800 
Clearance K12 
flow 
-0.57750 5.77420 
3.11830 0.01483 
5.89080 0.00744 
5.89480 0.00670 
5.89480 0.00603 
5.89480 0.00543 
5.89480 0.00488 
5.89480 0.00440 
5.89480 0.00396 
5.89480 0.00356 
Clearance K12 
flow 
-0.57750 5.77500 
-0.48012 2.50890 
-0.31266 1.23970 
-0.10436 0.74434 
0.07109 0.54427 
0.17598 0.45880 
0.22685 0.41697 
0.24870 0.39244 
0.25774 0.37473 
0.26138 0.35997 
Clearance K12 
flow 
-0.57750 5.77500 
-0.49213 3.17750 
-0.37237 1.93510 
-0.23908 1.34210 
-0 .12408 1. 05580 
-0.04504 0.91653 
0.00152 0.84626 
0.02623 0.80923 
0. 03877 0. 78781 
0.04493 0.77390 
K21 
flow 
0.00001 
0.09250 
0.08337 
0.07505 
0.06756 
0.06081 
0.05474 
0.04927 
0.04435 
0.03992 
K21 
flow 
0.00000 
0.42021 
0. 56726 
0.60904 
0. 61121 
0.59855 
0.58076 
0.56144 
0.54198 
0.52290 
K21 
flow 
0.00000 
0.46774 
0.68642 
0.78578 
0.82885 
0.84496 
0.84848 
0.84598 
0.84069 
0.83410 
Net 
flow 
-5.77420 
0.07768 
0.07593 
0.06835 
0.06153 
0.05538 
0.04985 
0.04488 
0.04039 
0.03636 
Net 
flow 
-5.77500 
-2.08870 
-0.67242 
-0.13530 
0.06694 
0.13975 
0.16379 
0.16900 
0.16725 
0.16293 
Net 
flow 
-5.77500 
-2.70980 
-1. 24860 
-0.55629 
-0.22691 
-0.07157 
0.00222 
0.03675 
0.05288 
0.06021 
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APPENDIX AA (cont.) 
Two compartment open model simulations with decreasing K10 
K12 0.05775, K21 = 0.01155 
K10 = 0.003 
TIME Cc 
0.00000 
10.00000 
20.00000 
30.00000 
40.00000 
50.00000 
60.00000 
70.00000 
80.00000 
90.00000 
10.00000 
5.66720 
3.54440 
2.50800 
1. 99800 
1. 74680 
1. 62020 
1. 55510 
1. 51960 
1. 49860 
KlO = 0.002 
TIME Cc 
0.00000 
10.00000 
20.00000 
30.00000 
40.00000 
50.00000 
60.00000 
70.00000 
80.00000 
90.00000 
10.00000 
5. 72330 
3. 61140 
2.57290 
2.05860 
1. 80440 
1. 67640 
1. 61120 
1. 57650 
1. 55690 
KlO = 0.0017 
TIME Cc 
0.00000 
10.00000 
20.00000 
30.00000 
40.00000 
50.00000 
60.00000 
70.00000 
80.00000 
90.00000 
10.00000 
5.74030 
3. 63180 
2.59270 
2.07720 
1. 82210 
1. 69370 
1. 62860 
1. 59420 
1. 57500 
Cp 
0.00007 
20.52800 
30.47000 
35.20700 
37.42300 
38.40000 
38.78200 
38.87000 
38.81700 
38.69500 
Cp 
0.00007 
20.62300 
30.72700 
35.61700 
37.96000 
39.03900 
39.50600 
39.66700 
39.68200 
39.62300 
Cp 
0.00007 
20.65100 
30.80500 
35.74200 
38.12300 
39.23400 
39.72700 
39.91200 
39.94700 
39.90800 
Clearance Kl2 
flow 
-0.57750 5.77500 
-0.49349 3.27280 
-0.37867 2.04690 
-0.25297 1.44840 
-0.14479 1.15380 
-0.06965 1.00880 
-0.02457 0.93567 
-0.00011 0.89807 
0.01258 0.87755 
0.01896 0.86545 
Clearance Kl2 
flow 
-0.57750 5.77500 
-0.49394 3.30520 
-0.38072 2.08560 
-0.25747 1.48580 
-0.15151 1.18880 
-0.07768 1.04200 
-0.03313 0.96812 
-0.00879 0.93048 
0.00394 0.91044 
0.01038 0.89913 
Clearance Kl2 
flow 
-0.57750 5.77500 
-0.49407 3.31500 
-0.38133 2.09740 
-o. 25880 1. 49730 
-0.15351 1.19960 
-0.08007 1.05230 
-0.03568 0.97813 
-0.01138 0.94050 
0.00135 0.92062 
0.00781 0.90957 
K21 
flow 
0.00000 
0.47420 
0.70385 
0.81327 
0.86447 
0.88704 
0.89586 
0.89789 
0.89667 
0.89386 
K21 
flow 
0.00000 
0.47639 
0.70980 
0.82276 
0.87687 
0.90180 
0.91258 
0.91632 
0.91665 
0.91529 
K21 
flow 
0.00000 
0.47705 
0.71160 
0.82563 
0.88064 
0.90630 
0.91769 
0.92196 
0.92278 
0.92188 
Net 
flow 
-5. 77500 
-2.79860 
-1. 34300 
-0.63511 
-0.28935 
-0.12175 
-0.03981 
-0.00018 
0.01912 
0.02841 
Net 
flow 
-5.77500 
-2.82880 
-1. 37580 
-0.66307 
-0.31195 
-0.14025 
-0.05554 
-0.01416 
0.00620 
0.01616 
Net 
flow 
-5.77500 
-2.83800 
-1.38580 
-0.67163 
-0.31892 
-0.14598 
-0.06044 
-0.01854 
0.00215 
0.01231 
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APPENDIX AA (cont.) 
Two compartment open model simulations with decreasing K10 
K12 0.05775, K21 = 0.01155 
K10 = 0.0014 
TIME Cc Cp Clearance K12 · K21 Net 
flow flow flow 
0.00000 10.00000 0.00007 -0.57750 5.77500 0.00000 -5.77500 
10.00000 5.75730 20.68000 -0.49420 3.32480 0.47771 -2.84710 
20.00000 3.65230 30.88400 -0.38194 2.10920 0.71341 -1. 39580 
30.00000 2.61260 35.86700 -0.26013 1. 50880 0.82852 -0.68027 
40.00000 2.09590 38.28700 -0.15550 1. 21040 0.88444 -0.32597 
50.00000 1. 84010 39.43000 -0.08246 1. 06260 0.91083 -0.15181 
60.00000 1. 71130 39.95000 -0.03823 0.98827 0.92285 -0.06543 
70.00000 1.64620 40.15900 -0.01396 0.95066 0.92766 -0.02299 
80.00000 1. 61200 40.21500 -0.00123 0.93095 0.92897 -0.00198 
90.00000 1.59340 40.19600 0.00525 0.92017 0.92854 0.00837 
K10 = 0.0012 
TIME Cc Cp Clearance K12 K21 Net 
flow flow flow 
0.00000 10.00000 0.00007 -0.57750 5. 77500 0.00000 -5.77500 
10.00000 5.76860 20.69900 -0.49429 3.33140 0.47815 -2.85320 
20.00000 3.66600 30.93600 -0.38234 2.11710 0.71462 -1. 40250 
30.00000 2.62600 35.95100 -0.26102 1. 51650 0.83046 -0.68608 
40.00000 2.10860 38.39800 -0.15682 1.21770 0.88698 -0.33072 
50.00000 1. 85210 39.56200 -0.08404 1. 06960 0.91388 -0.15574 
60.00000 1. 72310 40.10000 -0.03992 0.99511 0.92631 -0.06880 
70.00000 1. 65800 40.32400 -0.01569 0.95751 0.93149 -0.02601 
80.00000 1. 62410 40.39600 -0.00295 0.93792 0.93314 -0.00479 
90.00000 1.60580 40.39000 0.00354 0.92733 0.93302 0.00569 
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APPENDIX BB 
Closed model fit 
VC=9.859, VP=2.324 
K12=0.07014, K21=0.01185 
TIME 
0 
30 
60 
90 
120 
150 
180 
210 
240 
270 
300 
330 
360 
390 
420 
450 
480 
510 
540 
570 
600 
630 
660 
690 
720 
750 
780 
810 
840 
870 
900 
Cc Fit Cp Fit 
9.9982 0.007676 
2.1617 33.252 
1. 4973 36. 071 
11.242 37.763 
3.6119 70.13 
2.951 72.934 
12.708 74.574 
5.1045 106.83 
4.4259 109.71 
14.173 111.39 
6.5931 143.54 
5.8891 146.53 
15.639 148.2 
8.0789 180.27 
7.35 183.36 
17.106 185 
9.5182 217.19 
8.8148 220.18 
18.571 221.82 
11.044 253.75 
10.27 257.03 
20.037 258.63 
12.511 290.56 
11. 735 293. 85 
21.503 295.44 
13.977 327.37 
13.201 330.66 
22.969 332.25 
15.443 364.18 
14.667 367.47 
22.929 369 
Open model simulation 
Kl0=0.006 
K12=0.05775, K21=0.01155 
Cc Cp 
9.9985 0.006859 
2.3295 33.992 
1.4421 36.838 
11.022 37.55 
3.6133 69.174 
2.7026 70.995 
12.243 70.785 
4.8253 101.38 
3.8602 102.41 
13. 366 101. 35 
5.9371 131.01 
4.9176 131.33 
14.399 129.45 
6.9577 158.26 
5.8887 157.93 
15.349 155.29 
7.895 183.33 
6.7812 182.4 
16.223 179.05 
8.7469 206.43 
7.6037 204.88 
17.026 200.9 
9.5282 227.68 
8.3608 225.55 
17.765 220.99 
10.247 247.21 
9.0594 244.55 
18.445 239.46 
10.907 265.18 
9.7019 262.02 
17.583 256.39 
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APPENDIX BB (cont.) 
Closed model fit 
VC=9.966, VP=2.065 
K12=0.06017, K21=0.01160 
TIME Cc Fit Cp Fit 
0 9.9986 0.006581 
30 2.6089 35.671 
60 1.7108 40.005 
90 11.361 41.86 
120 4.2372 76.239 
150 3.3337 80.599 
180 12.981 82.467 
210 5.8883 116.7 
240 4.9464 121.24 
270 14.605 123.06 
300 7.5297 157.2 
330 6.557 161.9 
360 16.224 163.67 
390 9.1517 197.8 
420 8.1738 202.52 
450 17.846 204.27 
480 10.774 238.4 
510 9.7956 243.12 
540 19.468 244.87 
570 12.395 279 
600 11.417 283.72 
630 21.089 285.47 
660 14.017 319.6 
690 13.039 324.32 
720 22.711 326.07 
750 15.639 360.2 
780 14.661 364.92 
810 24.333 366.67 
840 17.261 400.8 
870 16.283 405.52 
900 24.463 407.2 
Open model simulation 
Kl0=0.0012 
K12=0.05775, K21=0.01155 
Cc Cp 
9.9987 0.006431 
2.6526 35.82 
1. 7063 40 .183 
11.31 41.843 
4.239 76 .  017 
3.2768 80.174 
12.871 81.6 
5.821 115.39 
4.8109 119.51 
14,405 120.65 
7.3605 154.14 
6.3182 158.15 
15.914 159.01 
8.8599 192.28 
7.8041 196.08 
17.395 196.7 
10.333 229.75 
9.2684 233.32 
18.851 233.73 
11.78 266.55 
10.707 269.91 
20.281 270.1 
13.202 302.71 
12.12 305.86 
21.686 305.83 
14.598 338.24 
13.509 341.17 
23.066 340.94 
15.971 373.13 
14.873 375.87 
22.935 375.36 
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APPENDIX BB (cont.) 
Simulated open model 
Kl0=0.0012 
K12=0.01155, K21=0.05775 
TIME 
0 
30 
60 
90 
120 
150 
180 
210 
240 
270 
300 
330 
360 
390 
420 
450 
480 
510 
540 
570 
600 
630 
660 
690 
720 
750 
780 
810 
840 
870 
900 
Cc Cp 
9.9997 0.001286 
8.2634 7.0865 
7.8235 7.8423 
17.512 7.9829 
15.615 14.536 
14.951 15.11 
24.432 15.025 
22.331 21.37 
21.469 21.743 
30. 757 21. 462 
28.471 27.617 
27.427 27.806 
36.54 27.346 
34.083 33.328 
32.874 33.349 
41.827 32.725 
39.214 38.549 
37.854 38.416 
46.659 37.643 
43.905 43.322 
42.406 43.048 
51. 077 42 .138 
48.192 47.685 
46.567 47.282 
55.116 46.248 
52.112 51.674 
50. 372 51.153 
58.808 50.005 
55.696 55.32 
53.849 54.692 
60.686 53.427 
Fitted closed model 
VC=9.865, VP=2.892 
K12=0.01707, K21=0.05794 
Cc Fit Cp Fit 
9.9996 0.001377 
7.9722 
7.7421 
17.777 
15.816 
15.569 
25.607 
23.646 
23.399 
33.437 
31. 476 
31.229 
41. 268 
39.306 
39.059 
49.098 
47.136 
46.889 
56.928 
54.967 
54.719 
64.758 
62.797 
62.549 
72.588 
70.627 
70.379 
80.418 
78.457 
78.21 
86.731 
6.917 
7.7019 
8.0495 
14.739 
15.582 
15.919 
22.608 
23.451 
23.788 
30.477 
31.32 
31. 657 
38.346 
39.189 
39.526 
46.215 
47.058 
47 .  395 
54.084 
54.927 
55.264 
61.953 
62.796 
63.133 
69.822 
70.665 
71. 002 
77.691 
78.534 
78.858 
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